Document:

Agreement dated September 1, 2006 between the Company and AstraZeneca AB

 Exhibit 10.30 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WIH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

by and between 
 ASTRAZENECA AB 
 and 

DYNAVAX TECHNOLOGIES CORPORATION 
 DATE:            1            September 2006 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 TABLE OF CONTENTS 
  

							
	Table of Contents	  	Page	 
			
	1.	  	Definitions	  	 	2	  
	2.	  	Construction	  	 	17	  
	3.	  	Conduct of the Joint Research Programme	  	 	17	  
			
	3.1	  	Overview	  	 	17	  
	3.2	  	Research Term	  	 	18	  
	3.3	  	Joint Research Plan	  	 	18	  
	3.4	  	Research Effort and Support	  	 	18	  
	3.5	  	Conduct of Research	  	 	19	  
	3.6	  	Materials and Information Transfer	  	 	21	  
	3.7	  	Cooperation	  	 	22	  
	3.8	  	Regulatory Records	  	 	22	  
	3.9	  	Reports	  	 	22	  
	3.10	  	Lead Candidate Development Decision	  	 	22	  
	3.11	  	CD Nomination	  	 	23	  
	3.12	  	Overview of Joint Research Programme	  	 	23	  
	3.13	  	Selection of Compounds	  	 	23	  
			
	4.	  	Support and Management of the Joint Research Programme	  	 	24	  
	4.1	  	Overview of the Management of the Joint Research Programme	  	 	24	  
	4.2	  	Responsibilities of JPT	  	 	24	  
	4.3	  	Formation of JPT	  	 	25	  
	4.4	  	JPT Meetings	  	 	26	  
	4.5	  	JPT Decision Making : Disputes	  	 	26	  
	4.6	  	JPT Minutes	  	 	26	  
	4.7	  	Dissolution of JPT	  	 	27	  
	4.8	  	Responsibilities of JSC	  	 	27	  
	4.9	  	Formation of JSC	  	 	28	  
	4.10	  	JSC Decision Making : Disputes	  	 	29	  
	4.11	  	JSC Decisions Requiring Consent	  	 	29	  
	4.12	  	JSC Meetings	  	 	29	  

  
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 (i)

  

							
	4.13	  	JSC Minutes	  	 	30	  
	4.14	  	Dissolution of JSC	  	 	30	  
	4.15	  	Advisory Board	  	 	30	  
	4.15	  	Expenses	  	 	31	  
	4.17	  	Access to Information	  	 	31	  
	4.18	  	Joint Research Programme Guidelines	  	 	31	  
			
	5.	  	Reports	  	 	31	  
	5.1	  	Joint Research Programme Progress Reports	  	 	31	  
	5.2	  	Copyrights	  	 	31	  
	5.3	  	AstraZeneca Reports	  	 	32	  
			
	6.	  	Ownership and Grant of Rights	  	 	32	  
	6.1	  	Ownership of Collaboration Technology	  	 	32	  
	6.2	  	Licences to AstraZeneca	  	 	32	  
	6.3	  	Licence to Dynavax	  	 	33	  
	6.4	  	Third Party Licences	  	 	34	  
	6.5	  	Exclusivity	  	 	35	  
	6.6	  	Sublicences	  	 	37	  
	6.7	  	Distributors	  	 	37	  
			
	6.8.	  	Confirmatory Patent Licences	  	 	38	  
			
	7.	  	Research Funding	  	 	38	  
	7.1	  	Funding	  	 	38	  
	7.2	  	Invoices; Reconciliation	  	 	38	  
	7.3	  	Records Retention; Audit	  	 	39	  
	7.4	  	Projected Cost Reports	  	 	40	  
			
	8.	  	Development and Commercialization	  	 	40	  
	8.1	  	Overview	  	 	40	  
	8.2	  	Development of Product	  	 	40	  
	8.3	  	Regulatory Affairs and Information Exchange	  	 	41	  
	8.4	  	Commercialization of Product and Combination Product	  	 	42	  
	8.5	  	Dynavax Option to Co-Promote in the United States	  	 	43	  
	8.6	  	Pricing, Price Approvals and Product Distribution	  	 	44	  
	8.7	  	Sales and Inventory	  	 	44	  

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 (ii)

  

							
	8.8	  	Advertising and Education	  	 	44	  
	8.9	  	Development and Commercialization Costs	  	 	44	  
	8.10	  	Diligence Obligations	  	 	45	  
	8.11	  	Breach of Diligence Obligations	  	 	46	  
	8.12	  	Reversion; Abandonment	  	 	47	  
			
	9.	  	Milestone Payments	  	 	48	  
	9.1	  	Total Obligation	  	 	48	  
	9.2	  	Access Fee	  	 	48	  
	9.3	  	Joint Research Programme Milestones	  	 	49	  
	9.4	  	Development Milestones	  	 	49	  
	9.5	  	Milestone Payments	  	 	49	  
			
	10.	  	Royalty Payments and Other Payment-Related Provisions	  	 	49	  
	10.1	  	Royalties	  	 	49	  
	10.2	  	Combination Products	  	 	50	  
	10.3	  	Sublicensees	  	 	51	  
	10.4	  	Royalty Stacking	  	 	51	  
	10.5	  	[ * ] Royalty and [ * ]	  	 	52	  
	10.6	  	Reduction of Royalty	  	 	53	  
	10.7	  	Royalty Floor	  	 	54	  
	10.8	  	Royalty Term	  	 	54	  
	10.9	  	Sales Subject to Royalties	  	 	54	  
	10.10	  	Royalty Payments	  	 	55	  
	10.10	  	Mode of Payment	  	 	55	  
	10.12	  	Currency	  	 	55	  
	10.13	  	Interest	  	 	55	  
	10.14	  	Records Retention; Audit	  	 	56	  
			
	11.	  	Taxes	  	 	56	  
	11.1	  	General	  	 	56	  
	11.2	  	Indirect Taxes	  	 	57	  
	11.3	  	Customs Duties	  	 	57	  
			
	12.	  	Manufacture and Supply	  	 	58	  
	12.1	  	Preclinical Supply	  	 	58	  

  
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 (iii)

  

							
	12.2	  	Clinical and Commercial Supply	  	 	58	  
	12.3	  	Manufacturing Know-How Transfer	  	 	58	  
			
	13.	  	Confidentiality and Non-Disclosure	  	 	59	  
	13.1	  	General Obligations	  	 	59	  
	13.2	  	Permitted Disclosures	  	 	60	  
	13.3	  	Exclusions	  	 	62	  
	13.4	  	Confidentiality of Agreement	  	 	62	  
	13.5	  	Publications and Presentations	  	 	63	  
	13.6	  	Use of Name/Publicity.	  	 	64	  
			
	14.	  	Patent Prosecution, Enforcement and Defence	  	 	65	  
	14.1	  	Disclosure	  	 	65	  
	14.2	  	Patent Prosecution and Maintenance	  	 	65	  
	14.3	  	Patent Term Restoration	  	 	66	  
	14.4	  	Enforcement of Patent Rights	  	 	67	  
	14.5	  	Third Party Litigation	  	 	68	  
	14.6	  	Invalidity or Unenforceability Defences or Actions	  	 	69	  
	14.7	  	Cooperation	  	 	71	  
	14.8	  	Compliance with Third Party Licences	  	 	71	  
	14.9	  	Costs and Expenses	  	 	71	  
			
	15.	  	Adverse Event Reporting	  	 	72	  
	15.1	  	Overview	  	 	72	  
			
	16.	  	Product Recall	  	 	72	  
	16.1	  	Notification and Recall	  	 	72	  
	16.2	  	Recall Expenses	  	 	73	  
			
	17.	  	Trademarks	  	 	73	  
			
	18.	  	Representations and Warranties	  	 	73	  
			
	19.	  	Indemnification and Insurance	  	 	78	  
			
	19.1	  	Indemnification of Dynavax	  	 	78	  
	19.2	  	Indemnification of AstraZeneca	  	 	79	  
	19.3	  	[ * ]	  
	19.4	  	Notice of Claim	  	 	80	  
	19.5	  	Indemnification Procedures	  	 	80	  

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 (iv)

  

							
	19.6	  	LIMITATION ON DAMAGES	  	 	82	  
	19.7	  	Insurance	  	 	83	  
			
	20.	  	Term and Termination	  	 	83	  
	20.1	  	Term	  	 	83	  
	20.2	  	Termination by AstraZeneca	  	 	83	  
	20.3	  	Termination for Infringement of Third Party Rights	  	 	84	  
	20.4	  	Termination by Dynavax for Lack of Diligence	  	 	84	  
	20.5	  	Termination by Either Party	  	 	85	  
	20.6	  	Change of Control	  	 	86	  
	20.7	  	Consequences of Termination	  	 	87	  
	20.8	  	Survival	  	 	90	  
	20.9	  	Rights in Bankruptcy	  	 	90	  
			
	21.	  	Force Majeure	  	 	91	  
			
	22.	  	Assignment	  	 	92	  
			
	23.	  	Severability	  	 	93	  
			
	24.	  	Dispute Resolution	  	 	93	  
	24.1	  	Disputes	  	 	93	  
	24.2	  	Arbitration	  	 	93	  
	24.3	  	Arbitrator	  	 	94	  
	24.4	  	Governing Law	  	 	94	  
	24.5	  	Decision	  	 	94	  
	24.6	  	Award	  	 	95	  
	24.7	  	Costs	  	 	96	  
	24.8	  	Injunctive Relief	  	 	96	  
	24.9	  	Confidentiality	  	 	96	  
	24.10	  	Survivability	  	 	96	  
	24.11	  	Jurisdiction	  	 	96	  
	24.12	  	Patents and Trademarks	  	 	97	  
	24.13	  	Provisions Unique to Arbitrations Pursuant to Section 8.10	  	 	97	  
			
	25.	  	Notices	  	 	97	  
	25.1	  	Notice Requirements.	  	 	97	  
	25.2	  	Address for Notice	  	 	98	  

  
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 (v)

  

							
	26.	  	Relationship of the Parties	  	 	98	  
			
	27.	  	Entire Agreement	  	 	99	  
			
	28.	  	English Language	  	 	99	  
			
	29.	  	Amendment	  	 	99	  
			
	30.	  	Waiver and Non-Exclusion of Remedies	  	 	100	  
			
	31.	  	No Benefit to Third Parties	  	 	100	  
			
	32.	  	Equitable Relief	  	 	100	  
			
	33.	  	Further Assurance	  	 	101	  
			
	34.	  	Expenses	  	 	102	  
			
	35.	  	Counterparts	  	 	102	  

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 (vi)

  

 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Research Collaboration and License Agreement (this “Agreement”) is effective as of
the                    day of September 2006 (the “Effective Date”), by and between 

 

	(1)	ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with offices at S-151 85 Södertälje, Sweden (“AstraZeneca”);
and 

  

	(2)	DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation with offices at 2929 Seventh Street, Suite 100, Berkeley, CA 94710-2753, USA
(“Dynavax”). 

 Recitals 

 

	(A)	WHEREAS, AstraZeneca is a global pharmaceutical company with substantial capabilities in the field of drug discovery, development and marketing of pharmaceutical
products in several therapy areas including asthma and chronic obstructive pulmonary disease; 

  

	(B)	WHEREAS, Dynavax is a pharmaceutical company engaged in the discovery and development of novel oligonucleotide agonists of TLR-9 for use in a variety of diseases and
disorders, including the treatment of asthma and chronic obstructive pulmonary disease; 

  

	(C)	WHEREAS, the Parties wish to engage in a collaborative research program utilising Dynavax’s knowledge, skills and proprietary technology to identify and develop
novel TLR-9 agonists for therapeutic use in the fields of asthma and chronic pulmonary disease with a mutual ambition of developing and marketing any resultant products on a global basis. 

Agreement 
 NOW, THEREFORE, in
consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 1 of 103

  

	1	Definitions 

 Unless
otherwise specifically provided in this Agreement, the following terms have the following meanings: 
  

	1.1	“Advisory Board” means the committee established and conducted according to Section 4.15. 

 

	1.2	“Affiliate” means, with respect to a Person, any Person that Controls, is Controlled by or is under common Control with such first Person, in all
cases, only for as long as Control actually exists. For purposes of this definition only, “Control” means (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through
ownership of voting securities or by contract relating to voting rights or corporate governance, or (b) to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such
Person. 

  

	1.3	“Alliance Manager” means a Party’s representative with responsibility for the activities described in Section 4.9. 

 

	1.4	“Annual Net Sales” means the Net Sales made during a given calendar year. 

 

	1.5	“Applicable Law” means the applicable laws, rules and regulations, including any rules, regulations, guidelines or other requirements of the regulatory
authorities, that may be in effect from time to time. 

  

	1.6	“Asthma” means an inflammatory pulmonary disorder that is characterized by reversible obstruction of the airways. 

 

	1.7	“AstraZeneca Information” has the meaning set forth in Section 13.1.2. 

 

	1.8	“AstraZeneca Know-How” means all Know-How Controlled by AstraZeneca or its Affiliates prior to and/or during the Term that is [ * ] for the research,
development, manufacture, importation, use or sale of Dynavax ISS, Collaboration ISS, Reverted ISS, CDs, Product or Combination Product(s), excluding Collaboration Know-How. 

 

	1.9	“AstraZeneca Patents” means any Patents Controlled by AstraZeneca or its Affiliates prior to and/or during the Term that are [ * ] for the research,
development, manufacture, importation, use or sale of Dynavax ISS, Collaboration ISS, Reverted ISS, Product or Combination Product(s), excluding Collaboration Patents. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 2 of 103

  

	1.10	“AstraZeneca Technology” means AstraZeneca Patents and AstraZeneca Know-How. 

 

	1.11	“Background Technology” means either the AstraZeneca Technology or the Dynavax Technology, as appropriate and Background Technologies means the
AstraZeneca Technology and the Dynavax Technology. 

  

	1.12	[ * ]. 

  

	1.13	“Candidate Drug” or “CD” means a Dynavax ISS or a Collaboration ISS that is a Lead Candidate satisfying the relevant Candidate Drug
Target Profile and [ * ] as a candidate for further Development and Commercialization as the Product or a Combination Product pursuant to Section 3.10; provided, however, upon the commencement of [ * ], such Collaboration ISS shall be deemed a
Candidate Drug regardless of whether such Collaboration ISS meets the Candidate Drug Target Profile. 

  

	1.14	“Candidate Drug Target Profile” means the target profile for a Candidate Drug as further defined under the Joint Research Plan, the criteria for which
are attached hereto as Exhibit A. 

  

	1.15	“CD Nomination” means the internal process, known by [ * ], by which [ * ]. 

 

	1.16	“CD Nomination Date” means the date upon which a CD Nomination is made. 

 

	1.17	“Change of Control,” with respect to either Party, means an event in which: 

 

	 	1.17.1	any other Person or group of Persons acquires beneficial ownership of securities of such Party representing more than fifty percent (50%) of the voting power of
the then outstanding securities of such Party with respect to the election of directors of such Party; or 

  

	 	1.17.2	such Party effects a merger, consolidation or similar transaction with another Person in which such Party is not the surviving entity in such transaction.

  

	1.18	[ * ]. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 3 of 103

  

	1.19	[ * ]. 

  

	1.20	“Collaboration” means all activities performed by or on behalf of Dynavax or AstraZeneca in the course of carrying out the Joint Research Programme and
Development Plan, as applicable, and otherwise performing their obligations set forth in this Agreement. 

  

	1.21	“Collaboration ISS” means a [ * ] generated during the course of the Joint Research Programme. For clarity, and in accordance with Section 3.12.2,
a particular ISS will cease being subject to Research under this Agreement, and will accordingly no longer be a Collaboration ISS but will thereupon become a Reverted ISS, when it is no longer prioritized or selected for further research under the
Joint Research Programme. 

  

	1.22	“Collaboration Know-How” means all Know-How generated by the Parties during the Research Term pursuant to the Joint Research Programme or otherwise
generated by either Party in connection with the Development of any Collaboration ISS or Product. 

  

	1.23	“Collaboration Patent” means a Patent filed after the Effective date claiming an invention generated pursuant to the Collaboration and which claims or
covers Collaboration Know-How and/or Collaboration ISS. 

  

	1.24	“Collaboration Technology” means Collaboration Patents, Collaboration Know-How and Collaboration ISS. 

 

	1.25	“Combination Product” means a pharmaceutical preparation [ * ]. 

 

	1.26	“Commence” or “Commencement” when used to describe a Phase I Trial, Phase II Trial, Phase III Trial or Phase IV Trial, means the first dosing
of the first human subject for such trial. 

  

	1.27	“Commercialization” means the performance of making, importing, using, selling, or offering for sale, including researching, developing, registering,
modifying, enhancing, improving, manufacturing, having manufactured, holding/keeping (whether for disposal or otherwise), formulating, optimising, having used, exporting, transporting, distributing, promoting, marketing or having sold or otherwise
disposing or offering to dispose of, a Product following Health Registration Approval of such Product in any part of the Territory under this Agreement. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 4 of 103

  

	1.28	“Commercially Reasonable Efforts” means, with respect to the carrying out of obligations or tasks, efforts and resources commonly used by a
pharmaceutical company [ * ], for the active development or commercialisation of a pharmaceutical product of a similar nature, with a similar commercial potential and at a similar stage in the clinical development process as the
Product or the applicable Combination Product, based on conditions then prevailing, including without limitation, [ * ], including [ * ]. Commercially Reasonable Efforts shall be determined on a market-by-market basis for
the Product or each Combination Product. Notwithstanding anything to the contrary herein, Commercially Reasonable Efforts requires that a Party, at a minimum, [ * ]. 

 

	1.29	“Confidential Information” means, subject to Section 13.3, any information, including any regulatory, scientific or other business information and
materials, of a Party and its Affiliates disclosed to the other Party pursuant to this Agreement, and before, on or after the Effective Date of this Agreement or protected under Section 13.1.2. 

 

	1.30	“Control” means, with respect to any item of information, Patent, Know-How, or other intellectual property, possession of the right, whether directly
or indirectly, and whether by ownership, licence or otherwise, to assign, or grant a licence, sublicense or other right to or under, such information, Patent or other intellectual property as provided for herein without violating the terms of any
agreement or other arrangement with any Third Party. 

  

	1.31	“COPD” or “Chronic Obstructive Pulmonary Disease” means a group of lung diseases involving limited airflow and varying degrees of air sac
enlargement, airway inflammation, and lung tissue destruction. 

  

	1.32	“Defending Party” has the meaning set forth in Section 14.7. 

 

	1.33	“Develop” or “Development” means the performance of preclinical, manufacturing and clinical development and regulatory activities following
the acceptance of an IND for a Candidate Drug (or the functional equivalency if the first human clinical trial of such Product or Combination Product is conducted without an IND) and that are reasonably required to obtain Health Registration
Approval of the Product or any Combination Product in any part of the Territory under this Agreement. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 5 of 103

  

	1.34	“Development Cost” means expenses and costs incurred by either Party during Development of a Candidate Drug, the Product or any Combination Product
until the First Commercial Sale of the Product or any Combination Product anywhere in the world. 

  

	1.35	“Development Milestone” has the meaning set forth in Section 9.4. 

 

	1.36	“Development Plan” has the meaning set forth in Section 8.2. 

 

	1.37	“Disclosing Party” has the meaning set forth in Section 13.1.1. 

 

	1.38	“Distributor” has the meaning set forth in Section 6.7. 

 

	1.39	“DMF” means a Drug Master File. 

  

	1.40	“Dynavax Know-How” means all Know-How Controlled by Dynavax or its Affiliates prior to and/or during the Term that is [ * ] for the
research, development, manufacture, importation, use or sale of the Dynavax ISS, Collaboration ISS, Product or Combination Product(s), excluding the Collaboration Know-How. 

 

	1.41	“Dynavax ISS” means those ISS synthesised by or on behalf of Dynavax prior to the Research Term and made available for identification and selection as
[ * ] candidates pursuant to the Joint Research Plan. 

  

	1.42	“Dynavax Patents” means any Patents Controlled by Dynavax or its Affiliates as of the Effective Date or during the Term that are [ * ]
for the research, development, manufacture, importation, use or sale of the Dynavax ISS, Collaboration ISS, Product or Combination Product(s), including without limitation, the Patents listed on Exhibit B, excluding the Collaboration Patents
and the AstraZeneca Patents. 

  

	1.43	“Dynavax Technology” means the Dynavax Patents, the Dynavax Know-How and Dynavax ISS. 

 

	1.44	“Effective Date” means the date as set forth in the preamble to this Agreement. 

 

	1.45	“Europe” means the European Economic Area as it may be constituted from time to time. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 6 of 103

  

	1.46	“Field” means the use of TLR-9 agonists that [ * ] for the treatment of human patients who have Asthma and/or COPD, including for the
prevention of the progression of Asthma and/or COPD in human patients. 

  

	1.47	“First Commercial Sale” means the first sale for monetary value for use or consumption by the general public of the Product or a Combination Product in
any country after Health Registration Approval for such Product or Combination Product has been obtained in such country. For the avoidance of doubt, sales prior to receipt of the Health Registration Approvals necessary to commence regular
commercial sales in a country, such as so-called “treatment IND sales,” “named patient sales” and “compassionate use sales,” shall not be construed as a First Commercial Sale in that country. 

 

	1.48	“First Indication” means the first Indication in which AstraZeneca obtains the first Health Registration Approval in respect of the Product or a
Combination Product. 

  

	1.49	“Force Majeure” has the meaning set forth in Section 21.1. 

 

	1.50	“Force Majeure Party” means a Party prevented or delayed in its performance under this Agreement by an event of Force Majeure.

  

	1.51	“FTE” means the equivalent of one person working full time for one 12-month period in a research, development, commercialization, regulatory or other
relevant capacity, approximating [ * ] hours per year. In the interests of clarity, though, a single individual who works more than [ * ] hours in a single year shall be treated as one FTE regardless of the number of
hours worked. FTE effort shall be charged by calculating the individual’s total hours dedicated to the applicable activities under this Agreement as a percentage of total hours worked multiplied by the FTE Rate. By way of example, and not in
limitation of the foregoing, (a) if a full-time, salaried employee spends 100% of his or her effort hours on the applicable activities under this Agreement, the FTE charge-out rate shall be calculated as the FTE Rate multiplied by 100%,
(b) if a full-time, salaried employee spends 50% of his or her effort hours on the applicable activities under this Agreement, the FTE charge-out rate shall be calculated as the FTE Rate multiplied by 50%, and (c) if a seventy-five percent
(75%)-time, salaried employee spends fifty percent (50%) of his or her efforts on the applicable activities under this Agreement, the FTE charge-out rate shall be 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 7 of 103

  

	 	
calculated as the FTE Rate multiplied by thirty-seven and one-half percent (37.5%) (50% x 75% = 37.5%). No FTE credit shall be given for overtime hours. The FTE Rate shall include: [ *
]. 

  

	1.52	“FTE Rate” means the amount of [ * ] and shall cover the items referred to in the last sentence of Section 1.51 provided, however, that
such FTE Rate shall be increased to [ * ] for FTE efforts provided by Dynavax in excess of those set forth in Section 3.4. 

  

	1.53	“Good Clinical Practices” or “GCP” means current Good Clinical Practices as specified in the United States Code of Federal Regulations, at
the time of testing, and all FDA and ICH guidelines, including the ICH Consolidated Guidelines on Good Clinical Practices. 

  

	1.54	“Good Laboratory Practices” or “GLP” means current Good Laboratory Practices as specified in the United States Code of Federal Regulations at
21 CFR § 58 at the time of testing and all applicable ICH guidelines. 

  

	1.55	“Governmental Authority” means any court, agency, department or other instrumentality of any national, federal, state, county, city or other political
subdivision. 

  

	1.56	“Health Registration Approval” means, with respect to a country, any and all approvals, licences, registrations or authorisations (including
supplements and amendments) of any national, supra-national (e.g., European Commission or the Council of the European Union or its equivalent), regional, state or local health or regulatory authority, agency, department, bureau, commission, council
or other governmental entity, necessary to commercially manufacture, distribute, sell or market the Product or a Combination Product in such country, including, where applicable, (a) pricing and reimbursement approval in such country,
(b) pre- and post-approval marketing authorisations (including any prerequisite manufacturing approval or authorisation related thereto), (c) labelling approval and (d) technical, medical and scientific licences.

  

	1.57	“IND” means an Investigational New Drug application with the FDA or its foreign equivalent application or filing filed with an equivalent agency or
Governmental Authority outside of the United States (including any supra-national agency such as in Europe) necessary to Commence human clinical trails in such jurisdiction, and consistent with all regulations at 21 CFR § 312 et. seq. and
equivalent foreign regulations. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 8 of 103

  

	1.58	“Indemnification Claim Notice” has the meaning set forth in Section 19.4. 

 

	1.59	“Indemnified Party” means a Party seeking to recover a Loss under Section 19.1 or 19.2. 

 

	1.60	“Indemnifying Party” means a Party from whom recovery of a Loss is sought under Section 19.1 or 19.2 

 

	1.61	“Indemnitee” has the meaning set forth in Section 19.4. 

 

	1.62	“Indication” means the treatment of Asthma, COPD, or any other disease or condition that the Parties agree, by amendment to this Agreement, to include
within the Field. 

  

	1.63	“Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar taxes. 

 

	1.64	“Information” means all technical, scientific and other information, trade secrets, patents and other legal information or descriptions, knowledge,
technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results
and other material, including: high-throughput screening, gene expression, genomics, proteomics and other drug discovery and development technology; biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical,
pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and protocols; assays and biological methodology; manufacturing and quality control procedures and data, including test procedures; and
synthesis, purification and isolation techniques, (whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed. 

 

	1.65	“Infringement Suit” has the meaning set forth in Section 14.5. 

 

	1.66	“IP” has the meaning set forth in Section 20.9. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 9 of 103

  

	1.67	“ISS” means any synthetic oligonucleotide sequence or chimeric oligonucleotide sequence that modulates an immune response and is a TLR-9 agonist,
including, but not limited to, such sequences referred to by Dynavax as immunostimulatory sequences, chimeric immunomodulatory compounds and branched immunomodulatory compounds. 

 

	1.68	“Joint Project Team” or “JPT” means the joint team established by the Parties pursuant to Article 4 to manage the day-to-day work
within the Joint Research Programme. 

  

	1.69	“Joint Research Plan” means the project plan that outlines the Joint Research Programme and each Party’s obligations thereunder, including the
allocation of FTEs by Dynavax, as further described in Section 3.3. 

  

	1.70	“Joint Research Programme” means the research programme described in the Joint Research Plan. 

 

	1.71	“Joint Research Programme Milestones” has the meaning set forth in Section 9.3. 

 

	1.72	“Joint Steering Committee” or “JSC” means the joint committee established by the Parties pursuant to Article 4 to oversee, manage
and steer the Joint Research Programme during the Collaboration Term. 

  

	1.73	“Know-How” means any non-public, proprietary Information and other data, instructions, processes, methods, formulae, materials, expert opinions and
information, including without limitation, biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information. Know-How does not include any rights
under Patents. 

  

	1.74	“Knowledge” means the knowledge, information or belief of any officer, or of any employee with the title of Global Vice President, Senior Scientist or
higher, of either Dynavax or AstraZeneca, as the case may be, after each of them has made reasonable inquiry into the relevant subject matter. 

  

	1.75	“Lead Candidate” means a Dynavax ISS or Collaboration ISS that, in accordance with the Joint Research Plan, has been [ * ] at the time of
its Lead Candidate Development Decision for further preclinical evaluation. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 10 of 103

  

	1.76	“Lead Candidate Development Decision” means the internal process, known by [ * ], by which [ * ]. 

 

	1.77	“Lead CD” means the CD nominated by AstraZeneca for Development and Commercialisation. 

 

	1.78	“Lead Research Candidate” means a Dynavax ISS or Collaboration ISS that has been [ * ] for further research. 

 

	1.79	“Losses” means any and all liabilities, claims, demands, causes of action, damages, loss and expenses, including interest, penalties, and reasonable
lawyers’ fees and disbursements. 

  

	1.80	“MAA” means a Marketing Authorization Application filed with the European Medicines Agency (known as the EMEA), or any substantial equivalent of such
application or entity. 

  

	1.81	“Major Markets” means [ * ]. 

  

	1.82	“NDA” means a New Drug Application (or other application for initial Health Registration Approval) filed with the FDA or the equivalent application or
filing filed with any equivalent Governmental Authority outside of the United States necessary for approval of a drug or biologic in such jurisdiction. 

  

	1.83	“Net Sales” means, with respect to the Product and/or any Combination Product (subject to Section 10.2 below), the gross invoiced amount on sales
of the Product or Combination Product by AstraZeneca, its Affiliates or their permitted Sublicensees to Third Parties (including Distributors) after deduction of (a) normal and customary trade, quantity or prompt settlement discounts (including
chargebacks and allowances) actually allowed; (b) amounts actually repaid or credited by reason of rejection, returns or recalls of goods, rebates or bona fide price reductions determined by AstraZeneca or its Affiliates in good faith;
(c) rebates and similar payments made with respect to sales paid for by any governmental or regulatory authority such as, by way of illustration and not in limitation of the Parties’ rights hereunder, Federal or state Medicaid, Medicare or
similar state program in the United States or equivalent governmental program in any other country; (d) [ * ] as an allowance for transportation costs, distribution expenses, special packaging and related insurance

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 11 of 103

  

	 	
charges; (e) any invoiced amounts which are not collected by AstraZeneca or its Affiliates, including bad debts; (f) excise taxes, Indirect Taxes, customs duties, customs levies and
import fees actually imposed on the sale, importation, use or distribution of the Product or Combination Product as applicable; and (g) any other similar and customary deductions that are consistent with generally accepted accounting
principles, or in the case of non-United States sales, other applicable accounting standards. Net Sales shall be calculated using AstraZeneca’s internal audited systems used to report such sales as adjusted for any of items (a) to
(g) above not taken into account in such systems. Deductions pursuant to subsection (e) above shall be taken in the calendar quarter in which such sales are no longer recorded as a receivable. 

 

	1.84	“Parties” means collectively AstraZeneca and Dynavax and “Party” means individually either of AstraZeneca or Dynavax.

  

	1.85	“Patents” means (a) all issued unexpired national, regional and international patents and (including inventor’s certificate) that has not
been held invalid or unenforceable by a court of competent jurisdiction from which no appeal can be taken or has been taken within the required time period; (b) all national, regional and international patent applications, including provisional
patent applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals, continuations,
continuations-in-part, provisionals, converted provisionals, and continued prosecution applications, (c) any and all unexpired patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including
utility models, petty patents and design patents and certificates of invention, (d) any and all substitutions, extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, renewal,
re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)), and (e) any similar rights, including so-called pipeline protection, or
any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications and patents. 

 

	1.86	“Payments” has the meaning set forth in Section 11.1. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 12 of 103

  

	1.87	“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability
company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or agency of a government. 

 

	1.88	“Phase I Trial” means a clinical trial that generally provides for the first introduction into humans of the Lead CD or any CD to be incorporated into
a Combination Product with the primary purpose of determining safety, metabolism and pharmacokinetic properties and clinical pharmacology of the relevant CD, and generally consistent with 21 CFR § 312.21(a). 

 

	1.89	“Phase II Trial” means a clinical trial of the CD or any CD to be incorporated into a Combination Product on patients, including possibly
pharmacokinetic studies, the principal purpose of which is to make a preliminary determination that such CD is safe for its intended use and to obtain sufficient information about the CD’s efficacy to permit the design of further clinical
trials, and generally consistent with 21 CFR § 312.21(b). 

  

	1.90	“Phase III Trial” means a clinical trial that provides for a pivotal human clinical trial of the Product or a Combination Product, which trial is
designed to: (a) establish that the Product or Combination Product is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the Product or Combination Product in the
dosage range to be prescribed; (c) support Health Registration Approval of such Product or Combination Product; and (d) generally consistent with 21 CFR § 312.21(c). 

 

	1.91	“Phase IV Trial” means a clinical trial of the Product or any Combination Product Commenced in a particular country after Health Registration Approval
for such Product or Combination Product in such country in order to support Commercialization of the Product or Combination Product, as appropriate. 

  

	1.92	“Primary ISS” means, in accordance with the Joint Research Plan, [ * ] Dynavax ISS or Collaboration ISS selected [ * ].

  

	1.93	“Primary Screening Phase” means, in accordance with the Joint Research Plan, the [ * ]. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 13 of 103

  

	1.94	“Product” means a pharmaceutical preparation [ * ]. 

 

	1.95	“Project Leader” means a Party’s representative with responsibility for the activities set forth in Section 4.3. 

 

	1.96	“Prosecuting Party” has the meaning set forth in Section 14.2.2. 

 

	1.97	“Receiving Party” has the meaning set forth in Section 13.1.1. 

 

	1.98	“Regents” has the meaning set forth in Section 10.5.1. 

 

	1.99	“Regulatory Authority” means any Governmental Authority with responsibility for granting any licenses or approvals necessary for the marketing and sale
of pharmaceutical products including, without limitation, the FDA and any drug regulatory authority of countries of Europe, and Japan, and where applicable any ethics committee or any equivalent review board. 

 

	1.100	“Regulatory Documentation” means, with respect to the Product or Combination Product, all Regulatory Filings and supporting documents created,
submitted to the FDA or any equivalent agency or government authority outside of the United States (including any supra-national agency such as in Europe) relating to such Product or Combination Product, and all data contained therein, including,
without limitation, any IND(s), NDA(s), MAA(s), Biological Licence Applications (BLA(s)), Investigator’s Brochures, DMF, correspondence to and from the FDA or any equivalent agency or Governmental Authority outside of the United States, minutes
from teleconferences with Regulatory Authorities, registrations and licenses, regulatory drug lists, advertising and promotion documents shared with Regulatory Authorities, adverse event files, complaint files and manufacturing records.

  

	1.101	“Regulatory Filing” means the NDA, MAA, BLA, IND, or any foreign counterparts thereof and any other filings required by regulatory authorities relating
to the study, manufacture or Commercialization of the Product or any Combination Product. 

  

	1.102	“Research” means, with respect to a particular Dynavax ISS or Collaboration ISS, Product or Combination Product, the research and preclinical
development activities undertaken in the Joint Research Programme up to and including the acceptance by the appropriate Regulatory Authority of an IND covering such Dynavax ISS, Collaboration ISS, Product or Combination Product (or first human
dosing if done without an IND). 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 14 of 103

  

	1.103	“Research Budget” means the funding to be provided by AstraZeneca to Dynavax in relation to the Joint Research Programme as specified in
Section 3.3. 

  

	1.104	“Research Budget Variance” means any variance to the Research Budget as set out in the Research Plan that is permitted without further agreement of the
Parties, and which variance shall not exceed [ * ] of the agreed research Budget. 

  

	1.105	“Research Term” has the meaning set forth in Section 3.2. 

 

	1.106	“Reverted ISS” means an ISS that once was a Dynavax ISS or Collaboration ISS but that was not prioritized or selected for further Research in
accordance with Section 3.10, or reverted in accordance with Sections 3.12.2 or 8.12, thereby reverting to Dynavax for use outside the Field and no longer subject to the Joint Research Programme. 

 

	1.107	“Round One Optimization Candidates” means, in accordance with the Joint Research Plan, those Collaboration ISS that are [ * ] using [ *
]. 

  

	1.108	“Round Two Optimization Candidates” means, in accordance with the Joint Research Plan, those Collaboration ISS that are [ * ], using [ *
]. 

  

	1.109	“Royalty-Bearing Claim” means, with respect to a Dynavax Patent or a Collaboration Patent: (a) [ * ], or (b) [ * ].

  

	1.110	“Royalty Term” has the meaning set forth in Section 10.8. 

 

	1.111	“Second Indication” means the second Indication in which AstraZeneca obtains a Health Registration Approval in respect of the Product or a Combination
Product. 

  

	1.112	“Secondary Screening Phase—Stage 1” means, in accordance with the Joint Research Plan, the [ * ]. 

 

	1.113	“Secondary Screening Phase—Stage 2” means, in accordance with the Joint Research Plan, the [ * ]. 

 

	1.114	“Sequence Modify” or “Sequence Modification” means to modify an ISS by changing, adding to, or subtracting from the [ * ].

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 15 of 103

  

	1.115	“Sublicensee” means any Person, other than an Affiliate or a Party, to which such Party has granted a sublicense under this Agreement.

  

	1.116	“Term” means the period beginning on the Effective Date and continuing until the earlier of the date upon which this Agreement expires by its terms or
is terminated in accordance with Article 20. 

  

	1.117	“Territory” means all countries in the World, except those countries in respect of which this Agreement has been terminated, pursuant to this
Agreement. 

  

	1.118	“Third Indication” means the third Indication in which AstraZeneca obtains a Health Registration Approval in respect of the Product or a Combination
Product. 

  

	1.119	“Third Party” means any Person not including the Parties, the Parties’ respective Affiliates or the Sublicensees. 

 

	1.120	“Third Party Claims” has the meaning set forth in Section 19.1. 

 

	1.121	“TLR-9” means toll-like receptor 9. 

  

	1.122	“Triggering Event” has the meaning set forth in Section 6.4.2. 

 

	1.123	“Valid Claim” means, with respect to a particular country, either: 

 

	 	1.123.1	any Royalty-Bearing Claim of a granted and unexpired Dynavax Patent and/or Collaboration Patent in such country that (a) has not been held permanently revoked,
unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal, and (b) has not been abandoned, disclaimed, denied or
admitted to be invalid or unenforceable through reissue or disclaimer or otherwise; or 

  

	 	1.123.2	a Royalty-Bearing Claim of a pending Dynavax Patent and/or Collaboration Patent application, which claim was filed and is being prosecuted in good faith and has not
been abandoned or finally disallowed without the possibility of appeal or re-filing of the application, provided that such application has not been pending for more than five (5) years. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 16 of 103

  

	2	Construction 

 Except
where the context requires otherwise, whenever used the singular includes the plural, the plural includes the singular, the use of any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the
phrase “and/or.” Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The headings of this Agreement are for convenience of reference only and do not define, describe, extend
or limit the scope or intent of this Agreement or the scope or intent of any provision contained in this Agreement. The term “including” or “includes” as used in this Agreement means including, without limiting the generality of
any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no rule of strict construction shall be applied against any Party. 

 

	3	Conduct of the Joint Research Programme 

  

	3.1	Overview .The objective of the Joint Research Programme shall be to identify and select for development, manufacture, and commercialization one Product and/or
Combination Product(s) based on one or more Candidate Drugs. As described in greater detail in the Joint Research Plan and this Article 3, Dynavax will identify and propose to AstraZeneca a pool of [ * ] Dynavax ISS representing each of the
three major classes of ISS. Thereafter, the Parties will engage in [ * ] primary and [ * ] secondary screening phases to optimize and select [ * ] Lead Candidate and [ * ]. After further characterization of the Lead
Candidate, a Lead Candidate Drug shall be selected for clinical development. The Parties may agree to conduct [ * ], will each consist of the synthesis and selection of [ * ] Dynavax ISS or Collaboration ISS, in each such optimization
phase. All decisions to select molecules for advancement or development shall be [ * ], subject to the terms of this Agreement; provided, however, that [ * ], or perform Research or Development on any ISS other than the Dynavax ISS or
the Collaboration ISS, selected for Research and Development pursuant to this Agreement. In conducting the foregoing work, Dynavax shall have no obligation to identify or present an ISS for inclusion in the Joint Research Programme if such ISS is
then currently under research in a separate Dynavax programme or is then currently subject to rights of a Third Party. 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 17 of 103

  

	3.2	Research Term. The research term (the “Research Term”) shall commence on the Effective Date and shall continue until the earlier of (a) the
third anniversary of the Effective Date or such later date as AstraZeneca may specify pursuant to this Section 3.2, and (b) the effective date of any termination of this Agreement pursuant to Article 20. The FTE funding commitments of
AstraZeneca set forth in Section 3.3 and the payment obligations of AstraZeneca set forth in Section 7.1 shall remain in force until the end of the Research Term. The Research Term may be extended by [ * ] no more than [ * ]
upon written agreement between the Parties at least [ * ] prior to the end of the third year or the relevant extension period thereof. 

  

	3.3	Joint Research Plan. The Joint Research Plan has been approved by the Parties concurrent with the execution of this Agreement. The Parties acknowledge and agree
that the Joint Research Plan attached hereto as Exhibit C sets forth the goals and objectives of the Joint Research Programme and the broad terms of the Parties’ respective undertakings to achieve those goals and objectives. The Joint
Research Plan will be reviewed and (if required) amended by the JSC (subject to Section 4.11) annually or from time to time during the Research Term to identify and define the specific undertakings of the Parties and the associated costs and
expenses required to implement the Joint Research Programme. In the event of any inconsistency or disagreement between a Joint Research Plan and this Agreement, the terms of this Agreement shall prevail. 

 

	3.4	Research Effort and Support. Dynavax shall supply [ * ] FTEs during each of the first [ * ] contract years of the Research Term and [ * ]
FTEs during the [ * ] contract year of the Research Term, unless otherwise mutually agreed by the Parties. Changes in such level of effort may be at the discretion of the JSC (subject to Section 4.11), provided Dynavax receives at least
[ * ] months prior notice of any change in the maximum level of FTEs provided hereunder. The JSC shall not be entitled to give notice of its intention to change the level of FTE effort within the first [ * ] months of the Research
Term. The Parties acknowledge that Dynavax may provide increasing level of technical assistance for the transfer of certain technology to AstraZeneca or its designee during the [ * ] contract year of the Research Term, which may lead the
number of FTEs to be provided by Dynavax in that time period to be increased by the Parties’ mutual agreement. In the event of an extension of the Research Term, the Parties shall agree at that time on the number of FTEs that Dynavax shall
supply in 

  
 [ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 18 of 103

  

	 	
such extension period of the Research Term. AstraZeneca shall fund such FTEs as set forth in Section 7.1. AstraZeneca understands and agrees that Dynavax retains complete discretion to alter
and reallocate the individuals who compose such FTEs and to alter the frequency and time which any individual devotes to the Joint Research Programme, provided that all such FTEs are appropriately skilled to perform the Joint Research Programme. All
scientific work on or directly related to the Joint Research Programme performed by such individuals shall count towards the fulfilment of Dynavax’s FTE commitment pursuant to this Section 3.4. Such work may include, but is not limited to,
experimental laboratory work, recording and writing up results, reviewing literature and references, holding scientific discussions, organizing and attending scientific meetings and conferences, managing and leading scientific staff, and carrying
out Joint Research Programme management duties (including service on the JPT). All JSC pre-approved external costs, if any, incurred by Dynavax in connection with its performance of its obligations under the Joint Research Programme throughout the
Research Term, to the extent not included in the FTE Rate, shall be separated invoiced by Dynavax to AstraZeneca and reimbursed by AstraZeneca pursuant to Section 7.2. The Parties acknowledge that the FTE Rate does not include the costs or
expenses of [ * ]. 

  

	3.5	Conduct of Research. 

  

	 	3.5.1	Commercially Reasonable Efforts. The Parties shall use Commercially Reasonable Efforts to conduct their respective tasks as assigned under the Joint Research
Plan, provided that Dynavax shall not be obligated to devote any resources to the Joint Research Programme in excess of the FTEs funded by AstraZeneca pursuant to Section 3.4. In addition, during the Research Term and under the direction and
supervision of the JSC, each Party shall (a) perform or cause to be performed its obligations under the Joint Research Programme in good scientific manner and in compliance in all material aspects with all Applicable Law, and (b) allocate
sufficient time, effort, equipment and skilled personnel to complete such activities successfully and promptly. 

  

	 	3.5.2	Facilities and Personnel. The Parties shall provide facilities, equipment and manpower that are reasonably necessary or useful to carry out the work to be

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 19 of 103

  

	 	
undertaken under the Joint Research Programme. Each of the Parties may perform or cause to be performed its obligations under the Joint Research Programme at its own facilities or at those of its
permitted subcontractors and Sublicensee(s), listed in Exhibit D, as applicable. 

  

	 	3.5.3	Use of Animals. Insofar as the Joint Research Programme involves the use of animals, each of AstraZeneca and Dynavax shall conduct all activities pursuant to the
Joint Research Programme in accordance with any local laws and regulations applicable to the facility in which such activities occur and in accordance with the AstraZeneca policy on such use applicable at the Effective Date, a copy of which has been
provided to Dynavax. 

  

	 	3.5.4	Subcontracting. Each Party shall be solely responsible for successfully completing its activities set forth in the Joint Research Plan. The Parties shall conduct
and carry out all activities provided for under the Joint Research Programme through its employees at the site(s) identified under Section 3.5.2 unless and only to the extent the JSC approves the Party’s engaging a subcontractor to carry
out a portion of such Research activities or, if applicable, approves a major outsourcing or collaboration agreement with a Third Party. Notwithstanding the foregoing, as of the Effective Date, each of Dynavax and AstraZeneca have agreed that
Dynavax may engage the Persons listed on Exhibit D to perform the specified activities of Dynavax under the Joint Research Plan. Any permitted subcontractor shall be subject to the applicable terms and conditions of this Agreement, including
Articles 6 and 13, and, upon a Party’s request, the other Party shall require each such subcontractor to enter into an undertaking, pursuant to which the terms and conditions of this Agreement shall apply directly between such subcontractor and
AstraZeneca or Dynavax, as applicable, prior to disclosing to such subcontractor any of the other Party’s Confidential Information; provided, however, that the subcontracting Party shall remain ultimately responsible for the performance of its
obligations under this Agreement. The costs incurred by Dynavax in subcontracting activities under the Joint Research 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 20 of 103

  

	 	
Programme shall be borne by Dynavax, except as provided in the following two sentences. All JSC pre-approved external costs, if any, incurred by Dynavax in connection with its performance of its
obligations under the Joint Research Programme throughout the Research Term, to the extent not included in the FTE Rate, shall be separately invoiced by Dynavax to AstraZeneca and reimbursed by AstraZeneca pursuant to Section 7.2. The Parties
acknowledge that the FTE Rate does not include the costs or expenses of [ * ]. 

  

	3.6	Materials and Information Transfer. Each Party shall, and shall cause its Affiliates to, [ * ], to the extent that they are legally permitted so to do,
(a) provide to the other Party the materials or equipment specified from time to time in this Agreement or the Joint Research Plan, and (b) disclose and make available to the other Party, in whatever form such Party may reasonably request,
all Background Technology and Collaboration Technology relating, directly or indirectly, to the Joint Research Programme, immediately after the Effective Date and thereafter immediately upon the earlier of the conception or reduction to practice,
discovery, development or making of such Background Technology and Collaboration Technology. All such Background Technology and Collaboration Technology shall be used by the receiving Party only as permitted under the applicable license rights
granted under Article 6 and subject to all other restrictions and obligations under this Agreement. Except as otherwise provided under this Agreement, all such Background Technology delivered to the other Party will remain the sole property of the
supplying Party, will be used only in furtherance of and in accordance with this Agreement, and together with the Collaboration Technology will not be used or delivered to or for the benefit of any Third Party without the prior written consent of
the supplying Party, and will be used in compliance with all Applicable Law, will be provided without any warranties, express or implied and the Party providing them shall obtain (or cause its Third Party collaborators to obtain or certify that they
have obtained) all appropriate and required consents from the source of such Background Technology and Collaboration Technology. The Background Technology and Collaboration Technology supplied under this Agreement shall be used with prudence and
appropriate caution in any experimental work because not all of their characteristics may be known. Without prejudice to the generality of the foregoing, if visits of either Party’s representatives to the other Party’s facilities are
reasonably requested for purposes of transferring the Background Technology and Collaboration Technology to such Party or for purposes of such requesting Party to acquire expertise on the practical application of the Background Technology and
Collaboration Technology or assisting on issues arising 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 21 of 103

  

	 	
during the Research, the other Party will send appropriate representatives to the requesting Party’s facilities, provided that the requesting Party shall reimburse the other Party for its
reasonable and verifiable expenses of travel and accommodations for such representatives. 

  

	3.7	Cooperation. Each Party shall cooperate with any and all reasonable requests for assistance from the other Party with respect to the activities under the Joint
Research Programme, including by making its employees, consultants and other scientific staff available upon reasonable notice during normal business hours at their respective places of employment to consult with such other Party on issues arising
in connection with the Joint Research Programme. 

  

	3.8	Regulatory Records. Dynavax and AstraZeneca each shall maintain, or cause to be maintained, records of its respective activities under the Joint Research
Programme in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall be complete and accurate and shall fully and properly reflect all work done and results achieved in the performance of its
respective activities under the Joint Research Programme, and which shall be retained by such Party for at least [ * ] years after the termination of this Agreement, or for such longer period as may be required by Applicable Law. Subject to bona
fide confidentiality obligations to a Third Party, each Party shall have the right, during normal business hours and upon reasonable notice, to inspect and copy any such records to the extent necessary for such Party to conduct its Research or
perform its other obligations under this Agreement, or to secure or enforce Patents licensed under this Agreement. 

  

	3.9	Reports. Each Party assigned an obligation under the Joint Research Programme shall report to the JPT no less than [ * ], which report shall include a written
progress report summarizing the work performed under the Joint Research Programme. The JPT shall define the format and the nature of the content of the [ * ] report, which format and nature shall be adopted by both Parties. 

 

	3.10	Lead Candidate Development Decision. 

 It is the objective of the Parties that [ * ] will be able to [ * ] within [ * ] days after the prioritization of the Lead Research Candidate and [ * ] thereto, whereby [ * ] will [ * ]. Upon written
notice of such selection, the Parties shall conduct further 
  
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

  
 Page 22 of 103

  

 
research and characterization of the Lead Candidate with the objective of determining whether the Lead Candidate satisfies the criteria as a Candidate Drug, as specified in Exhibit A,
together with any necessary further research and characterization of [ * ] by AstraZeneca as may reasonably be necessary, as determined by [ * ], to establish the relative merits of the selected Lead Candidate [ * ] so as to enable AstraZeneca to
progress one such candidate to CD Nomination. The Parties may agree to extend any particular phase of the Joint Research Plan. 
  

	3.11	CD Nomination. 

 It is
noted that [ * ] has the right, but not the obligation, to nominate all of the Lead Candidate [ * ] as CD’s pursuant to this Agreement. The first CD nominated shall be designated as the Lead CD and subject to the right to replace such CD as
specified in Section 8.10 below, all subsequent Development or Commercialisation by AstraZeneca pursuant to this Agreement shall be directed at such Lead CD. 
  

	3.12	Overview of Joint Research Programme  

  

	 	3.12.1	The Joint Research Programme shall be conducted in accordance with the Joint Research Plan attached as Exhibit C hereto. Once a Dynavax ISS or a Collaboration
ISS is designated a Candidate Drug [ * ], no further work shall be performed upon it pursuant to the Joint Research Programme, provided, however, if AstraZeneca desires Dynavax to perform further work on such Candidate Drug [ * ], Dynavax shall [ *
], provided that the Parties [ * ]. 

  

	 	3.12.2	All rights to any Dynavax ISS or Collaboration ISS, other than the Candidate Drug [ * ], not selected for advancement in the Joint Research Programme shall revert
immediately to Dynavax, and shall thereafter be Reverted ISS. 

  

	3.13	Selection of Compounds.The Parties acknowledge that [ * ] shall have the right in its sole discretion at any time during or after the Research Term, to determine
which, if any, Dynavax ISS or Collaboration ISS to select for further Research and selection for CD Nomination and which CD to select for further Research, Development and Commercialization, under this Agreement. [ * ] shall without delay notify in
writing [ * ], as applicable, of any such selections and decisions. For clarity, nothing in this Section 3.13 shall limit Dynavax’s rights to Reverted ISS. In particular, AstraZeneca shall have no rights to select a Reverted ISS for
further Research, Development or Commercialization under this Agreement. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 23 of 103

  

	4	Support and Management of the Joint Research Programme 

  

	4.1	Overview of the Management of the Joint Research Programme. The collaboration established by this Agreement shall be overseen by a Joint Steering Committee and a
Joint Project Team, each of which, shall be established by the Parties after the Effective Date. Without limiting anything set forth in this Article 4, the Joint Steering Committee shall manage and steer the overall Collaboration and the Joint
Project Team shall manage the day-to-day work within the Joint Research Programme during the Research Term. Following the CD Nomination Date, the Parties shall establish an Advisory Board to advise AstraZeneca in its Development and
Commercialization of the CD, Product or any Combination Product. 

  

	4.2	Responsibilities of JPT. The Parties shall establish a Joint Project Team (the “JPT”) within ten (10) days following the Effective Date which
shall be responsible for managing the day-to-day work within the Joint Research Programme and which shall report to the JSC. In particular, the responsibilities of the JPT shall include: 

 

	 	4.2.1	proposing the strategic research goals and directions for the Joint Research Programme; 

 

	 	4.2.2	preparing and proposing milestones, go/no go criteria and criteria for evaluation of the Joint Research Programme; 

 

	 	4.2.3	proposing the Joint Research Plan, Research Budget, Research Budget Variance and any amendments thereto; 

 

	 	4.2.4	monitoring the progress of the Joint Research Programme; 

  

	 	4.2.5	monitoring workflow and proposing the allocation of resources for carrying out the Joint Research Programme; 

 

	 	4.2.6	proposing priorities for the Joint Research Programme and in view of the capacities of the Parties; 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 24 of 103

  

	 	4.2.7	proposing prioritisation criteria for specific components under the Joint Research Programme, including setting proposed dates for experimental initiation and
completion of each stage of the Joint Research Programme; 

  

	 	4.2.8	approving the Candidate Drug Target Profile using the criteria set forth in Exhibit A; 

 

	 	4.2.9	[ * ]; 

  

	 	4.2.10	[ * ]; 

  

	 	4.2.11	developing and proposing updates of the Joint Research Programme; 

  

	 	4.2.12	proposing any subcontractor or major outsourcing and/or collaboration agreements with Third Parties as appropriate; 

 

	 	4.2.13	proposing a publications strategy and preparing and proposing specific items related to the Joint Research Programme for publication; and 

 

	 	4.2.14	preparing and monitoring budgets for the Joint Research Programme in discussion with the JSC. 

 

	4.3	Formation of JPT. The JPT shall consist of [ * ] members who are employees of either Dynavax or AstraZeneca or their Affiliates, as applicable, with the
requisite experience and seniority to enable them to make proposals on behalf of the Parties with respect to the Joint Research Programme, with equal numbers appointed by each respective Party, which shall include a Project Leader to be designated
by each Party. The Project Leaders shall each be responsible for all day-to-day Joint Research Programme activities undertaken by the appointing Party and shall supervise and coordinate the work of all personnel engaged by each Party in the Joint
Research Programme. Notwithstanding the foregoing, each Party shall continue to be responsible for performing the activities undertaken by it under the Joint Research Programme. Each Party shall have the right to replace its respective JPT
representatives upon written notice to the other Party, provided that any such substitute representative shall be an employee of such Party or its Affiliates and shall have substantially the equivalent experience and seniority as the representative
that such person replaces. Representatives of each Party other than the members of the JPT may attend JPT meetings at the invitation of either Party with the prior approval of the other Party, which approval shall not be unreasonably withheld.

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 25 of 103

  

	4.4	JPT Meetings. The JPT shall meet at least monthly and more frequently when required. The first JPT meeting will be held within twenty (20) days after the
Effective Date and thereafter meetings will be held alternately at the offices of Dynavax and AstraZeneca unless the Parties agree on another location, or by teleconference or videoconference. A quorum of the JPT shall exist whenever there is
present at a meeting each of the Project Leaders or their respective designees. The Project Leaders shall act as co-chairs for JPT meetings. In addition, the JPT may act without a formal meeting by a written memorandum signed by the Project Leaders.
The JPT may also invite other personnel of the Parties to attend meetings of the JPT as appropriate to the agenda for such meeting, after giving notice to the other Party. Whenever any action by the JPT is required hereunder during a time period in
which the JPT is not scheduled to meet, either Project Leader shall have the right to call a special meeting or the Project Leaders may cause the JPT to take the action without a meeting in the applicable time period. Any such additional meetings
shall be held at places and on dates selected by the Project Leaders. The JPT may by unanimous consent, amend or expand upon the foregoing procedures for its internal operations. 

 

	4.5	JPT Decision Making : Disputes. All decisions of the JPT made pursuant to this Agreement shall be made by unanimous consent of its members. If for any reason the
JPT cannot reach unanimity regarding a particular matter, then, such matter shall be resolved in a second meeting to be held within twenty (20) Business Days from the meeting in which the disputed matter has remained unresolved. In the event
that the JPT is again unable to resolve the matter the disputed matter shall be promptly referred to the JSC for resolution. 

  

	4.6	JPT Minutes. The JPT shall keep accurate minutes of its deliberations, which minutes shall record all proposed decisions and all actions recommended or taken.
Drafts of minutes shall be delivered to the Project Leaders within twenty (20) days after the respective meeting. The Parties, on an alternating basis, shall prepare and circulate the draft minutes. Draft minutes shall be edited by the Project
Leaders and shall be issued in final form only with the approval and agreement of the Project Leaders. 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 26 of 103

  

	4.7	Dissolution of JPT . Following the termination or expiration of the Research Term the JPT shall be dissolved. 

 

	4.8	Responsibilities of JSC. The Parties shall establish a Joint Steering Committee (the “JSC”) within ten (10) days following the Effective
Date, to oversee the initiation, planning and performance of the activities under the Joint Research Programme based on the proposals and activities of the JPT. In particular, the responsibilities of the JSC shall include: 

 

	 	4.8.1	approving the strategic research goals and direction for the Joint Research Programme; 

 

	 	4.8.2	approving the go/no go criteria and criteria for evaluation of the Joint Research Programme; 

 

	 	4.8.3	reviewing and approving the Research Project Plan, Research Budget, Research Budget Variance and any amendments thereto; 

 

	 	4.8.4	approving workflow and the allocation of resources for carrying out the Joint Research Programme taking into account each Party’s respective specific capabilities
and expertise in order to avoid duplication and enhance efficiency and synergies; 

  

	 	4.8.5	approving priorities for the Joint Research Programme and capacities of the Parties; 

 

	 	4.8.6	approving prioritisation criteria for specific components under the Joint Research Programme, including setting proposed dates for experimental initiation and
completion of each stage of the Joint Research Programme; 

  

	 	4.8.7	monitoring and ensuring timely execution of the Joint Research Programme, including compliance with budgets and timelines; 

 

	 	4.8.8	determining within [ * ] days of the completion of each stage of the Joint Research Programme whether the completion thereof has been successful and deciding whether or
not to continue the Joint Research Programme into the next stage (i.e., making “stop/go decisions”); 

  

	 	4.8.9	[ * ] 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 27 of 103

  

	 	4.8.10	[ * ] 

  

	 	4.8.11	approving any significant changes to the staffing (FTE) levels or the funding of the Joint Research Programme; 

 

	 	4.8.12	approving any subcontractors or major outsourcing and/or collaboration agreements with Third Parties as appropriate; 

 

	 	4.8.13	ensuring timely and appropriate support in the filing of Patent applications; 

 

	 	4.8.14	approving the publications strategy and approving specific items for publication (including but not limited to articles, presentations and press releases);

  

	 	4.8.15	resolving any issues that could not be resolved by the JPT; and 

  

	 	4.8.16	taking all other significant management decisions relating to the Joint Research Programme. 

 

	4.9	Formation of JSC. The JSC shall consist of [ * ] members who are employees of Dynavax or AstraZeneca or their Affiliates, as applicable, with the
requisite experience and seniority to enable them to make decisions on behalf of the Parties with respect to the Joint Research Programme, with equal numbers appointed by the respective Party, which shall include an Alliance Manager to be designated
by each Party. The Alliance Managers shall each be responsible for supervising and coordinating the activities of the JPT and JSC pursuant to the Joint Research Programme. The Alliance Managers shall serve as the primary contacts for the Parties on
all matters related to the Joint Research Programme. Notwithstanding the foregoing, each Party shall continue to be responsible for performing the activities undertaken by it under the Joint Research Programme. Each Party shall have the right to
replace its respective JSC representatives upon written notice to the other Party, provided that any such substitute representative shall be an employee of such Party or its Affiliates and shall have substantially the equivalent experience and
seniority as the representative that such person replaces. Representatives of each Party other than the members of the JSC may attend JSC meetings at the invitation of either Party with the prior approval of the other Party, which approval shall not
be unreasonably withheld. From time to time, the JSC may establish subcommittees or subordinate 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 28 of 103

  

	 	
committees (that may or may not include members of the JSC itself) to oversee particular projects or activities, and such subcommittees or subordinate committees shall be constituted and shall
operate as the JSC agrees. 

  

	4.10	JSC Decision Making; Disputes. All decisions of the JSC made pursuant to this Agreement shall be made by unanimous consent of the Parties, with each Party having
a single vote, irrespective of the number of representatives actually in attendance at a meeting. If for any reason the JSC cannot reach unanimity within [ * ] days following a JSC meeting at which a Party formally requests resolution
of such matter, then except as set forth in Section 4.11, the matter shall be referred to and resolved in good faith by the [ * ] of AstraZeneca and the [ * ] of Dynavax. Any final decision mutually agreed to by the
said senior managements of the Parties shall be in writing and shall be conclusive and binding on the Parties. If such resolution is unattainable by senior management within [ * ] days from the date the matter in dispute is first
brought to the attention of the senior management of the Parties, the dispute shall be [ * ]; provided, however, that, if [ * ], then [ * ]. 

 

	4.11	JSC Decisions Requiring Consent. Any [ * ] shall require the unanimous consent of the JSC. If the JSC fails to reach unanimous consent regarding
any such change to the Joint Research Programme, then [ * ]. In addition, neither Party shall have any right to make any changes to the Joint Research Plan relating to the Research of Dynavax ISS and/or Collaboration ISS that would
change the other Party’s [ * ], without the consent of the other Party. 

  

	4.12	JSC Meetings. Unless otherwise agreed, the JSC shall meet at least quarterly and more frequently when required. The first JSC meeting will be held within ninety
(90) days after the Effective Date and thereafter meetings will be held alternately at the offices of Dynavax and AstraZeneca unless the Parties agree on another location, or by teleconference or videoconference. A quorum of the JSC shall exist
whenever there is present at a meeting each of the Alliance Managers or their respective designees. A JSC representative for AstraZeneca shall chair the first JSC meeting and thereafter a JSC representative of the Party which is hosting such JSC
meeting at its offices, will chair such meeting. In addition, the JSC may act without a formal meeting by a written memorandum signed by the Alliance Managers. The JSC may also invite other personnel of the Parties to attend meetings of the JSC as
appropriate 

  
 [ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 29 of 103

  

	 	
to the agenda for such meeting, after giving notice to the other Party. Whenever any action by the JSC is required hereunder during a time period in which the JSC is not scheduled to meet, either
Alliance Manager shall have the right to call a special meeting or the Alliance Managers may cause the JSC to take the action without a meeting in the applicable time period. Any such additional meetings shall be held at places and on dates selected
by the Alliance Managers. The JSC may by unanimous consent, amend or expand upon the foregoing procedures for its internal operations. 

  

	4.13	JSC Minutes. The JSC shall keep accurate minutes of its deliberations, which minutes shall record all proposed decisions and all actions recommended or taken,
Joint Research Programme progress reports provided to the JSC pursuant to Section 5.1 , Collaboration Technology generated of interest in the Joint Research Programme and confirmation that Joint Research Programme Milestones have been reached.
In particular, all Dynavax ISS and Collaboration ISS [ * ] selected and/or nominated during the Research Term and any Candidate Drug selected therefrom, shall be recorded in the minutes of the JSC. Drafts of minutes shall be delivered to the
Alliance Managers within twenty (20) days after the respective meeting. The Parties, on an alternating basis, shall prepare and circulate the draft minutes. Draft minutes shall be edited by the Alliance Managers and shall be issued in final
form only with the approval and agreement of the Alliance Managers of both Parties. 

  

	4.14	Dissolution of JSC. Following the expiration or termination of the Research Term, the JSC shall be dissolved and Dynavax shall provide AstraZeneca with
consultation services as AstraZeneca may reasonably request for the continued Development and Commercialization of the Dynavax ISS and/or Collaboration ISS, the costs of which shall be managed in accordance with Section 8.9 below.

  

	4.15	Advisory Board. Within thirty (30) days following the CD Nomination Date, the Parties shall establish an Advisory Board, which shall consist of [ * ]
representatives of each Party and shall hold meetings no less frequently than every [ * ] months with the purpose of [ * ]. The Advisory Board shall [ * ] and its advice shall not in any way limit or restrict AstraZeneca’s rights and
obligations pursuant to Article 8. The Advisory Board shall meet in person at offices of Dynavax and AstraZeneca unless the Parties agree on another location, or by teleconference or videoconference. The Advisory Board may invite other personnel of
the Parties to attend meetings of the Advisory Board as appropriate after giving notice to the other Party. The Advisory Board shall dissolve upon the termination or expiration of this Agreement. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 30 of 103

  

	4.16	Expenses . Dynavax and AstraZeneca each shall bear all expenses of its JPT, JSC and Advisory Board members related to such members’ participation and
attendance at the JPT, JSC and/or Advisory Board meetings. 

  

	4.17	Access to Information. Each Party shall provide the JPT and JSC and their authorized representatives with reasonable access during regular business hours to all
records and documents of such Party that are specific to the Research or further Development of the Product or any Combination Product and that the JPT and JSC may reasonably require in order to perform their obligations hereunder, subject to any
bona fide obligations of confidentiality to a Third Party.  

  

	4.18	Joint Research Programme Guidelines. 

  

	 	4.18.1	General. In all matters related to the Joint Research Programme, the Parties shall be guided by [ * ], to further the Joint Research Programme and
[ * ]. 

  

	 	4.18.2	Independence. Subject to the terms of this Agreement, the activities and resources of each Party shall be managed by such Party, acting independently and in its
individual capacity. The relationship between Dynavax and AstraZeneca is that of independent contractors and neither Party shall have the power to bind or obligate the other Party in any manner, other than as is expressly set forth in this
Agreement. 

  

	5	Reports 

  

	5.1	Joint Research Programme Progress Reports. No later than [ * ] business days prior to each quarterly JSC meeting, the JPT shall prepare quarterly
update reports for presentation at JSC meetings. Such reports shall provide the JSC with a detailed written progress report in English containing information on the status of the Research efforts and any [ * ] and not previously
reported to the JSC. The JSC may provide further instructions on the timing and content of these reports. 

  

	5.2	Copyrights. Copyrights to reports provided for hereunder shall be jointly owned by the Parties. Neither Party shall, without the prior written approval of the
other Party, attribute to the other Party any abstract or interpretation of any such report for sales or promotion purposes. 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 31 of 103

  

	5.3	AstraZeneca Reports . Upon dissolution of the JSC pursuant to Section 4.14, AstraZeneca shall provide the Advisory Board with [ * ] progress
reports containing information on AstraZeneca Development and Commercialization activities in accordance with Sections 8.2 and 8.4. 

  

	6	Ownership and Grant of Rights  

  

	6.1	Ownership of Collaboration Technology. The Parties shall jointly own all Collaboration Technology, with each Party owning an undivided half interest in such
Collaboration Technology and, subject to the exclusive licences granted herein, each having the right to use and to license such Collaboration Technology for any purpose without a duty of accounting or obtaining consent from the other Party. Each
Party shall promptly disclose to the other Party in writing the development, making, conception or reduction to practice of any Collaboration Technology, and shall, and does hereby, assign, and shall cause its Affiliates and its and their employees
and agents, as applicable, to so assign, to such other Party, without additional compensation, such right, title and interest in and to any Collaboration Technology, as is necessary to fully effect the joint ownership provided for in the foregoing
sentence. 

  

	6.2	Licences to AstraZeneca. Subject to the terms of this Agreement, Dynavax hereby grants to AstraZeneca the following: 

 

	 	6.2.1	a worldwide, co-exclusive (with Dynavax), royalty-free license, without the right to sublicense except to Affiliates, under the Dynavax Technology solely to perform
AstraZeneca’s portion of the Research obligations under this Agreement with respect to any Dynavax ISS, Collaboration ISS, CD, Product and Combination Product in the Field and in the Territory; and 

 

	 	6.2.2	a worldwide, royalty bearing license, with the right to sublicense as set forth in Section 6.6, under the Dynavax Technology and Dynavax’s rights and interest
in the Collaboration Technology, to make, have made, use, offer for sale, sell and import the Product, and/or Combination Product(s) in the Field and in the Territory. The foregoing license shall be exclusive (even as to Dynavax) except that
AstraZeneca hereby acknowledges that Dynavax reserves the right to [ * ]. In the event that [ * ]. If Dynavax [ * ]. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 32 of 103

  

 Notwithstanding the above licences, it is noted that AstraZeneca shall have no right to
make, have made, use, offer for sale, sell and import the CDs or any products incorporating such CDs, outside of the Field in the Territory. 
 The Parties acknowledge that, at any time after the First Commercial Sale of the Product or a Combination Product, such Product or Combination Product may be used by end users outside the Field. The
Parties agree that such use shall not be deemed a breach by AstraZeneca of this Agreement, provided that AstraZeneca does not at any time, without the prior written consent of Dynavax, [ * ]. 

For the avoidance of doubt, the licenses granted to AstraZeneca in this Section 6.2 convey no rights with respect to any ISS
Controlled by Dynavax other than the Dynavax ISS and Collaboration ISS. 
  

	6.3	Licence to Dynavax. Subject to the terms of this Agreement, AstraZeneca hereby grants to Dynavax a worldwide, fully paid, non-exclusive license, with the right
to sublicense, under the AstraZeneca Technology and AstraZeneca’s rights and interest in the Collaboration Technology solely to perform Dynavax’s portion of the Research obligations under this Agreement with respect to Dynavax ISS and
Collaboration ISS, CDs, Product and Combination Products in the Field and in the Territory. In addition, AstraZeneca hereby grants to Dynavax, a worldwide, non-exclusive, royalty-free license under the AstraZeneca Technology and AstraZeneca’s
rights and interest in the Collaboration Technology to make, have made, use, offer for sale, sell and import Reverted ISS and products comprising Reverted ISS (i) for use outside the Field during the Term, but, in accordance with the limitation
specified in Section 6.5, excluding the right to make, have made, use, offer for sale, sell and import Reverted ISS and products comprising Reverted ISS for use in any Dynavax existing or future allergic respiratory disease programme, and
(ii) for use inside and outside of the Field following the Term if this Agreement is terminated for any reason other than by AstraZeneca pursuant to Section 20.5 (breach by Dynavax or other similar events specified therein).

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 33 of 103

  

 Notwithstanding the above licences, it is noted that during the Term, Dynavax shall have no
right to make, have made, use, offer for sale, sell and import the CDs or any products incorporating such CDs, inside or outside of the Field in the Territory, unless and until such CD becomes a Reverted ISS. 

 

	6.4	Third Party Licences. 

  

	 	6.4.1	The Parties, through the JPT and JSC, as appropriate, shall discuss whether licences under Third Party technology are necessary for the Research. If during the Research
Term, the JSC agrees that such a Third Party licence is necessary, then, AstraZeneca shall have the first right, but not the obligation, through counsel of its choosing, to negotiate and obtain a licence from such Third Party. If AstraZeneca incurs
Third Party [ * ] licence expenses as a result of [ * ], such costs relating to [ * ] may be recovered in part pursuant to the royalty-offset provision of Article 10 at AstraZeneca’s sole discretion, and such costs relating
to Third Parties [ * ] may be recovered in part pursuant to the royalty-offset provision of Article 10, subject to the prior written consent of Dynavax, [ * ]. 

 

	 	6.4.2	If, in the opinion of AstraZeneca, following discussion with the Advisory Board, the Development and/or Commercialization of the Dynavax ISS, Collaboration ISS, CDs,
Product or Combination Products by AstraZeneca, its Affiliates or any of their Sublicensees infringes or misappropriates any Patent or any Intellectual Property Right of a Third Party in any country, such that AstraZeneca or any of its Affiliates,
Distributors or Sublicensees cannot Develop and/or Commercialize the Dynavax ISS, Collaboration ISS, CDs or the Product or any Combination Product(s) in such country without infringing the Patent or intellectual property right of such Third Party (a
“Triggering Event”), then, AstraZeneca shall have the first right, but not the obligation, through counsel of its choosing, to negotiate and obtain a licence from such Third Party as necessary for AstraZeneca and its Affiliates and
Sublicensees to Develop and/or Commercialize the Dynavax ISS, Collaboration ISS, CDs, Product and any Combination Product(s) in such country. Nothing contained in this Section 6.4.2 shall be construed to limit AstraZeneca’s right to
terminate this Agreement pursuant to Section 20.3. If AstraZeneca incurs 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 34 of 103

  

	 	
Third Party [ * ] licence expenses as a result of [ * ], such costs relating to [ * ] may be recovered in part pursuant to the royalty-offset provision of Article 10 at
AstraZeneca’s sole discretion and such costs relating to Third Parties [ * ] may be recovered in part pursuant to the royalty-offset provision of Article 10, subject to the prior written consent of Dynavax, [ * ].

  

	6.5	Exclusivity. 

  

	 	6.5.1	During the Term, each Party and its respective Affiliates shall not, directly or indirectly, by itself or with any Third Party, conduct research on, develop or
commercialize in the Field any ISS other than the selection, Research, Development and Commercialization of Dynavax ISS and/or Collaboration ISS and/or CDs and/or Product and/or Combination Products in the Field pursuant to this Agreement.

  

	 	6.5.2	Dynavax acknowledge that as a necessary pre-requisite of AstraZeneca being able to benefit from the licence rights granted pursuant to Section 6.2, it is
appropriate and acceptable for Dynavax and its Affiliates to refrain from conducting research on, developing, commercialising, making, having made, using, offering for sale, selling and importing the Reverted ISS in the treatment of human patients
who have Asthma, COPD, and/or respiratory allergies. Accordingly for such time as AstraZeneca is Researching, Developing or Commercialising a Dynavax ISS, Collaboration ISS, CD, Product or Combination Product pursuant to this Agreement, Dynavax and
its Affiliates shall not, by themselves or with any Third Party, utilise any of the Reverted ISS within any existing or future Asthma, COPD, and/or respiratory allergy research, development and commercialisation programme. 

 

	 	6.5.3	The Parties acknowledge that all restrictions contained in this Section 6.5 are reasonable, valid and necessary for the adequate protection of the Product or any
Combination Product(s) and that neither AstraZeneca nor Dynavax would have entered into this Agreement with out the protection afforded it by this Section 6.5. 

 

	 	6.5.4	AstraZeneca’s exclusive position granted by Section 6.2 shall expire with respect to the Product and each separate Combination Product, on a country-

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 35 of 103

  

	 	
by-country basis, on the date when AstraZeneca’s obligation to pay royalties with respect to such Product or Combination Product (as appropriate) expires. Upon expiry of AstraZeneca’s
exclusive position with respect to the Product or any Combination Product in a country, AstraZeneca’s licence with respect to such Product or Combination Product in such country shall become non-exclusive, fully paid-up, perpetual and
irrevocable and the Net Sales of such Product or Combination Product in such country shall be excluded from the royalty calculations in Article 10 (including the thresholds and ceilings). AstraZeneca and its Affiliates and Sublicensees shall be
allowed to continue Developing and Commercializing such Product or Combination Product and using all related Patents, Know-How and Information in connection therewith on a [ * ] basis in such country with [ * ].

  

	6.5.5	During the Term, in line with Dynavax’s representation and warranty in 

 Section 18.1.6, Dynavax and/or any of its Affiliates covenant: 
  

	 	(a)	not, anywhere in the world, to institute or prosecute (or in any way aid any Third Party in instituting or prosecuting), at law or in equity, any claim, demand, action
or cause of action for damages, costs, expenses or compensation, or for an enjoinment, injunction, or any other equitable remedy, against AstraZeneca, its Affiliates, Sublicensees, suppliers, Distributors, vendors or customers alleging the
infringement by AstraZeneca in its Development and Commercialization in accordance with this Agreement of Dynavax ISS, Collaboration Technology, CDs, or Products or Combination Product(s), of any Patent that claims an invention that is based on,
derived from or otherwise relates to the Collaboration Technology or the Background Technology of a Party and is Controlled by Dynavax or its Affiliates; 

  

	 	(b)	not, anywhere in the world, to grant any rights or licences to any Third Party which are contrary to or inconsistent with the rights and licences granted to AstraZeneca
and its Affiliates pursuant to this Agreement; and 

  

	 	(c)	notwithstanding Dynavax’s representation and warranty in Section 18.1.6, in the event of any inadvertent grant of rights or licences to any

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 36 of 103

  

	 	
Third Party which are, or subsequently become, contrary to or inconsistent with the rights and licences granted to AstraZeneca and its Affiliates pursuant to this Agreement, to [ * ], with
the aim of ensuring that, [ * ], the rights and licences accorded to AstraZeneca supersede any conflicting rights and licences of Third Parties. Dynavax shall also offer full cooperation to allow AstraZeneca to [ * ].

  

	6.6	Sublicences. AstraZeneca shall have the right to grant sublicences, through multiple tiers of sublicensees, under the licences granted in Section 6.2.1 and
6.2.2, to (a) its Affiliates and (b) to any other Person, provided, however, that AstraZeneca shall first obtain the written consent of Dynavax before granting a sublicence under the licences granted in Section 6.2 for the Research,
Development or Commercialization of Dynavax ISS, Collaboration ISS, CDs, the Product or any Combination Product(s) in [ * ], except for sublicences limited to [ * ]. Where AstraZeneca grants a sublicense to a Person, which is not an
Affiliate of AstraZeneca, and such Person is not a Distributor, that Person shall be a “Sublicensee” for purposes of this Agreement. AstraZeneca shall use Commercially Reasonable Efforts to ensure that all Persons to which it grants
sublicences comply with all terms and conditions of this Agreement. In all countries outside of the Major Markets, AstraZeneca shall give written notice to Dynavax promptly following each sublicence granted hereunder, identifying the Sublicensee and
the rights granted. 

  

	6.7	Distributors. AstraZeneca shall have the right, in its sole discretion, to appoint its Affiliates, and AstraZeneca and its Affiliates shall have the right, in
their sole discretion, to appoint any other Persons, to distribute, market and sell the Product or any Combination Products (with or without packaging rights) in circumstances where the Person purchases its requirements of Product or Combination
Products from AstraZeneca or its Affiliates but does not otherwise make any royalty or other payment to AstraZeneca with respect to its intellectual property rights. In the event that AstraZeneca or its Affiliates so appoint a Person and such Person
is not an Affiliate of AstraZeneca, that Person shall be a “Distributor” for purposes of this Agreement. The term “packaging rights” in this Section 6.7 shall mean the right for the Distributor to [ * ].

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 37 of 103

  

 Except with the consent of Dynavax, [ * ], AstraZeneca, its Affiliates and
Sublicensees shall not sell Product or Combination product in unfinished form (in that it requires further filling or finishing) in any country of the [ * ]. 
  

	6.8	Confirmatory Patent Licences. Dynavax shall if requested to do so by AstraZeneca immediately enter into confirmatory licence agreements in the form or
substantially the form set out in Exhibit F for purposes of recording the licences granted under this Agreement with such Patent Offices in the Territory as AstraZeneca considers appropriate. Until the execution of any such confirmatory
licences, so far as may be legally possible, Dynavax and AstraZeneca shall have the same rights in respect of the licensed Patents and be under the same obligations to each other in all respects as if the said confirmatory licences had been
executed. 

  

	7	Research Funding 

  

	7.1	Funding. Each Party shall assume responsibility for its own costs and expenses for the Joint Research Programme with the sole exception that AstraZeneca shall
provide funding to Dynavax to support Dynavax’s efforts under the Joint Research Programme. During each contract year of the Research Term, AstraZeneca shall pay Dynavax an amount equal to the FTE Rate multiplied by the number of FTEs set forth
in Section 3.4 for such year. 

  

	7.2	Invoices; Reconciliation. 

  

	 	7.2.1	Each funding amount set forth in Section 7.1 above shall be paid to Dynavax [ * ]. AstraZeneca shall make its first such payment within [ * ] days of
the Effective Date (subject to receipt by AstraZeneca of an invoice in respect of such payment) and each subsequent payment on the [ * ] of each contract quarter during the Research Term (subject to receipt by AstraZeneca of an invoice in
respect of each such payment). 

  

	 	7.2.2	In addition to the advance payment set forth in Section 7.2.1, and subject to the JSC’s approval of any subcontractor or major outsourcing agreement other
than those Persons listed on Exhibit D hereto, any external costs or expenses incurred by Dynavax in connection with its performance of its obligations under the Joint Research Programme and not already included within the FTE Rate, shall be
separately invoiced to AstraZeneca and reimbursed on a pass- 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 38 of 103

  

	 	
through basis. Dynavax shall submit such invoice within [ * ] days after the end of the relevant quarter in which such pass- through expenses were incurred. AstraZeneca shall reimburse such
expense within [ * ] days after the date of receipt by AstraZeneca of the invoice. 

  

	 	7.2.3	Within [ * ] Business Days after the end of each contract quarter during the Research Term, Dynavax shall report to AstraZeneca Dynavax’s actual FTEs involved in
the Research during such quarter. Within [ * ] days after AstraZeneca’s receipt of such report, the JSC shall direct the remittance between the Parties of an amount to effectuate the difference between the advance payment made by AstraZeneca
and the actual Dynavax FTEs involved in the research during the applicable quarter. Any such payment shall be made, in any event, within [ * ] days of the date that the JSC directs the remittance. 

 

	7.3	Records Retention; Audit. 

  

	 	7.3.1	Dynavax shall keep or cause to be kept accurate records or books of account in accordance with applicable generally accepted accounting principles that, in reasonable
detail, fairly reflect the reimbursable Joint Research Programme expenses. Such books and records shall be maintained by Dynavax for at least [ * ] years following the end of the calendar year to which they pertain. 

 

	 	7.3.2	Upon the written request of AstraZeneca, Dynavax shall permit a certified public accountant or a person possessing similar professional status and associated with an
independent accounting firm reasonably acceptable to the Parties to inspect during regular business hours and no more than once a year and going back no more than [ * ] years after receipt of the respective invoice and report pursuant to
Section 7.2, all or any part of Dynavax’s records and books necessary to verify such invoices and reports. The accounting firm shall enter into appropriate obligations with Dynavax to treat all information it receives during its inspection
in confidence. The accounting firm shall disclose to Dynavax and AstraZeneca only whether such invoices and reports are correct and details concerning any discrepancies, but no other information shall be disclosed to AstraZeneca. The charges of the
accounting firm shall be paid by AstraZeneca, except that if the reimbursable Joint Research 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 39 of 103

  

	 	
Programme expenses have been overstated by more than [ * ], the charges shall be paid by Dynavax. Any overpayment of Joint Research Programme by AstraZeneca revealed by an examination and review
shall be fully-creditable against future Joint Research Programme expenses under Section 7.2 and AstraZeneca shall submit any underpayment so discovered within [ * ] days of receipt by AstraZeneca of an invoice in respect of such underpayment.

  

	7.4	Projected Cost Reports. During the Research Term and within [ * ] days after the end of each calendar quarter, Dynavax shall provide the JSC with an [ * ]
projected cost report including: FTE hours, reimbursable Joint Research Programme expenses and expected milestone payments by quarter. 

  

	8	Development and Commercialization 

  

	8.1	Overview. Subject to Dynavax’s option to co-promote Product in accordance with Section 8.5, AstraZeneca shall have sole responsibility for all
Development and Commercialization of CDs, Product and Combination Products, including the clinical and commercial manufacturing and supply thereof. 

  

	8.2	Development of Product. AstraZeneca shall be responsible for carrying out the Development of any CDs, the Product and any Combination Product. The Development of
any CD, the Product or Combination Product(s) shall each be governed by a development plan that describes the proposed overall program of Development (the “Development Plan”). AstraZeneca shall have the sole right and responsibility for
preparing and maintaining the Development Plan for the CD, Product or any Combination Product; provided, however, AstraZeneca shall consider in good faith the comments of Dynavax as provided through the JSC and/or Advisory Board as further described
below. The Development Plan shall include general information on AstraZeneca’s development activities in the previous twelve (12) months and a summary of the activities planned in the next twelve (12) months, together with a timetable
of planned and actual submissions for Health Registration Approvals. AstraZeneca shall promptly deliver a summary copy of each Development Plan, and updates, to the members of the JSC, and after its disbandment, to the Advisory Board. AstraZeneca
shall use Commercially Reasonable Efforts to conduct any Development of Product or any Combination Product in compliance in all material aspects with the requirements under all Applicable Laws 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 40 of 103

  

	8.3	Regulatory Affairs and Information Exchange 

  

	 	8.3.1	With regard to sharing of Regulatory Documentation and Regulatory Filings, each Party shall provide the other Party with reasonable access, and shall provide the other
Party with sufficient rights to reference and use in association with exercising its rights and performing its obligations under this Agreement, all of its, its Affiliates’ and their respective suppliers’ Regulatory Documents, Regulatory
Filings, and Health Registration Approvals for Product or any Combination Product. 

  

	 	8.3.2	Consistent with the Development Plan, but subject to the remainder of this Section 8.3, AstraZeneca shall be responsible for developing Regulatory Documentation
and preparing and submitting Regulatory Filings, seeking Health Registration Approvals, and maintaining Health Registration Approvals for Product or any Combination Product, including preparing all reports necessary as part of an IND, NDA, MAA, DMF,
BLA or other necessary filing reasonably required for Health Registration Approval. 

  

	 	8.3.3	Dynavax, at its sole cost and expense (but subject to the reimbursement provisions of this Section 8.3.3), will provide AstraZeneca with all reasonable assistance
required in order to transfer the Know-How to AstraZeneca in a timely manner or assist AstraZeneca with respect to the Development and Commercialization of the Dynavax ISS and/or Collaboration ISS and/or CD and/or the Product and/or the Combination
Product(s) (if any). AstraZeneca shall reimburse, pursuant to Section 7.1, all reasonable, AstraZeneca pre-approved, FTE costs incurred by Dynavax in connection with such technical assistance, and shall reimburse any and all external costs
incurred by Dynavax in connection with such technical assistance pursuant to Section 7.2. Without prejudice to the generality of the foregoing, if visits of Dynavax’s representatives to AstraZeneca’s facilities are reasonably
requested by AstraZeneca for purposes of transferring the Dynavax Know­How to AstraZeneca or for purposes of AstraZeneca acquiring expertise on the practical application of the Dynavax Know-How or assisting on issues arising

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 41 of 103

  

	 	
during such Development or Commercialization, Dynavax will send appropriate representatives to AstraZeneca’s facilities, provided that AstraZeneca shall reimburse Dynavax, in addition to the
FTE costs of such Dynavax representatives, at the FTE Rate defined in Section 1.52, for its reasonable and verifiable expenses of travel and accommodations for such representatives. 

 

	 	8.3.4	AstraZeneca shall keep Dynavax informed on an ongoing basis regarding the schedule and process for Regulatory Documents and Regulatory Filings. AstraZeneca shall
prepare all responses to correspondence that are received from any regulatory agency relating to any Regulatory Documents and any Regulatory Filing. If and when a Health Registration Approval is obtained in any country of the Territory, AstraZeneca
shall promptly inform Dynavax of such Health Registration Approval. 

  

	 	8.3.5	In conducting any Development activities hereunder, AstraZeneca shall use Commercially Reasonable Efforts to ensure that its employees, agents, clinical institutions
and clinical investigators comply with all FDA statutory and regulatory requirements with respect to the CDs, Product or any Combination Product, including but not limited to: the Federal Food, Drug and Cosmetic Act, as amended (FFDCA), the Public
Health Service Act (PHSA), regulatory provisions regarding protection of human subjects, financial disclosure by clinical investigators, Institutional Review Boards (IRB), GCP, GLP, IND regulations, and any conditions imposed by a reviewing IRB or
the FDA. 

  

	8.4	Commercialization of Product and Combination Product. Subject to Dynavax’s option to co-promote Product with AstraZeneca in the United States of America,
AstraZeneca shall have exclusive rights throughout the Territory over the Commercialization of all Product and Combination Product(s), including the supply of Product or Combination Product for use in all such Commercialization activities.
AstraZeneca shall keep Dynavax informed about all of AstraZeneca’s efforts to Commercialize the Product or any Combination Product, including summaries of AstraZeneca’s, and its Sublicensees’ marketing plans, as updated, and
significant developments in the Commercialization of the Product and/or Combination Product(s). 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 42 of 103

  

 8.5 Dynavax Option to Co-Promote in the United States AstraZeneca recognises that
Dynavax wishes to increase its capability for developing and commercialising pharmaceutical products in the future. Following written notice from AstraZeneca that it has decided to [ * ], Dynavax shall have an option to negotiate with AstraZeneca
terms under which Dynavax may co-promote the Product in the United States of America. In order for Dynavax to be eligible to co-promote Product in the United States of America, Dynavax must [ * ]. 

In the event that Dynavax [ * ] and wishes to commence discussions with AstraZeneca to co-promote Product in the United States of
America, Dynavax shall notify AstraZeneca in writing. The Parties shall meet to discuss such co-promotion in the United States of America within [ * ] days after receipt by AstraZeneca of such notification. 

The Parties shall thereafter [ * ]. If the Parties agree on such terms, the Parties shall seek to enter into a written co-promotion
agreement including mechanisms for participation and reward commensurate with the contributions of each Party. [ * ]. In no event shall Dynavax’s promotional effort exceed [ * ] of the total estimated promotional effort in the
United States of America without AstraZeneca’s prior written agreement. 
 In the event that the Parties enter into a
written co-promotion agreement pursuant to this Section 8.5, Dynavax shall be legally responsible and liable for the actions, omissions and conduct of all members of its sales force and other employees providing services thereunder. Dynavax
shall ensure that all such persons comply with: 
  

	 	8.5.1	all federal, state and local laws, and the rules, regulations, guidelines and guidances of all agencies, in effect from time to time applicable to the marketing,
promotion, distribution and sale of the product in the United States of America, including, but not limited to (a) the American Medical Association Guidelines on Gifts to Physicians from Industry and (b) the PhRMA Code on Interactions with
Healthcare Professionals; and 

  

	 	8.5.2	AstraZeneca’s US business policies, as amended from time to time by AstraZeneca. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 43 of 103

  

	8.6	Pricing, Price Approvals and Product Distribution. AstraZeneca shall determine the overall pricing strategy for the Product or any Combination Product in the
Territory. AstraZeneca shall obtain such Product and/or Combination Product pricing approvals as may be required and arrange for distribution of the Product or Combination Product in each applicable country in the Territory.

  

	8.7	Sales and Inventory. AstraZeneca shall be responsible for booking sales, stocking inventory for itself and its Sublicensees, distributing Product and
Collaboration Product(s) and collecting accounts receivable. 

  

	8.8	Advertising and Education. 

  

	 	8.8.1	AstraZeneca shall be responsible for developing or having developed advertising and education materials for the Product or any Combination Product(s). AstraZeneca shall
have the authority to select Trademarks for the Product and Combination Products and shall own all Trademarks in accordance with Article 17. 

  

	 	8.8.2	If any written and visual promotion or educational materials for the Product or any Combination Product refer to or identify either of the Parties, AstraZeneca and
Dynavax shall both be presented and described. Any such materials that specifically refer to any Party shall be subject to prior review and comment by that Party. All labelling, documentary information, promotional material and oral presentations
(where practical) regarding the detailing and promoting of the Product or any Combination Product shall display the names and logos of each Party. 

  

	 	8.8.3	Notwithstanding the foregoing, Sections 8.8.1 and 8.8.2 are subject to the requirements of Applicable Laws of each country in which such materials are presented or in
which such the Product or any such Combination Product is Commercialized. 

  

	8.9	Development and Commercialization Costs. Except as otherwise specified in Section 8.5 above, AstraZeneca shall be responsible for all costs associated with
the Development and Commercialization of any CDs, the Product or any Combination Product. If AstraZeneca requests Dynavax’s assistance with certain tasks related to the Development or Commercialization of any CDs, the Product or any Combination

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 44 of 103

  

	 	
Product, and Dynavax agrees to assist, then AstraZeneca shall reimburse Dynavax for any reasonable costs Dynavax should incur associated with such tasks. Within [ * ] days after the end of each
calendar quarter, Dynavax shall submit to AstraZeneca an accounting of all costs Dynavax incurs pursuant to the Development or Commercialization of any CDs, the Product or any Combination Product during that quarter. Such summary may include an
allocation of time spent by Dynavax personnel in conducting such Development or Commercialization activities, that shall be reimbursed at the FTE Rate. AstraZeneca shall on a quarterly basis, within [ * ] days after the end of each quarter, prepare
and submit to Dynavax a reimbursement of the costs incurred by Dynavax, subject to receipt by AstraZeneca of an invoice in respect of such payment. 

  

	8.10	Diligence Obligations. 

  

	 	8.10.1	AstraZeneca shall use Commercially Reasonable Efforts to Develop and Commercialise the Lead CD or Product during the Term of this Agreement. Specifically, but not in
limitation of the foregoing, AstraZeneca shall use Commercially Reasonable Efforts to achieve the following objectives (the “Diligence Objectives”): 

 

	 	(a)	to fulfil AstraZeneca’s Research obligations under the Joint Research Plan for any Dynavax ISS or Collaboration ISS according to timelines agreed upon by the JSC;

  

	 	(b)	if at any time AstraZeneca determines that it will cease Development of the Lead Candidate Drug or any Lead CD, then AstraZeneca shall choose another CD, or shall make
a CD Nomination from the [ * ], for Development within [ * ] months of such determination; 

  

	 	(c)	to endeavour to complete the Development of the Lead CD or Product in a way which [ * ]; and 

 

	 	(d)	to endeavour to [ * ]; 

provided, however, that such obligations are expressly conditioned upon Dynavax and its Affiliates performing their
respective obligations hereunder and such obligations of AstraZeneca shall be delayed or suspended as long as 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 45 of 103

  

 
any such condition exists. Further, Dynavax acknowledges and agrees that nothing in this Section 8.10 is intended, or shall be construed, to require AstraZeneca to Develop or Commercialise a
specific CD as the Lead CD or Product, or a specific Combination Product, if the Product does not proceed. In the event that AstraZeneca decides to discontinue the Development or Commercialization of any CD as the Lead CD or the Product in favour of
another CD, or if it decides to discontinue the Development or Commercialization of the Product in favour of a Combination Product its obligations under this Section 8.10 shall cease with respect to such initial CD or the Product (as
appropriate) in favour of such other CD or Combination Product. AstraZeneca shall perform its obligation under this Section 8.10 in good scientific manner and in compliance in all material respects with all Applicable Law. Upon satisfaction of
its obligations under this Section 8.10, AstraZeneca shall be deemed to satisfy all diligence obligations owed to Dynavax hereunder, whether contractually or under Applicable Law, with respect to the Development or Commercialization of the CDs,
Product or a Combination Product, and shall have no other obligation, express or implied, to Develop or Commercialize any CD, Product or any Combination Product. 
  

	 	8.10.2	Dynavax shall use Commercially Reasonable Efforts to fulfil Dynavax’s Research obligations under the Joint Research Plan for any Dynavax ISS or Collaboration ISS
according to timelines agreed upon by the JSC. 

  

	 	8.10.3	It is recognised that the process of drug development is uncertain and the [ * ]. 

 

	8.11	Breach of Diligence Obligations. 

  

	 	8.11.1	Notification and Meeting. If at any time Dynavax has a reasonable basis to believe that AstraZeneca is in material breach of its material obligations under
Section 8.10, then Dynavax shall so notify AstraZeneca, specifying the basis for its belief, and the Parties shall meet within [ * ] days after such notice to discuss in good faith Dynavax’s concerns and AstraZeneca’s Development and
Commercialisation plans with respect to any CD, the Product or any Combination Product. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 46 of 103

  

	 	8.11.2	Right of Arbitration. If, after such good faith discussions, (a) AstraZeneca is in material breach of its material obligations under Section 8.10, and
(b) AstraZeneca does not take reasonable steps designed to rectify such breach within [ * ] days of meeting with Dynavax pursuant to Section 8.11.1 (or, if such failure cannot be rectified within such [ * ]-day period, if AstraZeneca does
not commence actions to rectify such breach within such period and thereafter diligently pursue such actions) the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one
in-person meeting between representatives of each Party having decision-making authority (subject only to Board of Directors’ or equivalent approval, if required). All such discussions under this Section 8.11.2 shall be confidential and
shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. If the matter is not resolved within [ * ] days following the request for discussions, Dynavax may thereafter commence a special arbitration
pursuant to Section 24.13 in respect of such matter. 

  

	8.12	Reversion; Abandonment. 

  

	 	8.12.1	In the event that AstraZeneca abandons or puts the development of a Lead CD on hold for a consecutive period of time exceeding [ * ] months or an aggregate period of
time exceeding [ * ] months in any [ * ]-month period, and during such period [ * ], then AstraZeneca shall notify Dynavax in writing. Dynavax may (but is not so obligated), within [ * ] months from receipt of such notification, provide written
notice to AstraZeneca requesting that such Lead CD become a Reverted ISS and cease to be a Collaboration ISS or CD. Upon receipt of such notice by AstraZeneca, such CD shall be included in the license grant under Section 6.3.

 For the avoidance of doubt, the foregoing time periods shall not include any period of time during which
AstraZeneca is [ * ]. AstraZeneca shall have the right to satisfy its obligations under this Section 8.12 through one or more Affiliates, Sublicensees or subcontractors. 

 

	 	8.12.2	In the event that Dynavax fails to make a written request to AstraZeneca pursuant to Section 8.12.1, within [ * ] months following the date on which

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 47 of 103

  

	 	
Dynavax received from AstraZeneca the written notice referred to in the first sentence of such Section 8.12.1, AstraZeneca shall be under no further obligation to grant Dynavax any license
or other rights to such CD or to make any such above said assignments and AstraZeneca shall retain its exclusive rights and ownership to such CD pursuant to Article 6. 

 

	 	8.12.3	In the event of any abandonment of a CD by AstraZeneca and reversion to Dynavax pursuant to Section 8.12.1, AstraZeneca shall, [ * ]; provided, however, that
Dynavax’s above said rights shall be subject to [ * ]. 

  

	9	Milestone Payments  

  

	9.1	Total Obligation. Unless the Parties agree in writing otherwise, the access fee, milestone payments and royalty payments payable by AstraZeneca to Dynavax
pursuant to this Article 9 and Article 10, taken together with the funding to be provided by AstraZeneca to Dynavax pursuant to Article 7, represent all of AstraZeneca’s financial obligations to Dynavax hereunder and Dynavax
shall not be entitled to any additional compensation or remuneration from AstraZeneca under this Agreement. 

  

	9.2	Access Fee. AstraZeneca shall pay to Dynavax within ten (10) days following the Effective Date an access fee of ten million US Dollars ($10,000,000) subject
to receipt by AstraZeneca of an invoice in respect of such payment. Such access fee shall be non-refundable and non-creditable against future milestones and royalties payable pursuant to this Agreement. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 48 of 103

  

	9.3	Joint Research Programme Milestones. AstraZeneca shall pay to Dynavax a milestone payment in respect of each of the following Research and Development events in
the particular amounts specified below (in each case subject to receipt of an invoice in respect of each such payment) no later than [ * ] days following the occurrence of such milestone event as reasonably determined by AstraZeneca or the JSC as
applicable (whether such milestone event is achieved by AstraZeneca, its Affiliate or any of their respective Distributors or Sublicensees) (each a “Joint Research Programme Milestone”). AstraZeneca shall make the corresponding
non-refundable and non-creditable payments to Dynavax, as follows: 

  

	 	9.3.1	four million five hundred thousand US Dollars ($4,500,000) within [ * ] days following the first CD Nomination Date; 

 

	    	[ * ] 

  

	9.4	Development Milestones. AstraZeneca shall pay to Dynavax a milestone payment in respect of each of the following events in the particular amounts specified below
(in each case subject to receipt of an invoice in respect of each such payment) no later than [ * ] days following the first occurrence of such milestone event (whether such milestone event is achieved by AstraZeneca, its Affiliate or any of their
respective Sublicensees) (each a “Development Milestone”), AstraZeneca shall make the corresponding non-refundable and non-creditable payments to Dynavax, as follows: 

 

	    	[ * ] 

  

	9.5	Milestone Payments. Each of the payments in relation to the Joint Research Programme Milestones set forth under Section 9.3 and Development Milestones set
forth under Section 9.4 shall be made by AstraZeneca no more than once under this Agreement, collectively together with the Access Fee set forth in Section 9.2, amounting to an aggregate maximum amount of [ * ],
irrespective of the number of CDs that have achieved the milestone events set forth in Sections 9.3 and 9.4 or the number of countries or Major Markets in which such milestone events have been achieved. AstraZeneca shall promptly notify Dynavax
in writing of the achievement of any milestone; provided that AstraZeneca’s failure to do so shall not be construed as the non-occurrence of any milestone event. 

 

	10	Royalty Payments and Other Payment-Related Provisions  

  

	10.1	Royalties . AstraZeneca shall pay Dynavax a running royalty on Net Sales where the royalty rate is determined based on the aggregate amount of Annual Net Sales
for the Product and any Combination Product in the Territory occurring in the particular calendar year as follows: 

  

	 	10.1.1	[ * ] on the portion of Annual Net Sales not exceeding [ * ]; and 

 

	 	10.1.2	[ * ] on the portion of Annual Net Sales exceeding [ * ] but not exceeding [ * ]; and 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 49 of 103

  

	 	10.1.3	[ * ] on the portion of Annual Net Sales exceeding [ * ] but not exceeding [ * ]; and 

 

	 	10.1.4	[ * ] on the portion of Annual Net Sales exceeding [ * ]. 

  

	    	As used herein, “Annual Net Sales” means the Net Sales made during a given calendar year. 

 

	    	The calculation of royalties under this Section 10.1 shall be conducted as aggregate Net Sales for all Product and Combination Products for the applicable calendar
year. 

  

	10.2	Combination Products. With respect to Combination Products, the Annual Net Sales used for the calculation of the royalties under Section 10.1 shall be
determined as follows: 

  

					
		 		  	
	    A    	 	 x
	  	Net Sales of the Combination Product, where:
	A  -  B	 	  
			
	A  =	 		  	Standard sales price of the Product, containing the same amount of Dynavax ISS or Collaboration ISS as the sole active ingredient as the Combination Product in question, in the
given country.
			
	B  =	 		  	standard sales price of the ready­for­sale form of a product containing the same amount of the other therapeutically active ingredient(s) that is contained in the
Combination Product in question, in the given country.

 In the event, however, that if, in a specific country, (a) the other therapeutically active
ingredient(s) in such Combination Product are not sold separately in such country, Net Sales shall be adjusted by multiplying actual Net Sales of such Combination Product by the fraction A/C, where C is the standard sales price in such country of
such Combination Product, and (b) if the Product containing such Dynavax ISS or Collaboration ISS is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction C-B/C, where B
is the standard sales price in such country of the other therapeutically active ingredient(s) in the Combination Product and C is the standard sales price in such country of the Combination Product. The standard sales price for the Product
containing such Dynavax ISS or Collaboration ISS and for each other active ingredient shall be for a 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 50 of 103

  

 
quantity comparable to that used in such Combination Product and of the same class, purity and potency. If, in a specific country, both a Product containing the Dynavax ISS or or Collaboration
ISS and a product containing the other active ingredients in such Combination Product are not sold separately, a market price for such Product and such other active ingredients shall be negotiated by the Parties in good faith based upon the costs,
overhead and profit as are then incurred for such Combination Product and all products then being made and marketed by AstraZeneca and having an ascertainable market price that are comparable to such Product or such other active ingredients, as
applicable. If, in a specific country, the foregoing calculations do not fairly represent the value of the various active ingredients included in a Combination Product, the allocation of Net Sales for such Combination Product shall be negotiated by
the Parties in good faith. 
  

	10.3	Sublicensees. 

  

	 	10.3.1	In the event that an AstraZeneca Sublicensee sells Product or a Combination Product to Third Parties in the [ * ], such sales shall [ * ].

  

	 	10.3.2	For all sales of Product or Combination Product by a Sublicensee to Third Parties outside of the [ * ], any fees, milestones and/or royalty income which
AstraZeneca shall receive from the Sublicensees shall [ * ]. 

  

	 	10.3.3	In the event that AstraZeneca sublicenses the sale of Product or a Combination Product to Third Parties outside of the [ * ], the sublicense shall be
obliged to [ * ]. 

  

	10.4	Royalty Stacking. 

  

	 	10.4.1	For the Product or any Combination Product(s) sold by AstraZeneca or its Affiliates to Third Parties (including Distributors), where the sum of royalty payments
(excluding any royalty on delivery devices) owed by AstraZeneca and its Affiliates to Dynavax and any Third Parties in any calendar year exceeds [ * ] of Net Sales for a given Product or Combination Product for that period, the royalty
rate payable to Dynavax shall be reduced [ * ] such that the aggregate royalty rate payable by AstraZeneca on the Product or Combination Product, [ * ], would equal [ * ] of Net Sales thereof.

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 51 of 103

  

	10.4.2	In the case of the Product or a Combination Product which is developed or commercialised by a Sublicensee of AstraZeneca, where AstraZeneca is legally required to make
payment to one or more Third Parties in order that such Sublicensee may develop or commercialise such Product or Combination Product, then if the sum of royalty payments (excluding any royalty payments on delivery devices) owed by AstraZeneca and
its Affiliates to Dynavax and any such Third Parties exceeds [ * ] of all amounts received by AstraZeneca from such Sublicensee that are subject to the royalty obligations of AstraZeneca under Section 10.1 the royalty rate under
Section 10.1 shall be reduced [ * ] such that the aggregate amount payable by AstraZeneca to Dynavax and any such Third Parties with respect to such Product or Combination Product, [ * ], would equal [ *
] of the amounts received by AstraZeneca from such Sublicensee that are subject to the royalty obligations of AstraZeneca under Section 10.1. 

  

	10.5	[ * ] Royalty and [ * ]. 

  

	 	10.5.1	Subject to Section 10.3.3, Dynavax shall pay any and all royalties arising from the sale of the Product or any Combination Product(s) owed the [ * ]
under the [ * ]. 

  

	 	10.5.2	(a) To the extent that royalties payable by AstraZeneca under this Article 10, taken as a whole, [ * ], Dynavax shall [ * ] as a result of [
* ]. To the extent payments to Third Parties in respect of matters described in the previous sentence [ * ], then AstraZeneca shall [ * ]. 

 

	 	    	(b) In the event of a cross-license with a Third Party which includes payments described in Section 10.5.2(a), the Party or Parties which is/are responsible for
the payment under Section 10.5.2(a) shall [ * ]. 

  

	 	    	(c) In the event either Party makes payments to a Third Party in respect of the matters described in paragraph (a) of this Section 10.5.2 prior to the
commencement of Net Sales, such payment obligation shall [ * ]. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 52 of 103

  

	10.6	Reduction of Royalty . 

  

	 	10.6.1	Competition. In the event that, in a country in the Territory, generic competition with respect to the Product or a Combination Product occurs by a product or
products having [ * ] (each such product, a “Competing Product”), and such Competing Product has any sales in a Calendar Quarter in such country, then for the purposes of calculating the royalties of such Product or
Combination Product under Section 10.1, then, subject to Section 10.7, [ * ] of the Net Sales in such country shall be disregarded. The calculation of the royalty reduction under this Section 10.6.1 shall be conducted
separately for each Product or Combination Product. 

 If the number of units sold of a Competing Product
represents [ * ] of the aggregate number of units sold of all products in the relevant [ * ] class to which the Product or Collaboration Product has been allocated, including the Product and any Combination Product, in a country in the
Territory as reported by [ * ] or any comparable reporting agency in a Calendar Year, then AstraZeneca shall have the right, but not the obligation, to [ * ]. 

 

	 	10.6.2	Compulsory Licences. In the event that a court or a governmental agency of competent jurisdiction requires AstraZeneca or an AstraZeneca Affiliate or Sublicensee
to grant a compulsory licence to a Third Party permitting such Third Party to make and sell the Product or any Combination Products in a country in the Territory, then for the purposes of calculating the royalties of the Product or Combination
Product under Section 10.1, [ * ] of the Net Sales in the country in such country shall be disregarded. The calculation of the royalty reduction under this Section 10.6.2 shall be conducted separately for each Product or Combination
Product. In any country where the royalty reduction of Section 10.6.1 or 10.6.2 is in effect, there shall not be any further royalty reduction pursuant to this Section 10.6.2. 

 

	 	10.6.3	No Valid Claim. In the event that, and in such case from and after the date on which, a Product or Combination Product is Developed and/or Commercialized in a
country and is not covered by a Valid Claim or other governmental grant of exclusivity (for example, but without limitation, orphan 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 53 of 103

  

	 	
drug status, Chinese monitoring period exclusivity, or any other governmental grant of exclusivity of equivalent effect) in such country, then for the purposes of calculating the royalties of
such Product or Combination Product under Section 10.1, [ * ] of the Net Sales in such country shall be disregarded. 

  

	10.7	Royalty Floor. Notwithstanding anything to the contrary in this Agreement except for Section 10.6.2, during the Royalty Term, in no event shall the net
royalty rate received by Dynavax from the sale of Products be reduced to less than [ * ] of Net Sales (as determined before any reductions provided for in this Article 10 other than Section 10.6.2) for the period of time when
Dynavax makes royalty payments to [ * ] as set forth in Section 10.5, or to less than [ * ] of such Net Sales thereafter. Dynavax shall promptly notify AstraZeneca in writing when payments to [ * ] as set forth in
Section 10.5 are no longer being made. 

  

	10.8	Royalty Term. AstraZeneca’s obligation to pay royalties shall commence, on a country-by-country basis, with respect to each separate Product or Combination
Product, on the date of First Commercial Sale of such Product or Combination Product in such country. The obligation shall expire, on a country-by-country basis, with respect to each separate Product or Combination Product on the later to occur of
(a) the [ * ] anniversary of the First Commercial Sale of the first Product in such country and (b) the expiration date in such country of the last to expire of any issued Collaboration Patent or Dynavax Patent that includes
at least one Valid Claim covering the sale of such separate Product or Combination Product in such country (such period, the “Royalty Term”). 

 Upon termination of the royalty obligations of AstraZeneca under this Section 10.8, with respect to a Product or Combination Product in any country, the licence grants to AstraZeneca in
Section 6.2 shall become fully paid-up, perpetual and irrevocable with respect to such country and the Net Sales of such Product or Combination Product in such country shall be excluded from the royalty calculations in this Article 10
(including the thresholds and ceilings). 
  

	10.9	Sales Subject to Royalties. Sales between AstraZeneca, its Affiliates and Sublicensees shall not be subject to royalties hereunder. Royalties shall be calculated
on AstraZeneca’s and its Affiliates’ and Sublicensees’ sale of the Product or Combination Products to a Third Party (including Distributors). Royalties shall be 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 54 of 103

  

	 	
payable only once for any given batch of the Product or Combination Products. For purposes of determining Net Sales, the Product or Combination Product, as appropriate, shall be deemed to be sold
when invoiced and a “sale” shall not include, and no royalties shall be payable on, transfers by AstraZeneca, its Affiliates or Sublicensees of free samples of Products, Combination Products or clinical trial materials containing Dynavax
ISS and/or Collaboration ISS or other transfers or dispositions for charitable, promotional, pre-clinical, clinical, manufacturing, testing or qualification, regulatory or governmental purposes. 

 

	10.10	Royalty Payments. The royalties shall be calculated quarterly as of the last day of March, June, September and December respectively, for the calendar quarter
ending on that date. AstraZeneca shall pay the royalties in conjunction with the delivery of a written report to Dynavax within [ * ] days after the end of each calendar quarter that shows, with respect to each country and the Product or
Combination Product(s), the sales volume and Net Sales, by country, of each Product or Combination Product sold during such calendar quarter. 

  

	10.11	Mode of Payment. All payments set forth in this Article 10 shall be remitted by wire transfer to the following bank account of Dynavax or such other account as
Dynavax may designate in writing to AstraZeneca: 

  

	    	[ * ] 

  

	10.12	Currency. All payments required under this Agreement shall be made in U.S. Dollars. For the purpose of computing the Net Sales of Product or Combination Products
sold in a currency other than U.S. Dollars, such currency shall be converted from local currency to U.S. Dollars by AstraZeneca in accordance with the rates of exchange for the relevant month for converting such other currency into U.S. Dollars used
by AstraZeneca’s normal internal accounting systems, which are independently audited on an annual basis. 

  

	10.13	Interest. Unless any payment potentially due to Dynavax under this Agreement is in dispute, and in such circumstances from the date upon which such dispute is
resolved, if AstraZeneca fails to make any payment due to Dynavax under this Agreement, then interest shall accrue on a daily basis at a rate equal to the thirty (30) day U.S. dollar LIBOR rate effective for the date that payment was
due, as published by The Wall Street Journal (Western edition) plus [ * ]. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 55 of 103

  

	10.14	Records Retention; Audit. 

  

	 	10.14.1	AstraZeneca shall keep or cause to be kept accurate records or books of account in accordance with applicable generally accepted accounting principles showing the
information that is necessary for the accurate determination of the royalties due hereunder with respect to the sale of such Product or Combination Product. 

 

	 	10.14.2	Upon the written request of Dynavax, AstraZeneca shall permit a certified public accountant or a person possessing similar professional status and associated with an
independent accounting firm acceptable to the Parties to inspect during regular business hours and no more than once a year and going back no more than [ * ] years preceding the current year, all or any part of AstraZeneca’s records and
books necessary to check the accuracy of the royalties paid. The accounting firm shall enter into appropriate obligations with AstraZeneca to treat all information it receives during its inspection in confidence. The accounting firm shall disclose
to Dynavax and AstraZeneca only whether the royalty reports are correct and details concerning any discrepancies, but no other information shall be disclosed to Dynavax. The charges of the accounting firm shall be paid by Dynavax, except that if the
royalties have been understated by more than [ * ], the charges shall be paid by AstraZeneca. AstraZeneca shall promptly pay to Dynavax the amount of any underpayment of royalties revealed by an examination and review. Any overpayment of
royalties by AstraZeneca revealed by an examination and review shall be fully-creditable against future royalty payments under Sections 10.1. 

  

	11	Taxes 

  

	11.1	General. The royalties, milestones and other amounts payable by AstraZeneca to Dynavax pursuant to this Agreement (“Payments”) shall not be
reduced on account of any taxes unless required by Applicable Law. Dynavax alone shall be responsible for paying any and all taxes (other than withholding taxes required by Applicable Law 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 56 of 103

  

	 	
to be paid by AstraZeneca) levied on account of, or measured in whole or in part by reference to, any Payments it receives. AstraZeneca shall deduct or withhold from the Payments any taxes that
it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if Dynavax is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, any applicable withholding tax, it may deliver to
AstraZeneca or the appropriate governmental authority (with the assistance of AstraZeneca to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of
withholding or to relieve AstraZeneca of its obligation to withhold tax, and AstraZeneca shall apply the reduced rate of withholding, or dispense with withholding, as the case may be, provided that AstraZeneca has received evidence, in a form
satisfactory to AstraZeneca, of Dynavax’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least [ * ] days prior to the time that the Payments are due. If, in accordance with
the foregoing, AstraZeneca withholds any amount, it shall pay to Dynavax the balance when due, make timely payment to the proper taxing authority of the withheld amount, and send to Dynavax proof of such payment within [ * ] days following
that payment. For purposes of this Agreement, the stated amount of the Payments payable by AstraZeneca includes any sales tax that Dynavax may be required to collect. 

 

	11.2	Indirect Taxes. Notwithstanding anything contained in Section 11.1 or this Section 11.2 shall apply with respect to Indirect Taxes. All Payments are
exclusive of Indirect Taxes. If any Indirect Taxes is chargeable in respect of any Payments, AstraZeneca shall pay Indirect Taxes at the applicable rate in respect of any such Payments following the receipt of an Indirect Taxes invoice in the
appropriate form issued by Dynavax in respect of those Payments, such Indirect Taxes to be payable on the due date of the payment of the Payments to which such Indirect Taxes relate. 

 

	11.3	Customs Duties. The Parties shall co-operate in accordance with Applicable Laws to ensure where permissible no import duties are paid on imported clinical
product. Where import duties are payable, the Parties shall co-operate to ensure that the Party responsible for shipping as identified in the Joint Research Plan values the clinical product in accordance with Applicable Laws and minimises where
permissible any such duties and any related import taxes that are not reclaimable from the relevant authorities. 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 57 of 103

  

	12	Manufacture and Supply. 

  

	12.1	Preclinical Supply. Dynavax shall be responsible (at the expense of AstraZeneca), through either internal production capabilities or Third Party manufacturers
approved by the JSC, for the manufacture [ * ] of preclinical Dynavax ISS or Collaboration ISS for use in the Joint Research Programme through the Primary Screening Phase and Secondary Screening Phase for any such Dynavax ISS or Collaboration
ISS. AstraZeneca shall be solely responsible for all costs and expenses related to the manufacture and supply of preclinical Dynavax ISS or Collaboration ISS for use in the Joint Research Programme (other than those costs set forth in
Section 3.5.4 as included in the FTE Rate) and shall reimburse Dynavax any reasonable costs or expenses it incurs therefor. AstraZeneca shall be responsible for, or shall procure the final formulation and packaging, including any inhalation
device, of the Product or any Combination Product for preclinical use. 

  

	12.2	Clinical and Commercial Supply. AstraZeneca shall be responsible for, or shall procure, the manufacture of toxicology, clinical and commercial materials,
including without limitation any Candidate Drug, Product or Combination Product in the Territory and for all costs associated therewith. AstraZeneca shall use Commercially Reasonable Efforts to make necessary filings to obtain, or cause a Third
Party manufacturer to obtain, Health Registration Approval for the manufacture of Candidate Drugs or Product or any Combination Product(s) in the Territory. 

 

	12.3	Manufacturing Know-How Transfer. Dynavax shall transfer to AstraZeneca any manufacturing technology, material and data sufficient to enable AstraZeneca (or its
nominee) to produce and supply toxicology, clinical and commercial Candidate Drug for use in the Product or a Combination Product. Dynavax shall provide reasonable assistance to AstraZeneca to effect such transfers in an orderly fashion and to
enable AstraZeneca to begin manufacturing and supplying toxicology, clinical and commercial supply of Candidate Drug for use in the Product or a Combination Product. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 58 of 103

  

	13	Confidentiality and Non-Disclosure 

  

	13.1	General Obligations. 

  

	 	13.1.1	At all times during the term of this Agreement and for a period of [ * ] years following termination or expiration hereof, each Party (the “Receiving
Party”) shall, and shall cause its officers, directors, employees, agents, Affiliates, Distributors and Sublicensees to, keep confidential and not publish or otherwise disclose and not use, directly or indirectly, for any purpose, any
Confidential Information provided to it by the other Party (the “Disclosing Party”), except to the extent such disclosure or use is expressly permitted by the terms of this Agreement or is reasonably necessary for the performance of
this Agreement. 

  

	 	13.1.2	Dynavax recognises that by reason of AstraZeneca’s status as an exclusive licensee pursuant to certain grants under Article 6, AstraZeneca has an interest in
Dynavax’s retention in confidence of certain information of Dynavax. Accordingly, until the expiration of AstraZeneca’s exclusive position with respect to any CD, the Product or a Combination Product under this Agreement, Dynavax shall,
and shall cause its Affiliates and their respective officers, directors, employees and agents to, keep confidential, and not publish or otherwise disclose, and not use directly or indirectly for any purpose that would cause such publication or
disclosure, any information relating to (a) the CD, the Product or a Combination Product, including the Dynavax ISS or Collaboration ISS therein, or (b) the Research, Development and/or Commercialization of such Product or Combination
Product, including the Development Plans therefor (collectively the “AstraZeneca Information”); except to the extent (a) the AstraZeneca Information is in the public domain through no fault of Dynavax, its Affiliates or any of
their respective officers, directors, employees and agents, (b) such disclosure or use would be permitted under Section 13.2, or (c) such disclosure or use is otherwise expressly permitted by the terms of this Agreement or is
reasonably necessary for the performance of this Agreement. For clarification, the disclosure by Dynavax to AstraZeneca or by AstraZeneca to Dynavax of AstraZeneca Information shall not cause such information to cease to be subject to the
confidentiality provisions of this Section 13.1. 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 59 of 103

  

	 	    	Notwithstanding the foregoing, in the event Dynavax obtains an exclusive license under the AstraZeneca Technology in accordance with Section 20.7.3, Dynavax shall
be relieved of the foregoing obligations and AstraZeneca, instead of Dynavax, shall, and shall cause its Affiliates and their respective officers, directors, employees and agents to, keep confidential, and not publish or otherwise disclose, and not
use directly or indirectly for any purpose that would cause such publication or disclosure, any information relating to the AstraZeneca Information, except to the extent (a) the AstraZeneca Information is in the public domain through no fault
of AstraZeneca, its Affiliates or any of their respective officers, directors, employees and agents, (b) such disclosure or use would be permitted under Section 13.2, or (c) such disclosure or use is otherwise expressly permitted by
the terms of this Agreement or is reasonably necessary for the performance of this Agreement. 

  

	13.2	Permitted Disclosures. Each Party may disclose Confidential Information to the extent that such disclosure is: 

 

	 	13.2.1	made in response to a valid order of a court of competent jurisdiction or other competent authority; provided, however, that the Receiving Party shall first have given
notice to the Disclosing Party (if feasible) and given the Disclosing Party a reasonable opportunity to quash any such order or obtain a protective order requiring that the Confidential Information and documents that are the subject of such order be
held in confidence by such court or authority or, if disclosed, be used only for the purpose for which the order was issued; and provided further that if such order is not quashed or a protective order is not obtained, the Confidential Information
disclosed in response to such court or governmental order shall be limited to that information that is legally required to be disclosed in response to such court or governmental order; 

 

	 	13.2.2	made to a Regulatory Authority as may be necessary or useful in connection with any filing, application or request for a Health Registration Approval; provided,
however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 60 of 103

  

	 	13.2.3	made by the Receiving Party to a patent authority as may be necessary or useful for purposes of obtaining or enforcing a Patent (consistent with the terms and
conditions of Article 14); provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; 

 

	 	13.2.4	otherwise required by law, provided, however, that the Receiving Party shall (a) provide the Disclosing Party with reasonable advance notice of and an opportunity
to comment on any such required disclosure, (b) if requested by the Disclosing Party, seek confidential treatment with respect to any such disclosure to the extent available, and (c) use good faith efforts to incorporate the comments of
the Disclosing Party in any such disclosure or request for confidential treatment; or 

  

	 	13.2.5	made by the Receiving Party to its Affiliates, Distributors, Sublicensees, employees, consultants, or agents as may be necessary or useful in connection with the
Research, Development, or Commercialization of any CD, the Product or Combination Product(s) as contemplated by this Agreement, or otherwise in the exercise of its rights with respect to Collaboration Know-How, including subcontracting or
sublicensing transactions in connection therewith; provided prior to disclosure by the Receiving Party to each of the foregoing Persons must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to those set
forth in this Article 13. 

  

	    	Notwithstanding the foregoing, in the event that either Party is required by Applicable Law or the requirements of a national securities exchange or another similar
regulatory body to disclose this Agreement, in whole or in part, the Parties shall reasonably agree on a redacted version of this Agreement as necessary to protect the Confidential Information of the Parties prior to making such disclosure.

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 61 of 103

  

	13.3	Exclusions. Notwithstanding the foregoing, Confidential Information shall not include any information that: 

 

	 	13.3.1	is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no wrongful act, fault or negligence on the part of
the Receiving Party; 

  

	 	13.3.2	can be demonstrated by documentation or other competent proof to have been in the Receiving Party’s or its Affiliates’ possession prior to disclosure by the
Disclosing Party; 

  

	 	13.3.3	is subsequently received by the Receiving Party or its Affiliates from a Third Party who is lawfully in possession thereof and not bound by any obligation of
confidentiality with respect to the said information; 

  

	 	13.3.4	has been published by the Disclosing Party; or 

  

	 	13.3.5	is independently developed by or for the Receiving Party or its Affiliates without the application or use of the Disclosing Party’s Confidential Information.

  

	    	Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the Receiving Party merely because
the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party. Further, any combination of Confidential Information shall not be considered in the public domain or in the
possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and its principles are in the public domain or in the
possession of the Receiving Party. 

  

	13.4	Confidentiality of Agreement. The Parties acknowledge that the terms of this Agreement shall be treated as Confidential Information of both Parties. Such terms
may be disclosed by a Party to individuals or entities covered by 13.2.5 above, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 13.
Disclosure of the terms of this Agreement (but not other Confidential Information received from the other Party) may also be made, under binders of confidentiality and non-use at least equivalent in scope to those set forth in this Article 13, to
actual or potential bankers, lenders, investors and acquirors of the disclosing Party. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 62 of 103

  

	13.5	Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature
publication of results of the research and Development activities hereunder. Accordingly, during the Research Term neither Party shall publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or
Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of the JSC and after the Research Term Dynavax shall not publish, present or otherwise disclose any material related to the Joint Research
Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of AstraZeneca. Each Party’s contribution to such results shall be duly recognised in such publications.
For clarity, nothing in this Section 13.5 shall limit Dynavax’s right to publish or present, during the Research Term, the results of any studies carried out by or on behalf of Dynavax prior to the Effective Date. Each Party agrees to
provide the other Party the opportunity to review any proposed abstracts, manuscripts or presentations (including verbal presentations) that relate to any Dynavax ISS or Collaboration ISS or Product or Combination Product studied under the Agreement
at least [ * ] days prior to their intended submission for publication and agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is given a reasonable period of time (resulting in a total of
no more than [ * ] days from the provision of such abstracts, manuscripts or presentation by one Party to the other for review until such Party’s submission of such abstracts, manuscripts or presentation for publication) to secure patent
protection for any material in such publication which it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications. The Parties agree to
review and decide whether to delay the publication and filing of patent applications under certain circumstances. Neither Party shall have the right to publish or present Confidential Information of the other Party which is subject to
Section 13.1. With respect to any publication or presentation made by AstraZeneca pursuant to this Section 13.5, but without limiting anything set forth in Section 8.8.2 above, AstraZeneca shall give meaningful mention to
Dynavax’s participation and contribution to the Collaboration and shall specifically mention the use of Dynavax Technology in the Dynavax ISS, Collaboration ISS, CDs, Product and/or any Combination Product. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 63 of 103

  

	13.6	Use of Name/Publicity. 

  

	 	13.6.1	Neither Party shall mention or otherwise use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its Affiliates in any publication,
press release, promotional material or other form of publicity without the prior written consent of the other Party in each instance (which shall not be unreasonably withheld or delayed), except for those disclosures for which consent has previously
been obtained or which have previously been disclosed. The restrictions imposed by this Section 13.6.1 shall not prohibit either Party from making any disclosure identifying the other Party that is required by Applicable Law or the requirements
of a national securities exchange or another similar regulatory body, provided that any such disclosure shall be governed by this Article 13. Further, the restrictions imposed on each Party under this Section 13.6 are not intended, and
shall not be construed, to prohibit a Party from identifying the other Party in its internal business communications, provided that any Confidential Information in such communications remains subject to this Article 13.

  

	 	13.6.2	AstraZeneca and its Affiliates and Sublicensees shall have the right, with Dynavax’s prior written consent, to use the name of Dynavax and its Affiliates to the
extent necessary or useful in connection with the Development and Commercialization of Product or Combination Product as contemplated by this Agreement. Additionally, with respect to any public disclosure made by AstraZeneca pursuant to this
Section 13.6.2, AstraZeneca shall give meaningful mention to Dynavax’s participation and contribution to the Collaboration and shall specifically mention the use of Dynavax Technology in the Dynavax ISS, Collaboration ISS, CDs, Product
and/or Combination Product, the mention in such disclosures to be approved in writing by Dynavax. 

  

	 	13.6.3	An initial press release pertaining to this transaction shall be issued by the Parties and shall be materially in the form attached as Exhibit E to this
Agreement. Neither Party shall issue any other press release or make any 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 64 of 103

  

	 	
other public announcement or statement concerning this Agreement or the transactions covered by it without the prior written approval of the other Party, except that each Party (after
consultation with counsel) may make such announcements and disclosures, if any, as may be required by Applicable Law or the requirements of a national securities exchange or another similar regulatory body, or in connection with a public offering of
securities or any filing with the U.S. Securities and Exchange Commission or a foreign equivalent. 

  

	14	Patent Prosecution, Enforcement and Defence 

  

	14.1	Disclosure . Each Party shall promptly disclose to the other Party any invention discovered or reduced to practice pursuant to the Collaboration that it believes
may be patentable. 

  

	14.2	Patent Prosecution and Maintenance. 

  

	 	14.2.1	Dynavax shall direct the filing, prosecution (including any interferences, reissue proceedings and re-examinations), oppositions and maintenance of all Dynavax Patents.
Dynavax shall consult with AstraZeneca in connection with the continued prosecution and maintenance by Dynavax of the Dynavax Patents and [ * ]. Dynavax shall provide AstraZeneca with [ * ]. Dynavax shall bear one hundred percent
(100%) of the costs and expenses of the Dynavax Patents. Dynavax shall not abandon any Dynavax Patents without at least [ * ] days prior notice to AstraZeneca. If Dynavax decides to abandon any Dynavax Patents, AstraZeneca shall have the
option to continue the prosecution and maintenance of such patents and related applications at its expense. 

  

	 	14.2.2	AstraZeneca shall be the Party (the “Prosecuting Party”) responsible for or for procuring, the filing, prosecution (including any interferences,
reissue proceedings and re-examinations), oppositions and maintenance of all Collaboration Patents. AstraZeneca shall consult with Dynavax in connection with the continued prosecution and maintenance by AstraZeneca of the Collaboration Patents and
[ * ]. AstraZeneca shall provide Dynavax with [ * ]. AstraZeneca shall bear one hundred percent (100%) of the costs and 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 65 of 103

  

	 	
expenses of the Collaboration Patents. AstraZeneca shall promptly reimburse Dynavax for any costs or expenses that Dynavax incurs in connection with the prosecution and maintenance of the
Collaboration Patents. AstraZeneca shall not abandon any such Collaboration Patents without at least [ * ] days prior notice to Dynavax. If AstraZeneca decides to abandon any such Collaboration Patents, Dynavax shall have the option to
continue the prosecution and maintenance of such patents and related applications at its expense. 

  

	 	14.2.3	Where a patent application covers two or more Dynavax ISS and/or Collaboration ISS, at least one of which has a use in the Field and at least one of which has no use in
the Field but a use outside of the Field, the prosecuting attorney will [ * ]. 

  

	 	14.2.4	Each Party shall cooperate with the other and take all reasonable additional actions and execute such agreements, instruments and documents as may be reasonably
required to perfect the other’s ownership interest in accordance with the intent of this Agreement including, without limitation, the execution of necessary and appropriate instruments of assignment to achieve such joint ownership as set forth
in Section 14.1 and the provision, on a reasonable basis, of its employees, agents, consultants and independent contractors to the other Party (or to the other Party’s authorized attorneys, agents or representatives), to the extent
reasonably necessary to enable the prosecuting Party to undertake Patent prosecution for inventions arising out of the Collaboration, as provided in this Agreement. 

 

	14.3	Patent Term Restoration. The Parties shall cooperate with each other with respect to obtaining patent term restoration or supplemental protection certificates or
their equivalents in any country in the Territory where applicable to Dynavax Patents and Collaboration Patents in respect of the Product or any Combination Product(s). In the event that elections with respect to obtaining such patent term
restoration are to be made, AstraZeneca shall have the right to make the election and Dynavax agrees to abide by such election. 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 66 of 103

  

	14.4	Enforcement of Patent Rights. 

  

	 	14.4.1	In the event that either Party becomes aware of a suspected infringement by a Third Party of any Dynavax Patent licensed to AstraZeneca under this Agreement, such Party
shall notify the other Party promptly, and following such notification, the Parties shall confer. Other than in respect of any Dynavax Patent solely covering a CD, Dynavax shall have the right, but shall not be obligated, to bring an infringement
action at its own expense, in its own name and entirely under its own direction and control. AstraZeneca, upon request of Dynavax, agrees to join in any such litigation at Dynavax’s expense and to cooperate with Dynavax in connection with such
litigation. Where Dynavax notifies AstraZeneca that it does not intend to take measures to remove such infringement, Dynavax may nevertheless be joined as a party to any infringement action that is pursued and shall retain the right to be heard in
such proceedings and to defend the validity of the Patent asserted by AstraZeneca. With respect to any Dynavax Patent solely covering a CD or Product, AstraZeneca shall have the right, but shall not be obligated, to bring an infringement action at
its own expense, in its own name and entirely under its own direction and control. Dynavax, upon request of AstraZeneca, agrees to join in any such litigation at AstraZeneca’s expense and to cooperate with AstraZeneca in connection with such
litigation. Where AstraZeneca notifies Dynavax that it does not intend to take measures to remove such infringement, AstraZeneca may nevertheless be joined as a party to any infringement action that is pursued and shall retain the right to be heard
in such proceedings and to defend the validity of the Patent asserted by Dynavax. 

  

	 	14.4.2	In the event that either Party becomes aware of a suspected infringement of any Collaboration Patent, such Party shall notify the other Party promptly. Following such
notification, the Parties shall confer. Other than in respect of any Collaboration Patent solely covering a Reverted ISS, AstraZeneca shall have the right, but shall not be obligated, to bring an infringement action or to defend such proceedings at
its own expense, in its own name and entirely under its own direction and control. Dynavax, upon request of AstraZeneca, agrees to join in any such litigation at AstraZeneca’s expense and to cooperate with AstraZeneca in connection with such
litigation. Where AstraZeneca notifies Dynavax that it does not intend to take measures to remove such 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 67 of 103

  

	 	
infringement, AstraZeneca may nevertheless be joined as a party to any infringement action that is pursued and shall retain the right to be heard in such proceedings and to defend the validity of
the Patent asserted by Dynavax. With respect to any Collaboration Patent solely covering a Reverted ISS, Dynavax shall have the right, but shall not be obligated, to bring an infringement action at its own expense, in its own name and entirely under
its own direction and control. AstraZeneca, upon request of Dynavax, agrees to join in any such litigation at Dynavax’s expense and to cooperate with Dynavax in connection with such litigation. Where Dynavax notifies AstraZeneca that it does
not intend to take measures to remove such infringement, Dynavax may nevertheless be joined as a party to any infringement action that is pursued and shall retain the right to be heard in such proceedings and to defend the validity of the Patent
asserted by AstraZeneca. 

  

	 	14.4.3	If the Party having the first right to prosecute any action described in Sections 14.4.1 or 14.4.2 fails to do so within (a) [ * ] days following
notice of the alleged infringement or (b) [ * ] days before the time limit, if any, set forth in the appropriate laws and regulations for the filings of such actions, whichever comes first, then the other Party shall have the
right, but not the obligation, to bring and control any such litigation at its own expense, in it own name and entirely under its own direction and control. 

 

	 	14.4.4	In the event either Party exercises the rights conferred in this Section 14.4 and recovers any damages or other sums in such action, suit or proceeding or in
settlement thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by such Party in connection therewith, including reasonable attorneys fees. If after such reimbursement any funds shall
remain from such damages or other sums recovered, such funds shall be retained by such Party that controlled the litigation. 

  

	14.5	Third Party Litigation. In the event of any actual or threatened suit against Dynavax, AstraZeneca or its Affiliates, Sublicensees, Distributors or customers
alleging that the Development and/or Commercialization of CDs, Product or Combination Product, or 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 68 of 103

  

	 	
that the Development and/or Commercialization of a Collaboration Patent or the Background Technologies or any part thereof by or on behalf of AstraZeneca under this Agreement, infringes the
Patent or other intellectual property rights of any Person (an “Infringement Suit”), the Party first becoming aware of such Infringement Suit shall promptly give written notice to the other Party. AstraZeneca shall have the first
right, but not the obligation, through counsel of its choosing, to assume direction and control of the defence of claims arising therefrom (including the right to settle such claims at its sole discretion, subject to the provisions of this
Section 14.5). If AstraZeneca notifies Dynavax in writing that it does not wish to assume such direction and control, Dynavax shall have the right, but not the obligation to, at its sole cost and expense, defend against such claims; provided,
however, that Dynavax shall obtain the written consent of AstraZeneca prior to ceasing to defend, settling or otherwise disposing of such claims. Dynavax shall be entitled to be joined in any proceedings that may be brought against AstraZeneca in
relation to Dynavax’s Background Technology. If Dynavax does so elect to be joined, it shall pay its own costs and expenses in relation to the proceedings. AstraZeneca shall not make any admission or settle or otherwise compromise any
proceedings brought against it in relation to Dynavax’s Background Technology without first obtaining the written consent of Dynavax, which shall not be unreasonably withheld or delayed. Notwithstanding anything in the foregoing, each Party
shall have the right to defend itself, using the counsel of its choice and at its own expense, any claims or law suits brought against it by any Third Party, and each Party shall have the right to settle any such claims or law suits on its own
behalf, so long as such settlement does not provide for the payment of money by the other Party or performance obligations, or restrictions imposed upon, the other Party. 

 

	14.6	Invalidity or Unenforceability Defences or Actions. 

  

	 	14.6.1	In the event that a Third Party or Sublicensee asserts, as a defence or as a counterclaim in any Infringement Suit under Section 14.5, that any AstraZeneca Patent,
Dynavax Patent or Collaboration Patent covering a Dynavax ISS or Collaboration ISS is invalid or unenforceable, then the Party pursuing such Infringement Suit shall promptly give written notice to the other Party. AstraZeneca shall have the first
right, but not the obligation, through counsel of its choosing, to respond to such defence or defend against such 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 69 of 103

  

	 	
counterclaim (as applicable), including the right to settle or otherwise compromise such claim with respect to the AstraZeneca Patents and Collaboration Patents (other than in respect of any
Collaboration Patent solely covering a Reverted ISS for which Dynavax shall have the first right), and Dynavax shall have the first right to do so with respect to Dynavax Patents (other than in respect of any Dynavax Patent solely covering a CD or
Product for which AstraZeneca shall have the first right). If the Party having the first right notifies the other Party in writing that it does not wish to respond to such defence or defend against such counterclaim (as applicable), the other Party
shall, at its sole cost and expense, have the right but not the obligation to respond to such defence or defend against such counterclaim (as applicable); provided, however, that such other Party shall obtain the written consent of the Party having
the first right prior to ceasing to defend, settling or otherwise compromising such defence or counterclaim. 

  

	 	14.6.2	Similarly, if a Third Party or Sublicensee asserts, in a declaratory judgment action or similar action or claim filed by such Third Party or Sublicensee, that any
AstraZeneca Patent, Dynavax Patent or Collaboration Patent covering the Dynavax ISS or Collaboration ISS is invalid or unenforceable, then the Party first becoming aware of such action or claim shall promptly give written notice to the other Party.
AstraZeneca shall have the first right, but not the obligation, through counsel of its choosing, to defend against such action or claim, including the right to settle or otherwise compromise such claim with respect to AstraZeneca Patents and
Collaboration Patents (other than in respect of any Collaboration Patent solely covering a Reverted ISS for which Dynavax shall have the first right), and Dynavax shall have the right to do so with respect to the Dynavax Patents (other than in
respect of any Dynavax Patent solely covering a CD or Product for which AstraZeneca shall have the first right). If the Party having the first right to defend notifies the other Party in writing that it does not wish to respond to or defend against
or settle such action or claim, the other Party shall, at its sole cost and expense, have the right but not the obligation to defend against such action or claim; provided, however, that such other Party shall obtain the written consent of the Party
having the first right prior to ceasing to defend, settling or otherwise compromising of any such action or claim. 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 70 of 103

  

	14.7	Cooperation. The Party other than the Party defending an action or claim pursuant to this Article 14 (the “Non-Defending Party”) will provide to
the other Party (the “Defending Party”) all reasonable assistance requested by the Defending Party in connection with any action, claim or suit under Article 14, including allowing the Defending Party reasonable access to the
Non-Defending Party’s files and documents and to the Non-Defending Party’s personnel who may have possession of relevant information, in all cases, during normal business hours and with reasonable prior notice. In particular the
Non-Defending Party will promptly make available to the Defending Party, at the Defending Party’s expense, all information in its possession or control that it is aware will assist the Defending Party in responding to any such action, claim or
suit under Article 14. 

  

	14.8	Compliance with Third Party Licences. To the extent any provision in this Article 14 is inconsistent with the requirements in any licence agreement between a
Party and any Third Party existing as of the Effective Date (including without limitation the license agreement between Dynavax and the Regents), including without limitation the rights and procedures for the filing, prosecution and maintenance of
any Patents, the enforcement of any Patents, or the defense of any Third Party claims, the terms and conditions in such Third Party agreement(s) shall control. 

 

	14.9	Costs and Expenses. AstraZeneca shall have the right to [ * ]. Any royalties payable by AstraZeneca with respect to the manufacture, use or sale of
Products may result in a reduction of royalties payable to Dynavax, pursuant to Section 10.4 and subject to Section 10.7. For the avoidance of doubt, where Indirect Taxes apply to milestones, royalties or costs, the Parties shall invoice
these sums according to Applicable Law. Any amounts recovered by AstraZeneca in connection with any action, claim or suit under Article 14 shall first be applied to all out-of-pocket costs and expenses incurred by AstraZeneca in connection
therewith, including reasonable attorneys fees and any such sums remaining shall be retained by AstraZeneca and shall be included in the calculation of Net Sales. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 71 of 103

  

	15	Adverse Event Reporting 

  

	15.1	Overview. AstraZeneca shall maintain a record of all non-medical and medical Product-related or Combination Product-related complaints and reports of adverse
events that it receives with respect to any Product or Combination Product as appropriate. AstraZeneca shall be responsible for reporting to Regulatory Authorities any adverse experiences and safety issues for each Product and Combination Product in
compliance with the requirements of the U.S. Food, Drug and Cosmetic Act, 21 U.S.C. § 321 et seq., the regulations promulgated thereunder, and equivalent foreign laws, rules and regulations. Without limiting the foregoing, upon
AstraZeneca’s written request, Dynavax shall provide AstraZeneca with any information reasonably necessary for AstraZeneca to comply with all Applicable Law with respect to the Dynavax ISS, Collaboration ISS, the Product and Combination
Product(s), as the case may be. 

  

	    	In the event that Dynavax exercises its option to co-promote the Product or any Combination Product(s) in the United States of America and the Parties enter into a
written co-promotion agreement pursuant to Section 8.5, Dynavax shall, at least [ * ] months prior to commencing such co-promotion, develop appropriate adverse experience reporting procedures to record all non-medical and medical
product-related complaints and reports of adverse events that it receives with respect to any Product or Combination Product(s). 

  

	15.2	Complaints. AstraZeneca shall maintain a record of any and all complaints it receives with respect to the Product and any Combination Products. Dynavax shall
notify AstraZeneca in reasonable detail of any complaint received by it within [ * ] after the event, and in any event in sufficient time to allow AstraZeneca to comply with all Applicable Law in any country in which the Product or any
Combination Product is being developed, marketed or sold. 

  

	16	Product Recall  

  

	16.1	Notification and Recall. In the event that any Governmental Authority issues or requests a recall or takes similar action in connection with a CD, the Product or
any Combination Product, or in the event [ * ], AstraZeneca shall promptly advise Dynavax thereof by telephone or facsimile. Following notification of a recall, 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 72 of 103

  

	 	
AstraZeneca shall decide and have control of whether to conduct a recall or market withdrawal (except in the case of a government-mandated recall) in the Territory and the manner in which any
such recall or market withdrawal shall be conducted. 

  

	16.2	Recall Expenses. AstraZeneca shall bear the expenses of any recall of a CD, the Product or any Combination Product; provided, however, that Dynavax
shall bear the expense of a recall to the extent that such recall resulted from Dynavax’s breach of its obligations hereunder or Dynavax’s negligence or willful misconduct or intentional omission. Such expenses of recall shall include
expenses for notification, destruction and return of the recalled Product or Combination Product and any refund to customers of amounts paid for the recalled Product or Combination Product. 

 

	17	Trademarks. 

 AstraZeneca
shall have the sole right to select the Trademarks for the marketing and sale of the Product and any Combination Product(s) in the Territory. AstraZeneca shall own such Trademarks and all rights and goodwill with respect thereto. AstraZeneca agrees
not to adopt or use any trademarks, brand names, words, logos, symbols, letters, designs or marks that would be confusingly similar to Dynavax’s trademarks. Dynavax shall not, and shall not permit its Affiliates to, use any trademark that is
the same as or confusingly similar to, misleading or deceptive with respect to or that dilutes the Trademarks. 
  

	18	Representations and Warranties  

  

	18.1	Each Party represents and warrants to the other that: 

  

	 	18.1.1	it has full legal power to extend the rights and licences granted to the other under this Agreement and perform its obligations hereunder; 

 

	 	18.1.2	it has full power and authority to enter into this Agreement and has taken all necessary action on its part required to authorise the execution and delivery of this
Agreement; 

  

	 	18.1.3	its employees and agents who are performing any activities under this Agreement or who have access to Confidential Information are bound, without request for additional
compensation, to Articles 6, 13 and 14 of this Agreement; 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 73 of 103

  

	 	18.1.4	neither it nor any researcher engaged by it, in any capacity, in the Joint Research Programme has been debarred or is subject to debarment or has otherwise been
disqualified or suspended from performing scientific or clinical investigations or otherwise subjected to any restrictions or sanctions by the FDA or any other governmental or regulatory authority or professional body with respect to the performance
of scientific or clinical investigations; 

  

	 	18.1.5	to the best of its Knowledge and belief, this Agreement is legally binding upon it and enforceable in accordance with its terms, and the execution, delivery and
performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any Governmental Authority
having jurisdiction over it; 

  

	 	18.1.6	it has not granted, and will not grant during the Term of the Agreement, any right to any Third Party that would conflict with the rights granted to the other Party
hereunder; 

  

	 	18.1.7	it has (or will have at the time performance is due) maintained and will maintain and keep in full force and effect all agreements necessary to perform its obligations
hereunder; 

  

	 	18.1.8	it is aware of no action, suit or inquiry or investigation instituted by any governmental agency that questions or threatens the validity of this Agreement; and

  

	 	18.1.9	to the best of its Knowledge and belief, all necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained
by such Party to enter into, or perform its obligations under, this Agreement have been obtained. 

  

	18.2	Dynavax further represents and warrants that as of the Effective date: 

  

	 	18.2.1	Dynavax is the sole and exclusive owner of the entire right, title and interest in the Dynavax Patents listed on Exhibit B(1) (the “Owned
Patents”) and is 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 74 of 103

  

	 	
entitled to grant the licences specified herein. Such rights are not subject to any encumbrance, lien or claim of ownership by any Third Party. Dynavax is the sole and exclusive licensee of and
Controls all right, title and interest in and to the Dynavax Patents listed in Exhibit B(2) (the “In-licensed Patents”) and is entitled to grant the licences specified herein. Such rights are not subject to any encumbrance,
lien or claim of ownership by any Third Party, other than the Third Party from which such rights are licensed. True, complete and correct copies of the complete file wrapper and other documents and materials relating to the prosecution, defence,
maintenance, validity and enforceability of the Owned Patents and the In-licensed Patents and all license and other agreements regarding the In-licensed Patents (the “In-Licence Agreements”), as amended to the date hereof, have been
provided to AstraZeneca prior to the date first above written. The Owned Patents and the In-licensed Patents constitute all of the licensed Dynavax Patents as of the Effective Date. During the Term, Dynavax shall not encumber or diminish the rights
granted to AstraZeneca hereunder with respect to the licensed Dynavax Patents, including by not [ * ]. Dynavax shall promptly provide AstraZeneca with notice of any alleged, threatened or actual breach of any In-Licence Agreement. As of the
Effective Date, none of Dynavax, its Affiliates and, to the best of their Knowledge, any Third Party is in breach of any In-Licence Agreement; 

  

	 	18.2.2	All information and data provided by or on behalf of Dynavax to AstraZeneca on or before the Effective Date in contemplation of this Agreement was and is true and
accurate in all material respects, and Dynavax has not failed to disclose, or cause to be disclosed, any information or data that would cause the information and data that has been disclosed to be individually, or in the aggregate, misleading in any
material respect; 

  

	 	18.2.3	To Dynavax’s Knowledge, the licensed Dynavax Patents are being diligently procured from the respective Patent Offices in accordance with all applicable laws and
regulations. The licensed Dynavax Patents have been filed and maintained properly and correctly and all applicable fees have been paid on or before the due date for payment; 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 75 of 103

  

	 	18.2.4	As of the Effective Date, to the best of Dynavax’s and its Affiliates’ Knowledge, there is no actual infringement or threatened infringement of the licensed
Dynavax Patents, licensed Dynavax Know-How or any regulatory documentation by any Person. 

  

	 	18.2.5	To the best of Dynavax’s and its Affiliates’ Knowledge and except as disclosed in Schedule 18.2.5, AstraZeneca’s use Exploitation of the regulatory
documentation, the licensed Dynavax Patents or licensed Dynavax Know-How hereunder will not infringe any Patent or other intellectual property or proprietary right of any Person; 

 

	 	18.2.6	The licensed Dynavax Patents and the licensed Dynavax Know-How existing as of the Effective Date are subsisting and to the best of Dynavax’s knowledge are not
invalid or unenforceable, in whole or in part, except to the patent properties identified in Schedule 18.2.6, as to which no representation is made. To Dynavax’s Knowledge, the conception, development and reduction to practice of the regulatory
documentation, the licensed Dynavax Patents and licensed Dynavax Know-How existing as of the Effective Date have not constituted or involved the misappropriation of trade secrets or other rights or property of any Person. There are no claims,
judgments or settlements against or amounts with respect thereto owed by Dynavax relating to the regulatory documentation, the licensed Dynavax Patents or the licensed Dynavax Know-How. Except as disclosed in Schedule 18.2.6, no claim or litigation
has been brought or threatened by any Person alleging, and Dynavax is not aware of any possible claim, whether or not asserted, that (a) the licensed Dynavax Patents or the licensed Dynavax Know-How are invalid or unenforceable or (b) the
regulatory documentation, the licensed Dynavax Patents or the licensed Dynavax Know-How or the disclosing, copying, making, assigning, licensing or use of the regulatory documentation, the licensed Dynavax Patents or the licensed Dynavax Know-How,
or products and services embodying the regulatory documentation, or the Dynavax ISS, Collaboration ISS, CDs, Product or Combination Product(s) violates, infringes or otherwise conflicts or interferes with any intellectual property or proprietary
right of any Person; 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 76 of 103

  

	 	18.2.7	Dynavax has not previously entered into any agreement, whether written or oral, with respect to, or otherwise assigned, transferred, licensed, conveyed or otherwise
encumbered its right, title or interest in or to, the licensed Dynavax Patents, licensed Dynavax Know-How, regulatory documentation, or the Dynavax ISS and/or Collaboration ISS (including by granting any covenant not to sue with respect thereto)
that is inconsistent with the rights and licences granted to AstraZeneca under this Agreement; 

  

	 	18.2.8	In respect of the pending United States patent applications included in the licensed Dynavax Patents, Dynavax has presented all relevant prior art of which it has
Knowledge to the relevant Patent Examiner at the United States Patent and Trademark Office; 

  

	 	18.2.9	The licensed Dynavax Patents represent all Patents within Dynavax’s Control as of the Effective Date that are directly related to, or are necessary, for the
manufacture, use, offer for sale or sale of the Dynavax ISS and/or the Collaboration ISS; 

  

	 	18.2.10	Any licensed Dynavax Know-How has been kept confidential or has been disclosed to Third Parties only under terms of confidentiality; 

 

	 	18.2.11	Dynavax has made (and will make) available to AstraZeneca all regulatory documentation, licensed Dynavax Know-How and other Information in its possession or Control
directly related to any Dynavax ISS and/or Collaboration ISS and all such regulatory documentation, licensed Dynavax Know-How and other Information are (and, if made available after the Effective Date, will be) true, complete and correct. As of the
Effective Date, Dynavax has prepared, maintained and retained all regulatory documentation that is required to be maintained or reported pursuant to and in accordance with good laboratory and clinical practice and Applicable Law and all such
information is true, complete and correct and what it purports to be; 

  

	 	18.2.12	Dynavax shall obtain from each of its Affiliates, Sublicensees, employees and agents, and from the employees and agents of its Affiliates, Sublicensees and agents, who
are performing tests or studies, or are otherwise participating in the Research of the Dynavax ISS and/or Collaboration ISS, CDs, Product or 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 77 of 103

  

	 	
Combination Product or who otherwise have access to any AstraZeneca Confidential Information, rights to any and all Information that relate to the Dynavax ISS and/or Collaboration ISS, CDs,
Product and Combination Product, such that AstraZeneca shall, by virtue of this Agreement, receive from Dynavax, without payments beyond those required by this Agreement, the licences and other rights granted to AstraZeneca hereunder.

  

	18.3	Each Party shall comply with all laws, rules and regulations that govern the Party’s performance under this Agreement, including all United States and multilateral
export laws and regulations. 

  

	18.4	Nothing in this Agreement shall be construed as a warranty or representation by either Party of the success of the Joint Research Programme or the Joint Research Plan.

  

	18.5	DISCLAIMER. OTHER THAN AS PROVIDED IN THIS ARTICLE 18, THE PARTIES DISCLAIM ANY AND ALL WARRANTIES OF ANY KIND WITH REGARD TO THE COLLABORATION MATERIALS OR THE
BACKGROUND TECHNOLOGIES, WHETHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ANY WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE. 

 

	19	Indemnification and Insurance 

  

	19.1	Indemnification of Dynavax. In addition to any other remedy available to Dynavax, AstraZeneca shall indemnify, defend and hold harmless Dynavax, its Affiliates
and its and their respective directors, officers and employees in full and on demand, from and against any and all Losses incurred by them to the extent resulting from or arising out or in connection with any claims made or suits brought by a Third
Party (collectively, “Third Party Claims”) against Dynavax, its Affiliates, Sublicensees, and their respective directors, officers or employees: 

 

	 	19.1.1	that arise or result from any intentional misconduct or gross negligence on the part of AstraZeneca, its Affiliates, Distributors, Sublicensees or agents in performing
any activity contemplated by this Agreement, or the breach of any provision of this Agreement (including a breach of a warranty or Applicable Law) by AstraZeneca; or 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 78 of 103

  

	 	19.1.2	that allege that the claimant has suffered personal injury or death as a result of use of the Product or Combination Product(s) or of AstraZeneca’s Development,
manufacture, use, handling, storage, sale, offer for sale, importation, or other disposition of the Product or any Combination Product(s), 

 except for any Losses for which Dynavax has an obligation to indemnify AstraZeneca and its Affiliates pursuant to Section 19.2. 

 

	19.2	Indemnification of AstraZeneca. In addition to any other remedy available to AstraZeneca, Dynavax shall indemnify, defend and hold harmless AstraZeneca, its
Affiliates, Distributors, Sublicensees and its and their respective directors, officers and employees in full and on demand, from and against any and all Losses incurred by them to the extent resulting from or arising out of or in connection with
any Third Party Claims against AstraZeneca, its Affiliates, Distributors or Sublicensees or their respective directors, officers or employees that: 

  

	 	19.2.1	arise or result from any intentional misconduct or gross negligence on the part of Dynavax, its Affiliates, Sublicensees or agents in performing any activity
contemplated by this Agreement, or the breach of any provision of this Agreement by Dynavax; 

  

	 	19.2.2	allege that the claimant has suffered personal injury or death as a result of use of any product incorporating a Reverted ISS or reverted CD or of Dynavax’s
development, manufacture, use, handling, storage, sale, offer for sale, importation, or other disposition of such reverted ISS, product(s) or CD(s); 

  

	 	19.2.3	in the event that the Agreement is terminated and Dynavax continue to Develop and Commercialize any CD, Product or Combination Product directly or through a Third
Party, allege that the claimant has suffered personal injury or death as a result of use of any CD, Product or Combination Product or of Dynavax’s Development, manufacture, use, handling, storage, sale, offer for sale, importation, or other
disposition of such Product or Combination Product(s), after the date of termination; 

 in all cases except for
any Losses for which AstraZeneca has an obligation to indemnify Dynavax and its Affiliates pursuant to Section 19.1. 
  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 79 of 103

  

	19.3	[ * ] 

  

	19.4	Notice of Claim . An Indemnified Party shall give the Indemnifying Party prompt written notice of any Losses or discovery of fact upon which such Indemnified
Party intends to base a request for indemnification under Section 19.1, 19.2 or 19.3 (an “Indemnification Claim Notice”). In no event shall the Indemnifying Party be liable for any Loss that results from any delay in providing
the Indemnification Claim Notice. Each Indemnification Claim Notice shall contain a description of the claim and the nature and amount of the Loss claimed (to the extent that the nature and amount of such Loss is known at such time). The Indemnified
Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any such Loss. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates or their respective
directors, officers, employees and agents (each, an “Indemnitee”) shall be made solely by such Party to this Agreement. 

  

	19.5	Indemnification Procedures. The obligations of an Indemnifying Party under this Article 19 shall be governed by and contingent upon the following:

  

	 	19.5.1	Assumption of Defence. At its option, the Indemnifying Party may assume the defence of any Third Party Claim by giving written notice to the Indemnified Party
within [ * ] days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defence of a Third Party Claim by the Indemnifying Party shall not be construed as an acknowledgement that the Indemnifying Party
is liable to indemnify any Indemnitee in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defences it may assert against any Indemnified Party’s claim for indemnification.

  

	 	19.5.2	Control of Defence. Upon the assumption of the defence of a Third Party Claim by the Indemnifying Party: 

 

	 	(e)	the Indemnifying Party may appoint as lead counsel in the defence of the Third Party Claim any legal counsel selected by the Indemnifying Party, which shall be
reasonably acceptable to the Indemnified Party, and 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 80 of 103

  

	 	(f)	Except as expressly provided in Section 19.5.3, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by
such Indemnified Party or any Indemnitee in connection with the analysis, defence or settlement of the Third Party Claim. In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold
harmless an Indemnitee from and against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including lawyers’ fees and costs of suit) and any Loss incurred by the Indemnifying
Party in its defence of the Third Party Claim with respect to such Indemnified Party or Indemnitee. 

  

	 	19.5.3	Right to Participate in Defence. Without limiting Section 19.5.1 or 19.5.2, any Indemnitee shall be entitled to participate in, but not control, the defence
of a Third Party Claim and to retain counsel of its choice for such purpose; provided, however, that such retention shall be at the Indemnitee’s own expense unless, (a) the Indemnifying Party has failed to assume the defence and retain
counsel in accordance with Section 19.5.1 (in which case the Indemnified Party shall control the defence), or (b) the interests of the Indemnitee and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to
prohibit the representation by the same counsel of both parties under Applicable Law, ethical rules or equitable principles. 

  

	 	19.5.4	Settlement. With respect to all Losses, where the Indemnifying Party has assumed the defence of a Third Party Claim in accordance with Section 19.5.1,
(i) the Indemnifying Party shall have authority to consent to the entry of any judgement, enter into any settlement or otherwise dispose of such Losses, provided that it obtains the prior written consent of the Indemnified Party, which consent
shall not be unreasonably withheld or delayed, and (ii) no Indemnified Party or Indemnitee shall admit any liability with respect to, or settle, compromise or discharge, any such Third Party Claim without the prior written consent of the
Indemnifying Party, which consent shall not be unreasonably withheld. 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 81 of 103

  

	 	19.5.5	Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall, and shall cause each other Indemnitee
to, reasonably cooperate in the defence or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably
requested in connection therewith. Such cooperation shall include access during normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such
Third Party Claim, and making the Indemnified Party, the Indemnitees and its and their employees and agents available on a mutually convenient basis to provide additional information and explanation of any records or information provided, and the
Indemnifying Party shall reimburse the Indemnified Party for all of its related reasonable out-of-pocket expenses. 

  

	 	19.5.6	Expenses. Except as expressly provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the
Indemnified Party in connection with any claim shall be reimbursed on a quarterly basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject
to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

  

	19.6	LIMITATION ON DAMAGES. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES, OR WITH RESPECT TO THIRD PARTY CLAIMS
UNDER SECTION 19.1 OR 19.2, NO PARTY OR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, OR FOR LOST PROFITS, MILESTONES OR ROYALTIES, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT
LIABILITY OR OTHERWISE, ARISING OUT OF (a) THE DEVELOPMENT, MANUFACTURE, USE OR SALE OF ANY PRODUCT OR COLLABORATION ISS DEVELOPED, MANUFACTURED OR MARKETED HEREUNDER, OR (b) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF
THIS AGREEMENT. 

  
 [ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 82 of 103

  

	19.7	Insurance . Each Party shall have and maintain such type and amounts of liability insurance as is normal and customary in the pharmaceutical industry generally
for Persons similarly situated, and shall upon request provide the other Party with a copy of its policies of insurance in that regard, along with any amendments and revisions thereto. 

 

	20	Term and Termination  

  

	20.1	Term . This Agreement shall become effective on the Effective Date and shall continue in full force and effect until the earlier of (i) expiration or
termination of all payment obligations to Dynavax under this Agreement, or (ii) the effective date of termination pursuant to Sections 20.2, 20.3, 20.4, 20.5 or 20.6 or Section 21.4 below (the “Term”). The Term shall expire on
the Product, or a Combination Product by Combination Product and country by country basis within the Territory. 

  

	20.2	Termination by AstraZeneca. AstraZeneca may terminate this Agreement if it determines, in its sole discretion, that it does not wish to pursue the Joint Research
Programme or the further research, development, launch or sale of Dynavax ISS, Collaboration ISS, Candidate Drugs, Product or Combination Product(s) for any reason, including but not limited to, a scientific, technical, regulatory or commercial
reasons, including [ * ]. AstraZeneca shall promptly notify Dynavax in writing of such determination and provide Dynavax with the pertinent information with respect thereto. Promptly following the receipt of such notice from AstraZeneca, the Parties
shall discuss in more detail the reasons for such termination in good faith. Following such discussion, AstraZeneca may, at its sole discretion, terminate this Agreement in its entirety or with respect to the Product or one or more Combination
Products or one or more countries in the Territory upon [ * ] days’ prior written notice. Further, AstraZeneca shall have the right in its sole discretion to terminate this Agreement with respect to a country upon [ * ] days’ prior written
notice in the event that any Governmental Authority takes, fails to take, or reasonably could be expected to take or fail to take, any action with respect to the CD, Product or any Combination Product that could have an adverse effect on the
Development and/or Commercialization of the CD, Product or Combination Product(s) in such country; provided, however, that AstraZeneca shall have the right to terminate this Agreement with respect to all of Europe if such country is in
Europe and AstraZeneca shall have the right to terminate 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 83 of 103

  

	 	
this Agreement in its entirety if such country is or is in a Major Market. In the event of any such termination, if such termination occurs at a time when AstraZeneca is conducting or sponsoring
a clinical trial of a CD, the Product or any Combination Product, AstraZeneca shall [ * ]. 

  

	20.3	Termination for Infringement of Third Party Rights. 

  

	 	20.3.1	If a Triggering Event occurs with respect to a country, AstraZeneca shall have the right upon written notice to Dynavax to terminate this Agreement with respect to such
country if at any time (a) AstraZeneca is unable to obtain such a licence on commercially reasonable terms or (b) AstraZeneca in good faith believes that negotiation with a Third Party pursuant to Section 6.4 with respect to such
country is not likely to result in a commercially reasonable agreement; provided, however, that AstraZeneca shall have the right to terminate this Agreement with respect to all of Europe if such country is in Europe and AstraZeneca
shall have the right to terminate this Agreement in its entirety if such country is or is in a Major Market. 

  

	 	20.3.2	If a Third Party institutes an Infringement Suit with respect to a country, AstraZeneca shall have the right upon written notice to Dynavax to terminate this Agreement
with respect to such country if [ * ]; provided, however, that AstraZeneca shall have the right to terminate this Agreement with respect to all of Europe if such country is in Europe and AstraZeneca shall have the right to
terminate this Agreement in its entirety if such country is or is in a Major Market. 

  

	20.4	Termination by Dynavax for Lack of Diligence. In addition to the rights of termination in the event of material breach set forth in Section 20.5.1, Dynavax
may terminate this Agreement, in its entirety or on a Dynavax ISS-by-Dynavax ISS, Collaboration ISS-by-Collaboration ISS, CD by CD, Product or Combination Product-by-Combination Product basis, upon [ * ] days advance written notice to
AstraZeneca in the event that an arbitrator determines pursuant to Section 24.13 that AstraZeneca has failed to fulfil its Commercially Reasonable Efforts obligations under Section 8.10. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 84 of 103

  

	20.5	Termination by Either Party. In addition to any other provision of this Agreement expressly providing for termination of this Agreement, this Agreement may be
terminated immediately by either Party upon notice to the other Party: 

  

	 	20.5.1	if it believes that the other Party is in material breach of this Agreement, in which case the non-breaching Party may deliver notice of such material breach to the
other Party, such notice to describe in detail the nature of such breach. The allegedly breaching Party shall have [ * ] days from receipt of such notice to cure such breach (or, if such default cannot be cured within such [ * ] day
period, the breaching Party must commence actions to cure such default during such [ * ] day period and diligently continue such actions until the cure is effected). Any such termination shall become effective at the end of such [ * ]
day period unless the breaching Party has cured any such breach or default prior to the expiration of such [ * ] day period (or, if such default is capable of being cured but cannot be cured within such [ * ] day period, the breaching
Party has commenced and diligently continued actions to cure such default provided always that, in such instance, such cure must have occurred within [ * ] days after notice thereof was provided to the breaching Party by the non-breaching
Party to remedy such default); 

  

	 	20.5.2	if such other Party ceases or threatens to cease to carry on the whole or substantially the whole of its business or that part of its business to which this Agreement
relates; 

  

	 	20.5.3	if such other Party shall file in any court or agency, pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for
reorganization or for an the appointment of a receiver or trustee of such other Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an
involuntary petition against it, filed in any insolvency proceeding, or if the other Party shall propose or be a Party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of its creditors;

  

	 	20.5.4	if any encumbrancer takes possession of any material part of the assets of another Party; or 

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 85 of 103

  

	 	20.5.5	if any distress, execution or other such process is levied or enforced upon or against any of the material assets of the other Party. 

It is understood that termination pursuant to this Section 20.5 shall be a remedy of last resort and may be invoked only in the case
where the breach cannot be reasonably remedied by the payment of money damages. If a Party gives notice of termination under this Section 20.5, and the other Party disputes whether such notice was proper, then the issue of whether this
Agreement has been terminated shall be resolved in accordance with Article 24. If as a result of such dispute resolution process it is determined that the notice of termination was proper, then such termination shall be deemed to have been effective
[ * ] days following the date of receipt of the notice of termination. If as a result of such dispute resolution process it is determined that the notice of termination was improper, then no termination shall have occurred and this Agreement
shall remain in effect. 
  

	20.6	Change of Control. Upon a Change of Control of Dynavax at any time during the Joint Research Programme, AstraZeneca shall have the right to (a) terminate
this Agreement in its entirety by delivering written notice of termination to Dynavax at any time within [ * ] months after the date of such Change of Control or (b) terminate only the Parties’ collaboration under the Joint Research
Programme with immediate effect thereby ending the Research Term. In the event AstraZeneca exercises the latter option, AstraZeneca shall be under no obligation to provide Dynavax with any further compensation pursuant to Article 7 but shall
remain responsible for payments under Articles 9 and 10. Following such termination of the Research Term, Dynavax shall immediately provide AstraZeneca with all Collaboration Technology generated by it under the Joint Research Programme and not
previously provided to AstraZeneca and shall immediately return to AstraZeneca all AstraZeneca Confidential Information, including any and all copies thereof, and those portions of any documents, memoranda, notes, studies, analyses or other material
prepared by or on behalf of Dynavax that incorporate or are derived from such Confidential Information. For the avoidance of doubt, in the event of such termination, Dynavax shall have no further rights to use any Collaboration Technology,
AstraZeneca Technology or AstraZeneca Confidential Information for any purpose in the Field. [ * ]. The Agreement shall remain valid and in full force and effect in all other respects. Upon a Change of Control of AstraZeneca at any time

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 86 of 103

  

	 	
during the Term, the successor in interest and/or surviving entity shall continue to perform the obligations of and exercise the rights of AstraZeneca pursuant to this Agreement in the same
manner as intended by AstraZeneca as of the Effective Date. 

  

	20.7	Consequences of Termination. 

  

	 	20.7.1	Payment by AstraZeneca. Upon termination of this Agreement by AstraZeneca pursuant to Section 20.2 prior to the [ * ] anniversary of the Effective
Date, AstraZeneca shall make a lump sum payment to Dynavax to compensate Dynavax for such early termination in an amount equal to [ * ]; provided, however, that AstraZeneca shall have no obligation to make such payment in the event it
terminates this Agreement pursuant to Section 20.5.1 or 20.6 or Section 21.4. For clarity, the foregoing lump sum payment shall be in addition to any ongoing payment obligations AstraZeneca may have for existing clinical trials pursuant to
Section 20.2. In addition to the lump sum, and on condition that Dynavax maintain the level of internal Dynavax FTE support existing as at the date of termination to any continuing research activities previously covered by the Joint Research
Programme, AstraZeneca shall meet [ * ] of any reasonable external FTE costs Dynavax incurs during the period of [ * ] months following immediately after the date of the termination. AstraZeneca shall have no obligation to make such
additional external FTE contribution in the event it terminates this Agreement pursuant to Section 20.5.1 or 20.6 or Section 21.4. 

  

	 	20.7.2	Cessation of Obligations; Return of Materials. Upon termination of this Agreement, Dynavax shall promptly cease its performance of obligations under this
Agreement. The expiration or termination of this Agreement shall be without prejudice to any rights or obligations of the Parties that may have accrued prior to such expiration or termination and, except as otherwise expressly provided herein, shall
not limit any rights or remedies which may be available at law or otherwise. Upon the termination or expiration of this Agreement, each Party shall, at its sole expense, promptly return to the other Party all Confidential Information of such other
Party and, at such other Party’s option, either destroy or return to such other Party all materials 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 87 of 103

  

	 	
received from such other Party, except to the extent that the Receiving Party has a continuing licence to use such materials. Notwithstanding the foregoing, the General Counsel of each Party may
retain one copy of each business document generated by such Party in connection with this Agreement for archival purposes only, and all such retained documents shall be subject to the confidentiality obligations of this Agreement.

  

	 	20.7.3	Licences. 

  

	 	(g)	Upon termination of this Agreement in its entirety by AstraZeneca pursuant to Section 20.2 or 20.3 or by Dynavax pursuant to Section 20.4 or
Section 20.5, all licenses to AstraZeneca under Section 6.2 shall terminate, and (A) AstraZeneca shall, and hereby does, grant to Dynavax an exclusive, worldwide, perpetual, irrevocable, royalty-free license, with right to sublicense
and to enforce patents, under the AstraZeneca Technology, to make, have made, use, import, offer for sale and sell the then current Dynavax ISS, Collaboration ISS, CD, Product and Combination Product(s) in the Field, and (B) [ * ].
Dynavax shall have the right to use [ * ]. 

  

	 	(h)	Upon termination by AstraZeneca of AstraZeneca’s obligations and/or license rights to a specific Dynavax ISS, Collaboration ISS, CD, Product and/or Combination
Product pursuant to Sections 20.2 or 20.3, the license to AstraZeneca under Section 6.2 shall terminate solely as to such Dynavax ISS, Collaboration ISS, CD, Product and/or Combination Product(s), and (A) AstraZeneca shall, and hereby
does, grant to Dynavax an exclusive, worldwide, perpetual, irrevocable, royalty-free license, with right to sublicense and to enforce patents, under the AstraZeneca Technology, to make, have made, use, import, offer for sale and sell such Dynavax
ISS, Collaboration ISS, CD, Product and Combination Product(s) in the Field, and (B) [ * ]. Dynavax shall have the right to use [ * ]. 

  

	 	(i)	Upon termination by AstraZeneca of AstraZeneca’s obligations and/or license rights to a specific Dynavax ISS, Collaboration ISS, CD, Product and/or Combination
Product in a particular country pursuant to 

  
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

  
 Page 88 of 103

  

	 	
Sections 20.2 or 20.3, the license to AstraZeneca under Section 6.2 shall terminate solely as to such Dynavax ISS, Collaboration ISS, CD, Product and/or Combination Product(s) in such
country, and (A) AstraZeneca shall, and hereby does, grant to Dynavax an exclusive, worldwide, perpetual, irrevocable, royalty-free license, with right to sublicense and to enforce patents, under the AstraZeneca Technology, to make, have made,
use, import, offer for sale and sell such Dynavax ISS, Collaboration ISS, CD, Product and Combination Product(s) in the Field in such country only and (B) [ * ]. Dynavax shall have the right to use [ * ]. 

 

	 	(j)	Upon termination of this Agreement by AstraZeneca pursuant to Section 20.5.1, the licenses to AstraZeneca under Section 6.2 shall remain in effect. In such
case, AstraZeneca shall remain liable for [ * ] of the milestone payments and [ * ] of the royalties due under Article 10 and Section 10.7 shall cease to apply. The foregoing milestone and royalty reduction shall not be an
exclusive remedy, but any claim for money damages by AstraZeneca shall be reduced by the economic effect of such [ * ] reduction in milestone payments and royalty obligations. Following termination under Section 20.5.1 AstraZeneca shall
be relieved of its remaining obligations to Dynavax under this Agreement except for AstraZeneca’s obligations under Articles 9, 10 (other than Section 10.7), 13, 14, and 19. 

 

	 	(k)	For clarity, in the event of termination of this Agreement in its entirety or in part by AstraZeneca or Dynavax (as appropriate) pursuant to Sections 20.2, 20.3, 20.4
or 20.5, if the Product or Combination Product at the time of termination is being Commercialized with or has been the subject of human clinical trials that included a delivery device, AstraZeneca shall [ * ]. In particular, if such device
was a proprietary AstraZeneca device, then for the purposes of the above sentence, AstraZeneca shall [ * ]. If such device was a Third Party device, then AstraZeneca shall [ * ]. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 89 of 103

  

	 	20.7.4	Manufacturing. Upon termination of this Agreement in whole or in part by AstraZeneca pursuant to Sections 20.2 or 20.3 or by Dynavax pursuant to
Section 20.4, AstraZeneca shall immediately provide to Dynavax copies of process and manufacturing technology, material and data sufficient to enable Dynavax concurrently to produce and supply any Product or Combination Product that was being
Commercialized. AstraZeneca shall provide reasonable assistance to Dynavax to effect such transfers in an orderly fashion and to enable Dynavax to begin manufacturing and supplying the Product and/or Combination Product as soon as possible to
minimize any disruption in the continuity of supply. 

  

	20.8	Survival. The following provisions shall survive the expiration or termination of this Agreement: Articles 1, 2, 13, 19, 23 through 28, 30, 31 and 32 and
Sections 3.8, 7.3, 10.14, 18.5, 20.7 and 20.8, together with any sections referenced in such surviving provisions or necessary to give them effect. Termination of this Agreement shall not relieve the Parties of any liability that accrued hereunder
prior to the effective date of such termination. Termination of this Agreement shall not preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor
prejudice either Party’s right to obtain performance of any obligation. 

  

	20.9	Rights in Bankruptcy. All rights and licences granted under or pursuant to this Agreement by Dynavax are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States, licences of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code or analogous
provisions of Applicable Law outside the United States (hereinafter “IP”). The Parties agree that each of the Parties, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and
elections under the U.S. Bankruptcy Code or any other provisions of Applicable Law outside the United States that provide similar protection for IP. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or
against Dynavax on the one hand, or AstraZeneca on the other hand, under the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States, AstraZeneca or Dynavax, as applicable, shall be entitled to a complete duplicate
of (or complete access to, as appropriate) any 

  
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

  
 Page 90 of 103

  

	 	
such IP and all embodiments of such IP, which, if not already in such Party’s possession, shall be promptly delivered to it upon such Party’s written request therefor.

  

	21	Force Majeure  

  

	21.1	In this Agreement, “Force Majeure” means an event which is beyond a non-performing Party’s reasonable control, including an act of God, act of the
other Party, strike, lock-out or other industrial/labour dispute (whether involving the workforce of the Party so prevented or of any other Person), war, riot, civil commotion, terrorist act, malicious damage, epidemic, quarantine, fire, flood,
earthquake, storm, natural disaster or compliance with any law or governmental order, rule, regulation or direction (including changes in the requirements of the health authorities), whether or not it is later held to be invalid. Notwithstanding the
foregoing, the payment of invoices due and owing hereunder shall not be delayed by the payer because of a Force Majeure affecting the payer, unless such Force Majeure specifically precludes the payment process. 

 

	21.2	The Force Majeure Party shall, within [ * ] days of the occurrence of a Force Majeure event, give notice in writing to the other Party specifying the nature and
extent of the event of Force Majeure, its anticipated duration and any action being taken to avoid or minimize its effect. Subject to providing such notice and to Section 21.1, the Force Majeure Party shall not be liable for delay in
performance or for non-performance of its obligations under this Agreement, in whole or in part, nor shall the other Party have the right to terminate this Agreement, except as otherwise provided in this Agreement, where non-performance or delay in
performance has resulted from an event of Force Majeure. The suspension of performance allowed hereunder shall be of no greater scope and no longer duration than is reasonably required. 

 

	21.3	The Force Majeure Party shall use reasonable endeavours, without being obligated to incur any expenditure or cost, to bring the Force Majeure event to a close or to
find a solution by which this Agreement may be performed despite the continuation of the event of Force Majeure. 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 91 of 103

  

	21.4	If the Force Majeure Party is prevented from performing its obligations due to a Force Majeure event for a continuous period in excess of [ * ] days after the
date of the occurrence of the Force Majeure event, and such failure to perform would constitute a material breach of this Agreement in the absence of such Force Majeure event, the Parties shall meet and discuss in good faith any amendments to this
Agreement to permit the other Party to exercise its rights under this Agreement. If the Parties are not able to agree on such amendments within [ * ] days of commencement of such discussions and if the suspension of performance continues,
such other Party may terminate this Agreement immediately by written notice to the Force Majeure Party, in which case neither Party shall have any liability to the other except for those rights and liabilities that accrued prior to the date of
termination. 

  

	22	Assignment 

  

	22.1	Neither Party may assign its rights or, except as provided in Sections 3.5.4 , 6.6 and 6.7, delegate its obligations under this Agreement in whole or in part
without the prior written consent of the other Party, except that a Party shall always have the right, without such consent, on written notice to the other Party, assign any or all of its rights and delegate any or all of its obligations hereunder
to any of its Affiliates or to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the business to which this Agreement relates. Any permitted successor of a Party or any permitted
assignee of all of a Party’s rights under this Agreement that has also assumed all of such Party’s obligations hereunder in writing shall, upon any such succession or assignment and assumption, be deemed to be a party to this Agreement as
though named herein in substitution for the assigning Party, whereupon the assigning Party shall cease to be a party to this Agreement and shall cease to have any rights or obligations under this Agreement. All validly assigned rights of a Party
shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted successors and assigns of such Party. Any attempted assignment or delegation in
violation of this Article 22 shall be void. 

  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 92 of 103

  

	23	Severability 

 To the
fullest extent permitted by applicable law, the Parties waive any provision of law that would render any provision of this Agreement invalid, illegal or unenforceable in any respect. If any provision of this Agreement is held to be invalid, illegal
or unenforceable, in any respect, then such provision will be given no effect by the Parties and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights or obligations of any Party will not be
materially and adversely affected all other provisions of this Agreement shall remain in full force and effect, and the Parties shall use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or
unenforceable that is consistent with Applicable Law and achieves, as nearly as possible, the original intention of the Parties. 
  

	24	Dispute Resolution. 

  

	24.1	Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during the Term which relate to either Party’s rights and/or
obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this
objective, the Parties agree to follow the procedures set forth in this Article 24 if and when a dispute arises under this Agreement. In the event of any disputes, controversies or differences which may arise between the Parties, out of or in
relation to or in connection with this Agreement, or for the breach thereof, upon the request of either Party, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one
in-person meeting between representatives of each Party having decision-making authority (subject only to Board of Directors’ or equivalent approval, if required). All such discussions under this Section shall be confidential and shall be
treated as compromise and settlement negotiations for purposes of applicable rules of evidence. If the matter is not resolved within [ * ] days following the request for discussions, either Party may then invoke the provisions of
Section 24.2 below. 

  

	24.2	Arbitration. Any dispute, controversy or claim arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance,
application 

  
 [ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 93 of 103

  

	 	
or termination of this Agreement that is not resolved pursuant to Section 24.1, except for a dispute, claim or controversy under Section 24.13, shall be settled by binding arbitration
administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures of JAMS then in effect (the “JAMS Rules”), except as otherwise provided herein. The arbitration shall be governed by the United States Federal Arbitration
Act, 9 U.S.C. §§ 1-16 (the “Federal Arbitration Act”), to the exclusion of any inconsistent state laws. The arbitration will be conducted in Wilmington, Delaware and the Parties consent to the personal jurisdiction of the United
States federal courts, for any case arising out of or otherwise related to this arbitration, its conduct and its enforcement. The language used in the arbitration proceedings shall be English. Any situation not expressly covered by this Agreement
shall be decided in accordance with the JAMS Rules. 

  

	24.3	Arbitrator. 

 The
arbitrator shall be one (1) neutral, independent and impartial arbitrator selected from a pool of retired federal judges to be presented to the Parties by JAMS. Failing the agreement of the Parties as to the selection of the arbitrator within
thirty (30) days, the arbitrator shall be appointed by JAMSin accordance with the JAMS Rules. 
  

	24.4	Governing Law. Resolution of all disputes arising out of or related to this Agreement or the validity, construction, interpretation, enforcement, breach,
performance, application or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that
might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

  

	24.5	Decision. The power of the arbitrator to fashion procedures and remedies within the scope of this Agreement is recognized by the Parties as essential to the
success of the arbitration process. The arbitrator shall not have the authority to fashion remedies which would not be available to a federal judge hearing the same dispute. The arbitrator is encouraged to operate on this premise in an effort to
reach a fair and just decision. Reasons for the arbitrator’s decisions should be complete and explicit, including all determinations of law and fact. The written reasons should also include the basis for any damages awarded and a statement of
how the damages were 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 94 of 103

  

	 	
calculated. Such a written decision shall be rendered by the arbitrator following a full comprehensive hearing, no later than [ * ] months following the selection of the arbitrator as provided
for in Section 24.3. 

  

	24.6	Award. 

  

	 	24.6.1	Any award shall be paid in U.S. dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent
permitted by law, be charged against the Party resisting enforcement. 

  

	 	24.6.2	If as to any issue the arbitrator should determine under the applicable law that the position taken by a Party is frivolous or otherwise irresponsible or that any
wrongdoing they find is in callous disregard of law and equity or the rights of the other Party, the arbitrator shall also award an appropriate allocation of the adversary’s reasonable attorney fees, costs and expenses to be paid by the
offending Party, the precise sums to be determined after a bill of attorney fees, expenses and costs consistent with such award has been presented following the award on the merits. 

 

	 	24.6.3	Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 24, and agrees that, subject to the Federal Arbitration Act,
judgment may be entered upon the final award in the Federal District Court in Delaware and that other courts may award full faith and credit to such judgment in order to enforce such award. 

 

	 	24.6.4	The award shall include interest from the date of any damages incurred for breach of the Agreement, and from the date of the award until paid in full, at a rate fixed
by the arbitrator. 

  

	 	24.6.5	With respect to money damages, nothing contained herein shall be construed to permit the arbitrator or any court or any other forum to award punitive or exemplary
damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for punitive or exemplary damages. The only damages recoverable under this Agreement are compensatory damages (including, without limitation, consequential
damages). 

  
 [ * ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 95 of 103

  

	24.7	Costs. Except as set forth in Section 24.6.2, each Party shall bear its own legal fees. The arbitrator shall assess his or her costs, fees and expenses
against the Party losing the arbitration unless he or she believes that neither Party is the clear loser, in which case the arbitrator shall divide his or her fees, costs and expenses according to his or her sole discretion.

  

	24.8	Injunctive Relief. Provided a Party has made a sufficient showing under the rules and standards set forth in the Federal Rules of Civil Procedure and applicable
case law, the arbitrator shall have the freedom to invoke, and the Parties agree to abide by, injunctive measures after either Party submits in writing for arbitration claims requiring immediate relief. Nothing in this Article 24 will preclude
either Party from seeking equitable relief in accordance with Article 32 or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief,
concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. 

 

	24.9	Confidentiality. The arbitration proceeding shall be confidential and the arbitrator shall issue appropriate protective orders to safeguard each Party’s
Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator to make) any public announcement with respect to the proceedings or decision of the arbitrator without prior written consent of the other Party. The
existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator, except as required in connection with the enforcement of such award or as otherwise required by applicable law.

  

	24.10	Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of the contract for any reason.

  

	24.11	Jurisdiction. For the purposes of this Article 24, the parties acknowledge their diversity (AstraZeneca having its principal places of business in Sweden and the
UK and Dynavax having its principal place of business in California) and agree to accept the jurisdiction of the Federal District Court in Delaware for the purposes of enforcing or appealing any awards entered pursuant to this Article 24 and for
enforcing the agreements reflected in this Article 24 and agree not to commence any action, suit or proceeding related thereto except in such courts. 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 96 of 103

  

	24.12	Patents and Trademarks. Any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Patent rights covering the
manufacture, use, importation, offer for sale or sale of the Product or any Combination Product or of any AstraZeneca trademarks, Dynavax trademarks, or trademark rights related to the Product or any Combination Product shall be submitted to a court
of competent jurisdiction in the country in which such Patent or trademark rights were granted or arose. 

  

	24.13	Provisions Unique to Arbitrations Pursuant to Section 8.10. Notwithstanding anything to the contrary in this Article 24, if the arbitration is commenced
pursuant to Section 8.10 in connection with a dispute regarding whether either Party has met its diligence obligations, then such arbitration shall be conducted by the arbitrator selected pursuant to Section 24.3 together with two experts
having at least ten (10) years of experience in drug discovery or development, either in a commercial setting or as a full time faculty member at a university or medical institute (the “Expert”). One such Expert shall be selected by
AstraZeneca and the other Expert shall be selected by Dynavax. Such Experts shall participate in the arbitration solely as advisors and shall not assume any of the authority of the arbitrator. 

 

	25	Notices 

  

	25.1	Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing
and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally recognised overnight delivery service that maintains records of delivery, addressed to the Parties at their
respective addresses specified in Section 25.2 or to such other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Article 25. Such notice shall be deemed to have been given as
of the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second business day (at the place of delivery) after deposit with an internationally recognised overnight delivery service. Any notice delivered by
facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Article 25 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the
terms of this Agreement. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 97 of 103

  

	25.2	Address for Notice  

  

					
	                  For:           
         	  	AstraZeneca AB	  	
			
		  	Address:	  	 AstraZeneca R&D Lund,

Schelegatan 10
 Sweden

		  	Facsimile:	  	[ * ]
		  	For the attention of: Director Discovery Alliances
		
	
                  With a copy 
to:
	  	AstraZeneca UK Limited
		  	Address:	  	Alderley House, Alderley Park, Macclesfield, Cheshire SK10 4TF
		  	Facsimile:	  	[ * ]
		  	For the attention of: Assistant General Counsel
		
	For:                    	  	Dynavax Pharmaceuticals, Inc.
		  	2929 Seventh Street
		  	Suite 100
		  	Berkeley, CA 94710-2753
		  	Fax: [ * ]
		  	Attn: D. Kevin Kwok, Vice President & Chief Business Officer
		
	 Witha copy to:
	  	
		  	Cooley Godward LLP
		  	Five Palo Alto Square
		  	3000 El Camino Real
		  	Palo Alto, CA 94306-2155
		  	Fax: [ * ]
		  	Attention: Robert L. Jones, Esq.

  

	26	Relationship of the Parties 

 The status of a Party under this Agreement shall be that of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 98 of 103

  

 
venture or agency relationship between the Parties or, except as otherwise expressly provided in this Agreement, as granting either Party the authority to bind or contract any obligation in the
name of or on the account of the other Party or to make any statements, representations, warranties or commitments on behalf of the other Party. All persons employed by a Party shall be employees of such Party and not of the other Party and all
costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party. 
  

	27	Entire Agreement 

 This
Agreement constitutes the entire agreement between the Parties with respect to the subject matter of this Agreement. This Agreement supersedes all prior agreements, whether written or oral, with respect to the subject matter of this Agreement. In
particular, this Agreement supersedes the Confidentiality Agreement between the Parties, effective 12 October 2004, and all confidential information exchanged between the Parties under such Confidentiality Agreement shall be deemed the
Confidential Information of the corresponding Party and protected under this Agreement. Each Party confirms that it is not relying on any representations, warranties or covenants of the other Party except as specifically set out in this Agreement.
Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Schedules and Exhibits referred to in this Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. In the
event of any inconsistency between any such schedules or Exhibits and this Agreement, the terms of this Agreement shall govern. 
  

	28	English Language 

 This
Agreement is written and executed in the English language. Any translation into any other language shall not be an official version of this Agreement and in the event of any conflict in interpretation between the English version and such
translation, the English version shall prevail. 
  

	29	Amendment 

 Any amendment
or modification of this Agreement must be in writing and signed by authorised representatives of both Parties. 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 99 of 103

  

	30	Waiver and Non-Exclusion of Remedies 

 A Party’s failure to enforce, at any time or for any period of time, any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or
remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any waiver must be in writing. The rights and remedies provided herein are cumulative and do not exclude any
other right or remedy provided by law or otherwise available except as expressly set forth herein. 
  

	31	No Benefit to Third Parties 

 The provisions of this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights in any other Persons except as
otherwise expressly provided Article 22. 
 The Contracts (Rights of Third Parties) Act 1999 shall not apply to this
Agreement. Except as expressly provide in Article 22, no Person who is not a party to this Agreement (including any employee, officer, agent, representative or subcontractor of either Party) shall have the right (whether under the Contracts
(Rights of Third Parties) Act 1999 or otherwise) to enforce any term of this Agreement which expressly or by implication confers a benefit on that Person without the express prior agreement in writing of the Parties, which agreement must refer to
this Article 31. 
  

	32	Equitable Relief 

 Each
Party acknowledges and agrees that the restrictions set forth in this Agreement are reasonable and necessary to protect the legitimate interests of the other Party and that neither Party would have entered into this Agreement in the absence of such
restrictions, and that any breach or threatened breach of any provision of this Agreement may result in irreparable injury to the non-breaching Party for which there will be no adequate remedy at law. In the event of a breach or threatened breach of
any provision of this Agreement, the non-breaching Party shall be authorised and entitled to obtain from any court of competent jurisdiction equitable relief, whether preliminary or permanent, specific performance and an equitable accounting of all
earnings, profits and other benefits arising from such breach, which rights shall be 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 100 of
103 
  

 
cumulative and in addition to any other rights or remedies to which such non-breaching Party may be entitled in law or equity. Each of Dynavax and AstraZeneca agrees to waive any requirement that
the non-breaching Party (a) post a bond or other security as a condition for obtaining any such relief, and (b) show irreparable harm, balancing of harms, consideration of the public interest or inadequacy of monetary damages as a remedy.
Nothing in this Article 32 is intended, or should be construed, to limit a non-breaching Party’s right to equitable relief or any other remedy for a breach of any other provision of this Agreement, provided, however, that resolution of
disputes between the Parties is subject to the provisions of Article 24. 
  

	33	Further Assurance 

  

	33.1	Each Party shall perform all further acts and things and execute and deliver such further documents as may be necessary or as the other Party may reasonably require to
implement or give effect to this Agreement. 

  

	33.2	The Parties recognize that each may perform some or all of its obligations and exercise any or all of its rights under this Agreement, without the prior consent of the
other Party, through Affiliates or Sublicensees, provided, however, that each Party shall remain responsible for the performance by its Affiliates and Sublicensees and shall cause its Affiliates and Sublicensees to comply with the provisions
of this Agreement in connection with such performance. In particular, if any Affiliate of a Party or a Sublicensee participates in research under this Agreement or with respect to the Product or any Combination Product(s), (a) the restrictions
of this Agreement which apply to the activities of a Party with respect to a CD, the Product or any Combination Product(s) shall apply equally to the activities of such Affiliate and Sublicensee, and (b) the Party affiliated with such Affiliate
or Sublicensee shall assure that any intellectual property developed by such Affiliate or Sublicensee shall be governed by the provisions of this Agreement (and subject to the licenses set forth in Article 6) as if such intellectual property
had been developed by the Party. Any action or omission by a Party’s Affiliate or a Sublicensee which would, if such action or omission were conducted by the Party, constitute a breach of the Party’s obligations under this Agreement will
constitute a breach of such obligation by the Party (unless such obligation were otherwise satisfied by such Party or another of its Affiliates or Sublicensees). 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 101 of
103 
  

	34	Expenses 

 Except as
otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this
Agreement. 
  

	35	Counterparts 

 This
Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall be deemed to constitute one and the same instrument. An executed signature page of this Agreement delivered by
facsimile transmission shall be as effective as an original executed signature page. 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 102 of
103 
  

 THIS AGREEMENT IS EXECUTED by the authorised representatives of the Parties, in duplicate, as of the date
first written above. 
  

							
	SIGNED for and on behalf of	 	SIGNED for and on behalf of
		
	AstraZeneca AB (publ)	 	Dynavax Technologies Corporation
		
	 /s/ Jan M Lundberg
	 	 /s/ Dino Dina

	Signature	 	Signature
	Name:	 	 Jan M Lundberg
	 	Name:	 	 Dino Dina, M.D.

	Title:	 	 EVP, Global Discovery
	 	Title:	 	 President and CEO

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Page 103 of
103 
  

 EXHIBIT A 

CRITERIA FOR CANDIDATE DRUG TARGET PROFILE

 [ * ] 
  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT B 

DYNAVAX PATENTS 
 EXHIBIT B(1) 
 [ * ] 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT B(2) 

[ * ] 
  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT C 

JOINT RESEARCH PLAN 

Description of Joint Research 
 [ * ] 
  
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 EXHIBIT D 

PRE-APPROVED DYNAVAX SUBCONTRACTORS 

[ * ] 
  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT E 

PRESS RELEASE 
 

 
 2929 Seventh Street, Suite 100 
 Berkeley, CA 94710 
 Contact: 
 Dynavax Technologies Corporation 
 Jane M. Green, PhD 

Corporate Communications 
 Phone
(510) 665-4630 
 Email: jgreen@dvax.com 
 DYNAVAX ESTABLISHES COLLABORATION FOR 
 TLR-9 AGONISTS FOR ASTHMA AND COPD WITH
ASTRAZENECA 
 Berkeley, CA – [Date] – Dynavax Technologies Corporation (NASDAQ:DVAX) has entered into an a three-year research
collaboration and a License agreement with AstraZeneca for the discovery and development of TLR-9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The collaboration will utilize Dynavax’s
proprietary second-generation TLR-9 agonist immunostimulatory sequences or ISS. 
 Under the terms of the agreement, Dynavax and AstraZeneca
will collaborate to identify lead TLR-9 agonists and conduct appropriate research phase studies. AstraZeneca will be responsible for any development and worldwide commercialisation of products arising out of the research programme. Dynavax may have
an opportunity for partial co-promotion in the United States of products arising from the collaboration. 
 Financial terms of the collaboration
include an upfront fee of $10 million plus research funding and preclinical milestones that could bring the total committed funding of up to $20 million. Dynavax may also receive additional development milestones potentially resulting in a
collaboration value of up to approximately $129 million. Upon commercialization, Dynavax is also eligible to receive royalties based on product sales. 
 “The management of respiratory diseases such as asthma and COPD remains a major health challenge affecting 150 million people worldwide and representing a significant financial 

 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
burden to the global healthcare system,” said Claude Bertrand, Vice President Respiratory and Inflammation Research at AstraZeneca. “New approaches that have the potential to reverse
the course of respiratory disease are needed. AstraZeneca believes that Dynavax’s ISS-based technology represents an innovative, next-generation therapeutic intervention that could potentially expand and strengthen AstraZeneca’s strong
position in the respiratory disease field.” 
 “We believe that AstraZeneca is the ideal partner for the development of asthma and
COPD ISS-based therapies, as they have one of the most widely respected and commercially successful respiratory product portfolios in the industry,” said Dino Dina, MD, Dynavax’s chief executive officer. “We appreciate
AstraZeneca’s recognition of the innovative, disease-modifying potential of our TLR-9 agonist based approaches and are optimistic that with our combined resources and know-how, we will be able to create novel therapeutics that may provide
benefit to patients suffering from these diseases.” 
 Continued Dr. Dina: “We believe that the positive clinical experience we
have previously demonstrated provides a strong foundation for applying ISS-based agonists to treat asthma and COPD. We are hopeful that this collaboration, the goal of which is to explore the potential of ISS alone to treat respiratory diseases,
will help to expand our existing portfolio of ISS-based products.” 
 [[Conference Call Today]] 

Dynavax will hold a conference call to discuss [[ ]] today at [5:00] p.m. Eastern. Interested parties may listen to the webcast live at
http://www.dynavax.com by clicking on the “Events” tab under the heading, “Investors.” The webcast is also being distributed over CCBN’s Investor Distribution Network to both institutional and individual investors.
Individual investors can listen to the call through CCBN’s individual investor center at http://www.fulldisclosure.com or by visiting any of the investor sites in CCBN’s Individual Investor Network. Institutional investors can access the
call via CCBN’s password-protected event management site, StreetEvents, at http://www.streetevents.com. A telephonic replay will be available through [[date]] by dialing 888.286.8010, access code: xxxxxxxx. International callers can dial
617.801.6888, access code: xxxxxxxx. 
 Forward Looking Statements 
 Dynavax cautions you that this press release contains forward-looking statements, including without limitation [[ ]]. Actual results may differ materially from those set forth in this release due to the
risks and uncertainties inherent in Dynavax’s business including, without limitation, risks relating to: [[ ]] the progress and timing of its current and anticipated clinical trials; difficulties or delays in developing, testing and
manufacturing products to support clinical development plans; the scope and validity of patent protection for product candidates; competition from other companies working with ISS technologies and products; the ability to obtain additional financing
to support operations; and other risks detailed in the “Risk Factors” section of Dynavax’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q. All forward-looking statements are made as of the date hereof and Dynavax
undertakes no obligation to revise or update information provided in this press release. 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 About Dynavax 
 Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR-9 agonist-based products to treat and prevent allergies, infectious diseases, and chronic inflammatory
diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability
of the immune system to fight disease and control chronic inflammation. Dynavax’s pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a
supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine that is currently in a Phase 3 clinical trial; SUPERVAX, a hepatitis B vaccine; a cancer therapy currently in a Phase 2 clinical trial in non-Hodgkins
lymphoma;[ * ]; and preclinical programs in hepatitis B therapy and hepatitis C therapy. 
 About AstraZeneca 

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals
and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of $23.95 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and
infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. 
  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT F 

CONFIRMATORY PATENT LICENCE 
 Patent Licence Agreement 
 Date: 

Parties: 
  

	(1)	‘The Licensor’:                     having its registered
office at                     . 

  

	(2)	‘The Licensee’:                     having its registered
office at                     . 

 Recitals: 
 By an Agreement (‘the Main Agreement’) dated
                    and made between the Licensor and the Licensee the Licensor granted for the consideration therein contained to the Licensee a
licence under [UK Patent No                     ] [European Patent (UK) No
                    ] (‘the Patent’). 
 Operative provisions: 
  

	1.	In pursuance of the Main Agreement and for the consideration referred to in the Main Agreement the Licensor hereby confirms the grant to the Licensee of the exclusive
licence from the Effective Date for the term specified in the Main Agreement to manufacture, market, sell and otherwise dispose of Licensed Products (as defined in the Main Agreement) for the life of the Patent and subject to the provisions of the
Main Agreement. 

  

	2.	Subject as provided in the Main Agreement this Licence shall terminate without notice in the event of the termination for any reason of the Main Agreement.

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 IN WITNESS of which this Agreement has been executed as a deed and delivered the day and year first above
written. 
  

	
	 EXECUTED as a Deed by
                     acting by:
 [name of
director] and:
 [name of director/secretary]

	
	 EXECUTED as a Deed by
                    acting by:
 [name of
director] and:
 [name of director/secretary]

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 18.2.5 
 [ * ] 
  

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 18.2.6 
 [ * ] 
  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.<![CDATA[Form of Purchase Agreement - Manning & Napier Group, LLC]]>

 Exhibit 10.18 
 PURCHASE AGREEMENT 
 This PURCHASE AGREEMENT (this
“Agreement”) is made this      day of             , 2011, by and between Manning & Napier, Inc., a Delaware corporation (the
“Company”), and Manning & Napier Group, LLC, a Delaware limited liability company (“Manning & Napier Group”). 
 W I T N E S S E T H: 
 WHEREAS, on the date hereof, the Company has consummated the initial public offering of its Class A common stock, par value $0.01 per share (the “Initial Public Offering”); and

 WHEREAS, pursuant to the terms and conditions set forth herein, the Company desires to purchase, and Manning &
Napier Group desires to issue, Class A units of Manning & Napier Group with a portion of the net proceeds it received in the Initial Public Offering. 
 NOW, THEREFORE, in consideration of the foregoing premises, the respective covenants and agreements set forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, hereby agree as follows: 
 1.
Purchase of Class A Units. 
 (a) Subject to the terms and conditions set forth in this Agreement, Manning &
Napier Group shall issue to the Company, and the Company shall purchase from Manning & Napier Group,      Class A units of Manning & Napier Group (the “Class A Units”) for an aggregate cash
purchase price equal to $     (the “Purchase Price”). The price per Class A Unit shall be equal to the price per share of the Company’s Class A common stock in the Initial Public Offering.

 (b) The closing of such issuance and purchase shall take place on the date hereof and shall be effected by
(i) Manning & Napier Group delivering to the Company all instruments necessary to effect the issuance and transfer of the Class A Units and (ii) the Company delivering the Purchase Price to Manning & Napier Group by
wire transfer of immediately available funds to an account designed by Manning & Napier Group in writing. 
 2.
Representations and Warranties of the Company. The Company hereby represents and warrants to Manning & Napier Group as follows: 

 (a) Corporate Organization. The Company is a corporation duly organized, validly
existing and in good standing under the laws of its jurisdiction of organization. 
 (b) Authorization and Validity of
Agreement. The Company has all requisite corporate power and authority to enter into this Agreement and to carry out its obligations hereunder. The execution and delivery of this Agreement and the performance of the Company’s obligations
hereunder have been duly authorized by all necessary corporate action, and no other corporate proceedings on the part of the Company is necessary to authorize such execution, delivery and performance. This Agreement has been duly executed by the
Company and, assuming due execution by Manning & Napier Group, constitutes its valid and binding obligation, enforceable against it in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, moratorium or
similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity. 
 (c) No Conflict or Violation. The execution, delivery and performance by the Company of this Agreement does not and will not (i) violate or conflict with any provision of the organizational
documents of the Company or (ii) violate any provision of law, or any order, judgment or decree of any court or other governmental entity. 
 (d) Accredited Investor; Investigation. The Company (i) is an “accredited investor” as such term is defined in Rule 501 promulgated under the Securities Act of 1933, as amended (the
“Securities Act”), (ii) is acquiring the Class A Units for investment and for the Company’s own account and not with a view to, or for resale in connection with, any distribution, except pursuant to registration under
the Securities Act or an exemption from such registration available under the Securities Act, and in compliance with foreign securities laws, as applicable, (iii) understands that the Class A Units have not been registered under the
Securities Act or under any securities or blue sky laws and, as a result, are subject to substantial restrictions on transfer, (iv) has had the opportunity to ask questions of, and to receive answers from, appropriate officers and employees of
Manning & Napier Group with respect to the terms and conditions of the transactions contemplated hereby and with respect to Manning & Napier Group and the Class A Units and (v) has had access to such financial and other
information as requested in order for the undersigned to make an informed decision as to an investment in Manning & Napier Group, and has had the opportunity to obtain any additional information required to verify any of such information to
which the undersigned has had access. 
 3. Representations and Warranties of Manning & Napier Group.
Manning & Napier Group hereby represents and warrants to the Company as follows: 
 (a) Organization.
Manning & Napier Group is a limited liability company duly organized, validly existing and in good standing under the laws of its jurisdiction of formation. 

  
 2 

 (b) Authorization and Validity of Agreement. Manning & Napier Group has all
requisite limited liability company power and authority to enter into this Agreement and to carry out its obligations hereunder. The execution and delivery of this Agreement and the performance of Manning & Napier Group’s obligations
hereunder have been duly authorized by all necessary limited liability company action, and no other limited liability company proceedings on the part of Manning & Napier Group is necessary to authorize such execution, delivery and
performance. This Agreement has been duly executed by Manning & Napier Group and, assuming due execution by the Company, constitutes its valid and binding obligation, enforceable against it in accordance with its terms, except as may be
limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity. 

(c) No Conflict or Violation. The execution, delivery and performance by Manning & Napier Group of this Agreement does
not and will not (i) violate or conflict with any provision of the organizational documents of Manning & Napier Group or (ii) violate any provision of law, or any order, judgment or decree of any court or other governmental
entity. 
 4. Miscellaneous. 
 (a) Further Assurances. Each party hereto shall execute, deliver, file and record, or cause to be executed, delivered, filed and recorded, such further agreements, instruments and other documents,
and take, or cause to be taken, such further actions, as any other party hereto may reasonably request as being necessary or advisable to effect or evidence the transactions contemplated by this Agreement. 

(b) Entire Agreement. This Agreement constitutes the entire agreement and understanding between the parties with regard to the
subject matter hereof. 
 (c) Amendments; Waivers. This Agreement may be amended, modified or superseded, and any of the
terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by parties hereto. No waiver of any provision of this Agreement shall be valid unless in writing and signed by the party against
whom enforcement is sought. The failure of any party at any time or times to require performance of any provisions hereof will in no manner affect the right at a later time to enforce the same. No waiver by any party of any condition, or of any
breach of any term, covenant, representation or warranty contained in this Agreement, in any one or more instances, will be deemed to be or construed as a further or continuing waiver of any such condition or breach or a waiver of any other
condition or of any breach of any other term, covenant, representation or warranty. 
 (d) Successors and Assigns. All of
the terms, covenants, representations, warranties and conditions of this Agreement will be binding upon, and inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and assigns. 

  
 3 

 (e) Governing Law. This Agreement shall be governed by and construed in accordance
with the domestic laws of the State of New York, without giving effect to any choice of law or conflict of law provisions or rule that would cause the application of the laws of any jurisdiction other than the State of New York. 

(f) Severability. If any provision of this Agreement shall become illegal, invalid, unenforceable or against public policy for any
reason, or shall be held by any court of competent jurisdiction to be illegal, invalid, unenforceable or against public policy, then such provision shall be severed from this Agreement and the remaining provisions of this Agreement shall not be
affected thereby and shall remain in full force and effect. In lieu of each provision that becomes or is held to be illegal, invalid, unenforceable or against public policy, there shall be automatically added to this Agreement a provision as similar
in substance to the objectionable provision as may be possible and still be legal, valid, enforceable and in compliance with public policy. 
 (g) Section and Paragraph Headings. The section and paragraph headings in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

 (h) Counterparts. This Agreement may be executed in any number of counterparts with the same effect as if all parties
hereto had executed the same document. All such counterparts shall be construed together and shall constitute one instrument. 

[Remainder of Page Intentionally Left Blank; Signature Page Follows] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
above written. 
  

			
	MANNING & NAPIER, INC.
		
	By:	 	  

		 	Name:
		 	Title:
	
	MANNING & NAPIER GROUP, LLC
		
	By:	 	  

		 	Name:
		 	Title:

 [Signature Page to Purchase Agreement of Manning & Napier, Inc. and Manning &
Napier Group, LLC]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]